Prediction and identification of B-cell epitopes using protein structure information by Andersen, Pernille
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 18, 2017
Prediction and identification of B-cell epitopes using protein structure information
Andersen, Pernille; Lund, Ole
Publication date:
2007
Document Version
Early version, also known as pre-print
Link back to DTU Orbit
Citation (APA):
Andersen, P., & Lund, O. (2007). Prediction and identification of B-cell epitopes using protein structure
information. Kgs. Lyngby, Denmark: Technical University of Denmark (DTU).
Ph.D. Thesis
Prediction and identification of
B-cell epitopes using protein
structure information
Pernille Andersen
September 14th, 2007
Center for Biological Sequence Analysis
BioCentrum
Technical University of Denmark

Abstract
Recognition of antigens by antibodies is a fundamental mechanism in the im-
mune system. A major challenge in immunological research is to identify the
molecular entities recognized by antibodies (B-cell epitopes). The identification
of B-cell epitopes can lead to a better understanding of the mechanisms involved
in host-pathogen interactions, and can additionally facilitate vaccine develop-
ment. The use of protein structure information in B-cell epitope identification
is the general topic of this thesis.
Bioinformatic methods for prediction of B-cell epitopes have been used for more
than 20 years with the major aim of reducing experimental work in the iden-
tification process. These methods have mostly been based on protein sequence
information. Recently, the field of bioinformatics has developed considerably,
and the amount of structural information on antigen-antibody complexes has
increased. This allows for the development of new prediction methods for B-
cell epitopes. This thesis describes the development of a new method entitled
DiscoTope; the method is based on protein three-dimensional information and
predicts residues part of B-cell epitopes. The development of the method was
based on a dataset of 76 epitopes from experimentally determined structures
of antigen-antibody complexes. It is shown that the new method has a bet-
ter performance than a classical sequence-based method for predicting residues
in contact with antibodies. Additionally, it is demonstrated that the method
successfully predicts residues in epitopes which have been identified by using
different experimental and sequence analysis methods. The DiscoTope method
has a potential for guiding B-cell epitope identification experiments and is avail-
able in public web-servers at the Centre for Biological Sequence Analysis (CBS)
and via the Immune Epitope Database (IEDB).
Pregnancy-associated malaria (PAM) causes thousands of cases of low birth
weight and severe maternal anemia every year. The protein VAR2CSA is
thought to play a major role in pregnancy-associated disease, and is expressed on
the surface of erythrocytes infected with malaria. Here, the identification of B-
cell epitopes in the VAR2CSA protein is described. Human serum from women
that are immune to the disease was used for pepscan analysis, which identified
several epitopes in the different domains of the protein. The structures of these
VAR2CSA domains were predicted and this allowed for the analysis of identified
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B-cell epitopes in a three-dimensional context. It is shown, that in general, the
identified surface-exposed B-cell epitopes are found in particular sub-domains,
and on the same side of the structures. These findings have implications for
further development of a VAR2CSA-based vaccine and lead to a better under-
standing of the overall structure of the VAR2CSA protein on the surface of
erythrocytes.
The main conclusion of this thesis is that protein structure information in gen-
eral has several useful applications in the field of B-cell epitope identification
and vaccine design.
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Dansk Resume
Antistoffers genkendelse af antigener er en af immunsystemets fundamentale
mekanismer. En af de store udfordringer i immunologisk forskning er at identifi-
cere de molekylære enheder, som kan genkendes af antistoffer (B-celle epitoper).
Identifikation af B-celle epitoper kan føre til bedre forståelse af de mekanismer
som er involveret i vært-patogen interaktioner, og kan yderligere bidrage til
udviklingen af vacciner. Brugen af information om proteiners strukturer til
identifikation af B-celle epitoper er det overordnede emne i denne afhandling.
Bioinformatiske metoder til forudsigelse af B-celle epitoper har været brugt i
mere end 20 år med det primære formål at reducere det eksperimentelle ar-
bejde i identifikationsprocessen. Metoderne har hovedsageligt været baseret
på information om proteinsekvenser. Igennem de sidste år har bioinformatik-
feltet udviklet sig betydeligt og mængden af strukturel information om antigen-
antistofkomplekser er øget. Dette har muliggjort udviklingen af nye metoder
til forudsigelse af B-celle epitoper. I denne afhandling beskrives udviklingen af
DiscoTope, en ny metode som forudsiger aminosyre-rester i B-celle epitoper, og
som er baseret på proteiners tredimensionelle struktur. Udviklingen af metoden
er baseret på et datasæt bestående af 76 epitoper fra eksperimentelt bestemte
strukturer af antigen-antistofkomplekser. Det vises, at metoden forudsiger amino-
syre-rester, som er i kontakt med antistoffer, mere nøjagtigt end en klassisk,
sekvensbaseret metode. Desuden vises det, at metoden kan forudsige rester i
epitoper, som er identificeret ved hjælp af forskellige eksperimentelle og sekvens-
analytiske metoder. Metoden har potentiale til at støtte eksperimenter til iden-
tifikation af B-celle epitoper og er tilgængelig igennem offentlige web-servere på
Center for Biologisk Sekvens Analyse (CBS) og via the Immune Epitope Data-
base (IEDB).
Graviditets-associeret malaria forårsager årligt tusinder af tilfælde af lav fød-
selsvægt hos spædbørn og alvorlig anæmi hos mødre. Proteinet VAR2CSA
spiller sandsynligvis en stor rolle i denne graviditets-associerede sygdom, og er
udtrykt på overfladen af malaria-inficerede erythrocytter. I denne afhandling
beskrives identifikationen af B-celle epitoper i VAR2CSA. Humane sera fra kvin-
der med immunitet overfor sygdommen blev brugt i pepscan-analyse til at iden-
tificere adskillige epitoper i proteinets forskellige domæner. Strukturerne af flere
af VAR2CSA proteinets domæner blev forudsagt. Dette muliggjorde analyse af
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de identificerede B-celle epitoper i en tredimensionel kontekst. Vores resultater
viser, at de identificerede overflade-eksponerede B-celle epitoper generelt findes
i bestemte subdomæner af strukturerne og på den samme side af strukturerne.
Disse opdagelser har betydning for den videre udvikling af en VAR2CSA-baseret
vaccine og giver bedre forståelse af VAR2CSA-proteinets overordnede struktur
på overfladen af erythrocytter.
Den generelle konklusion af afhandlingen er, at information om proteiners struk-
turer har mange nyttige anvendelser inden for identifikation af B-celle epitoper
og i vaccinedesign.
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Preface
Protein structure is one of my major interests. Coming from the field of protein
structural biology, my view of the world is quite biased. The work in my years
as a Ph.D. student has allowed me to combine my interest in protein structure
with research in the promising field of B-cell epitopes and vaccine design. It
has been highly motivating for me to work on several projects in immunological
bioinformatics with the overall goal of improving health in society.
This Ph.D. thesis was written at BioCentrum at the Technical University of
Denmark under the supervision of Associate Professor Ole Lund at the Center
for Biological Sequence Analysis (CBS). The work was funded by NIH contracts
HHSN26620040083C and HHSN266200400025C. My work presented in this the-
sis falls within two major areas: Prediction of B-cell epitopes in general, and
identification of B-cell epitopes in a malaria vaccine project. The work in both
projects was done in collaboration with other researchers from CBS, and the
latter project included additional collaboration with researchers at the Centre
for Medical Parasitology, University of Copenhagen and Copenhagen University
Hospital. I have chosen to present my results from the two projects in the form
of published and submitted articles. This way of presenting scientific results
was chosen because this is the most common way of publishing of scientific re-
sults today, as opposed to the more traditional approach where all results are
assembled into one report.
During my years in the immunological bioinformatics group, I have worked on
several projects. Initially, I started training artificial neural networks for pro-
tein secondary structure prediction. During this project, I learned many basic
principles of bioinformatics, which helped shaping my mind for the work pre-
sented in the papers within this thesis. The project led to an in-house program
for secondary structure prediction but did not lead to a publication, since the
performance of the method was comparable to other methods available in the
field, but not significantly better. Therefore, the work on this project has not
been included in this Ph.D. thesis.
As part of my Ph.D. program, I had the wonderful opportunity of visiting the
group of Professor David Baker, Department of Biochemistry, University of
Washington, Seattle, US. I was working 5 months in the start-up phase of an
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HIV gp120 redesign project, which was supervised by Ph.D. Bill Schief. The
visit was an absolutely outstanding opportunity to interact with and learn from
top-researchers in the field of protein structure prediction, protein design and
HIV vaccine design. The project goals however, turned out to be harder to
reach than expected, and were not pursued further. Despite this experience, I
still see a bright future for the combination of protein structure prediction and
protein design in vaccine development.
In order to facilitate the reading and understanding of the different presented
projects, this thesis starts with an introduction to antibodies, B-cell epitopes,
and prediction methods of the latter. This general introduction is followed
by two main chapters presenting the different areas and projects I have been
working on. Each of these chapters are initiated by introductions on the subjects
and some methods mentioned in the papers. The final chapter summarizes the
results, conclusions and perspectives of my work.
Pernille Andersen
September 2007
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Chapter1
Background
Recognition of antigens by antibodies is an essential mechanism in the immune
system. A general challenge in immunological research is to identify the molec-
ular entities recognized by antibodies (B-cell epitopes). This identification can
lead to a better understanding of the mechanisms involved in host-pathogen in-
teractions, and can additionally facilitate vaccine development. This chapter is
devoted to a general introduction to antibodies and B-cell epitopes. First in this
introduction, is a short description of the humoral immune response, antibod-
ies, their structures and interaction with B-cell epitopes. Secondly, a number of
sections describe B-cell epitope classification, identification and B-cell epitopes
in vaccine design. The last sections of the chapter describe prediction meth-
ods for B-cell epitopes. A major part of the following sections, which describe
the immune system in general, is based on informations from the book "‘Im-
munobiology"’ by Janeway, Travers, Walport and Shlomchik (Janeway et al.
2005).
1.1 The vertebrate immune system
The immune system is the body’s defense against foreign agents, such as infec-
tious organisms, toxins and other molecules that are not part of the body. The
defense can be divided into the innate and adaptive responses, which constitute
the first and second lines of defense, respectively. The innate immune response is
rapid and non-specific; it is mediated by the recognition of conserved structural
patterns found primarily in microorganisms. The adaptive immune response is
directed specifically to target individual infectious agents and is developed over
time. After the infection is resolved, memory cells persist in the body and can
induce a rapid and effective response if the harmful agent or infectious organism
is encountered again.
The adaptive immune system has two major branches: the cellular immune
response mediated by the T lymphocytes (T cells) and the humoral immune re-
sponse mediated by antibody-secreting B lymphocytes (B cells). The responses
of both systems are based on receptors which specifically bind minor parts of the
foreign agent called epitopes. The molecules containing the epitopes are called
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antigens. Antibodies recognize epitopes exposed on the surface of infectious or-
ganisms, where the antigens are in the native conformations. In contrast, T-cell
receptors recognize short linear peptides, which are products of intra-cellular
enzymatic digestion. T-cell epitopes are presented by the major histocompati-
bility complex (MHC) proteins to bind the T-cell receptors, and the binding may
result in a CD4+ T-helper cell response or a CD8+ cytotoxic T-cell response.
1.2 Mechanisms of antibody-mediated immunity
Antibodies contribute to the immunity against pathogens in three main ways.
The first is by neutralization, a process where antibodies bind functional sites
of antigens, thereby hindering the binding of antigens to receptors on target
cells. Neutralization is important for immunity against microorganisms, which
infect host cells by adhesion and subsequently enter the target cell to mul-
tiply. Neutralization can additionally prevent bacterial toxins from entering
cells. Opsonization is the second way of antibody-mediated immunity; in this
process, antibodies cover the surface of pathogens and mediate the destruction
of the pathogen by phagocytosis. Finally, binding of antibodies can activate
the complement system, which leads to binding of complement proteins to the
pathogen. Complement proteins facilitate opsonization of the pathogen, and
can form pores in the membrane of pathogens, thus leading to lysis of the cells.
1.3 B-cell development and antibody production
B lymphocytes originate in the bone marrow. Here, in the early lymphoid
development, rearrangement of the V, D, J genes ensures expression of a variety
of B-cell receptors (BCRs) on the surface of the immature B cells. These BCRs
are membrane-anchored versions of the antibody type immunoglobulin (Ig) M,
which in general bind epitopes with low affinity. Subsequently, B cells develop
further outside the bone marrow into mature, naïve B cells expressing antibodies
of the IgM and IgD types on the surface (Radbruch et al. 2006).
Binding of protein antigens to BCRs on the surface of B cells leads to the inter-
nalization and intra-cellular degradation of antigens. Single IgM binding sites
generally bind epitopes with low affinity, but if the density of epitopes on the
surface of an antigen or organism is high, the simultaneous binding of epitopes
by multiple IgM binding sites can lead to high-avidity interactions. After in-
ternalization and degradation of the antigen, peptide fragments of antigens are
presented on the surface of the B cell by MHC class II molecules. If CD4+
T-helper cells recognize peptides presented by the MHC class II molecules as
foreign, they can activate the B cells, which then undergo further development
of antibodies in the germinal centers of secondary lymphoid tissues. This devel-
opment leads to affinity maturation of the antibodies by somatic hypermutation,
and to isotype switching.
Somatic hypermutation is an iterative process of directed mutations in the
V gene segments, which encode the antibodies, and of subsequent antigen-
mediated selection. It leads to the development of antibodies that bind epi-
topes with high affinity. Following affinity maturation, the process of isotype
switching involves changes in the expression of C domain genes, which lead to
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the expression of high-affinity antibodies of the types IgG, IgA, and IgE.
After the switching has occurred, the B cell may differentiate into a plasma
cell or a memory B cell. Plasma B cells are specialized for high expression of
antibodies. Antibodies produced by plasma B cells are secreted and do not
contain a trans-membrane region. Long-lived plasma cells ensure the secretion
of high-affinity antibodies, which provide immediate protection if the antigen is
encountered again during a second infection.
Memory B cells are additionally long-lived; they do not secrete antibodies, but
express antibodies on the cell surface. When antigens are bound to these an-
tibodies during a second infection, memory cells can differentiate into plasma
cells. These plasma cells can mediate rapid responses of greater magnitude with
antibodies of higher affinity than those secreted during the primary infections.
Therefore, both long-lived plasma cells and memory cells are crucial to immunity
(Tarlinton and Lew 2007).
Activation of B cells through the BCR can also occur without T-helper cells.
Especially the binding of bacterial polysaccharides to IgM on the surface of
B cells can lead to the secretion of IgM and generation of memory B cells,
which have not gone through somatic hypermutations or isotype switching. The
immunity provided by these cells is based on high-avidity binding of the antigens.
In addition, the binding of several repeated epitopes can lead to cross-linking of
BCRs. This cross-linking leads the B cell to further differentiation and mediates
immunological memory (Weintraub 2003).
1.4 Antibody structure
A single antibody is formed by four polypeptide chains, two heavy (H) chains
and two light (L) chains. The H and L chains together form heterodimers which
interact to form a Y or T-shaped homodimer (Figure 1.1). The basic tertiary
structure of both H and L chains is the immunoglobulin domain, a sandwich of
β-sheets stabilized by disulfide bridges, which is also found in the T-cell receptor.
The L chains contain two immunoglobulin domains, and the H chains contain
four or more. The conformation between the H and L chains in the antibody
is stabilized by disulfide bridges, hydrophobic interactions and hydrogen bonds
(Paul 2003).
1.4.1 The variable antibody regions
Antibody domains are divided into variable (V) domains and constant (C)
domains. The V domains contain the complementarity determining regions
(CDRs), which are varied by the process of affinity maturation to bind epi-
topes. These CDRs are loop regions in the V immunoglobulin domains, which
define the overall shape of the epitope binding regions, called paratopes. A
monomeric antibody has two paratopes, each at the end of the two antibody
arms. Each paratope can be formed by residues of three CDR loops from the H
chain (H1-3) and three CDR loops from the L chain (L1-3) (see Figure 1.1).
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Figure 1.1: An example of an IgG antibody structure. A secreted mouse anti-
body (PDB code 1GTT)(Harris et al. 1997) is shown here. Light chains are highlighted
in yellow colors and heavy chains are highlighted in white and blue colors. Ellipses
indicate a single Ig domain (Ig), a Fab fragment (Fab) and the Fc fragment (Fc). Intra
chain disulfide bridges linking the heavy chains in the Fc fragment are shown in red.
Complementarity determining regions (CDRs) are colored in pink and indicated with
asterisks.
1.4.2 The constant antibody regions
As mentioned previously, isotype switching is caused by changes in expressions
of C domain genes. The isotype of secreted antibodies influence their properties
of multimerization: IgG, IgD and IgE are always in monomeric forms, while
IgM forms pentamers and more rarely hexamers, and IgA can form dimers in
addition to monomers. The isotype of the antibodies additionally mediates a
different localization of antibodies. IgG is the most prevalent type of Ig in
plasma. IgM is also found in plasma, while IgA is the major isotype of the
mucosa and IgE is more frequent in the skin (Paul 2003).
1.4.3 Fragments of antibodies
Antibodies can be cleaved enzymatically in a flexible hinge region of the heavy
chains, and this leads to different types of fragments. The Fab (fragment an-
tibody binding) consists of a single arm of the antibody, including both C and
V domains and binds antigens monovalently. The remaining fragment, the Fc
(fragment crystallizable) contains the rest of the C domains. Despite the nam-
ing of the Fc fragments, it is the Fab fragments that have played the primary
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role in crystallographic studies of antibodies, because they are used to study the
antibody-antigen interactions.
1.5 Antibody-antigen interactions
B-cell epitopes are defined by their binding of antibodies. Therefore, detailed
analysis of antibody paratopes can provide more insight in the characteristics
of epitope-antibody binding, and this knowledge is essential for a general un-
derstanding of B-cell epitopes, which can potentially be used for B-cell epitope
prediction or identification.
1.5.1 Paratope topography
A diversity in length of the CDRs contributes to different overall topographies
of the paratopes. It has been shown that paratope-binding haptens (which are
small organic molecules) often are concave or forming deep pockets, whereas
peptide-binding paratopes more frequently are either moderately concave or
forming grooves. Protein-binding paratopes are more likely either moderately
concave or planar (MacCallum et al. 1996; Collis et al. 2003). However,
paratope shapes against protein antigens are diverse. For instance, Saphire et
al. have shown that the human antibody IgG b12 paratope has a unusually
long, protruding CDR H3 loop (Saphire et al. 2001).
1.5.2 Amino acid composition
Sequence composition in paratopes from a number of X-ray crystallography
structures has been investigated by Collis et al. In general, it was shown that
amino acids tyrosine, tryptophan, isoleucine and serine are more abundant in
paratopes binding protein antigens than in a set of generic protein loops. Espe-
cially tyrosine and tryptophan are both capable of forming a variety of different
interactions with other amino acids because of their aromatic, hydrophobic, and
hydrophilic character. The amino acids glutamate, aspartate, lysine, cysteine
and proline had a lower abundance in protein binding paratopes, compared to
generic protein loops (Collis et al. 2003).
1.5.3 Binding forces
The binding of antibodies to antigens is mediated by a number of different forces.
Electrostatic forces play a role in salt bridges and hydrogen bonds between polar
and charged groups in the binding interface. These types of electrostatic inter-
actions are relatively long-ranged, whereas electrostatic van der Waals forces are
short-ranged. Van der Waals forces are also important for the packing of non-
polar, hydrophobic groups in the interface. In addition, hydrophobic forces can
stabilize the binding by exclusion of water molecules from the local environment
of hydrophobic groups (Lo Conte et al. 1999). However, water molecules in the
interface can also stabilize the binding by mediating hydrogen bonds between
the paratope and epitope (Cohen et al. 2005). Crystal structures of antibody-
antigen complexes have additionally shown that interfaces have a high degree of
shape-complementarity. This ensures a high degree of packing, which is similar
to protein interiors, and facilitates binding interactions (Lo Conte et al. 1999).
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1.5.4 Models of binding mechanisms
Conformational changes in antibody-antigen binding have been studied by a
number of groups; X-ray crystallography has been used to determine struc-
tures of antibodies and antigens in bound and unbound conformations. These
have shown that small conformational changes are not uncommon for antibod-
ies binding protein antigens. The mechanism for this type of binding has been
described as the “induced-fit” model (Wilson and Stanfield 1993; Stanfield et al.
2007). However, a more rigid binding has been described for antibodies binding
haptens, leading to the conclusion that the binding mechanism is closer to a
“lock-and-key” fit (Wedemayer et al. 1997).
1.6 B-cell epitopes
As described previously, antibodies can bind a variety of different types of mole-
cules including proteins, peptides, haptens, and polysaccharides. Often, a B-cell
epitope is characterized by the type of antigen it is derived from, and this can
be misleading. An antibody recognizes an entity composed of atoms with spe-
cific chemical features and spatial arrangement. For protein epitopes, this often
means that only part of the residues in the epitope are included in the antibody
binding entity (Van Regenmortel 1996). The entity may also be formed by
antigens of different nature. For instance, a peptide may be able to cross-react
with an antibody raised against a carbohydrate epitope (Lo Passo et al. 2007).
Such substances, which can mimic the natural epitopes, are called mimotopes.
However, because the main focus in this report is the identification of epitopes
in protein antigens, the term epitope in the following text will refer to residues
in proteinaceous B-cell epitopes.
1.6.1 Classification of B-cell epitopes
B-cell epitopes are classified into two different groups. The first group consists
of linear or continuous epitopes. A continuous epitope comprises a single, con-
secutive stretch of amino acids in the protein sequence, which is specifically
recognized by an antibody raised against the intact protein.
The second group is formed by conformational or discontinuous epitopes. These
are epitopes which are composed of residues separated in the protein sequence,
but in spatial proximity because of the protein fold. An example of a discon-
tinuous epitope is shown in Figure 1.2. The mouse antibody 184.1 binds on
the surface of the Borrelia burgdorferi outer surface protein A (OspA), and the
epitope is formed by several loops which are proximal in the folded protein (see
Figure 1.2A and B), but separated in the sequence. Together, the residues of
the discontinuous epitope form a more continuous surface which can interact
with the antibody (see Figure 1.2C)(Li et al. 1997).
However, the limit separating the two groups of B-cell epitopes is not completely
clear. A discontinuous epitope may consist of several linear epitopes, which to-
gether form the antibody interaction site. In addition, continuous epitopes may
contain residues which are not interacting with the antibody (Van Regenmortel
1996). Since the majority of antibodies raised against complete proteins does
not cross-react with peptide fragments, which are derived from the same protein,
it is thought that the most epitopes are discontinuous. It has been estimated
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Figure 1.2: An example of a discontinuous epitope. The structure of the Borrelia
burgdorferi outer surface protein A (OspA) in a complex with the mouse antibody
184.1 (PDB code 1OSP) (Li et al. 1997). The OspA protein is shown in yellow, the
Fab heavy chain is shown in blue and the Fab light chain in green. (A) The overall
structure of OspA and the Fab fragment. Note the different loops interacting with the
Fab fragment. (B) The Fab fragment surface and the OspA epitope residues shown as
sticks. (C) Surface representations of the Fab and the epitope.
that approximately 90% of B-cell epitopes in globular proteins are discontinuous
in nature (Thornton et al. 1986; Barlow et al. 1986).
1.6.2 B-cell epitope identification
Several different experimental methods can be used for B-cell epitope mapping
or identification, and most of them are useful for studies of protein-protein
interactions in general. Here is described a number of different experimental
methods, which are referred to or applied in the articles of this thesis.
Phage display
In phage display, a set of peptides (called a library) is expressed on the surface
of bacteriophages by using recombinant gene technology techniques. In B-cell
epitope identification experiments, phages are incubated with antibodies to se-
lect phages which express specifically binding peptides. These selected phages
are then amplified by infection of E.coli and subsequently sequenced to identify
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the binding peptides. Libraries expressed in phages can be a random set of
peptides or a genome fragment library; the latter can represent peptides from a
specific organism or protein of interest (Wang and Yu 2004). Phage display is
most commonly used for identifying linear epitopes, but discontinuous epitopes
have also been identified using this technique. The latter is a more complex
task, because an antibody directed against a discontinuous epitope may only
cross-bind peptides with sequences that are not found in the native protein.
Lately, a number of bioinformatic tools have been developed which can be used
to map identified cross-binding peptides to the three-dimensional (3D) antigen
structures (Enshell-Seijffers et al. 2003; Mumey et al. 2003; Schreiber et al.
2005; Moreau et al. 2006; Bublil et al. 2007; Castrignano et al. 2007). In
addition to epitope mapping, phage display technology can also be used for dis-
covering mimotopes and carbohydrate epitopes binding to antibodies of special
interest (Wang and Yu 2004; Untersmayr et al. 2006; Lo Passo et al. 2007;
Mayrose et al. 2007; Saphire et al. 2007).
Pepscan analysis
In pepscan analysis, a library of synthetic peptides is tested for antibody bind-
ing (Geysen et al. 1984). The peptides are often overlapping fragments of the
antigen of interest, but can also be libraries of random peptides (Slootstra et al.
1997). Synthetic peptides are immobilized on surfaces of pins or cards, for ex-
ample by inserting a cysteine residue in the middle of the peptide and using it for
covalent linking. Subsequently, enzyme linked immunosorbent assays (ELISAs)
are used to test the binding of antibodies to the individual peptides (Uthaip-
ibull et al. 2001; Hijnen et al. 2004). Similarly to phage display, the method
is mostly used for identifying linear epitopes, but can also be used for mapping
discontinuous epitopes and discovery of mimotopes (Timmerman et al. 2004).
In chapter 3 research results are described from a malaria vaccine project, where
pepscan analysis of 31-mer peptides was used. The peptides were overlapping
by 6 residues, and attached to a card by a covalent link to a cysteine inserted
in the middle of the peptide.
Site directed mutagenesis
Mutational studies of antigens have been shown to be useful for detailed epitope
mapping. A simple approach is alanine-scanning, where single amino acids are
replaced by alanine residues, and the effects on the antibody binding affinity
are measured (Tarr et al. 2006). Mutagenesis of a single amino acid in an
epitope can help to determine if the residue contributes to binding. More elegant
substitutions can also be used: for instance, the role of the positive charge in a
lysine residue can be investigated by replacement with isoleucine (Uthaipibull
et al. 2001). Isoleucine is similar in size and hydrophobicity, but lacks the
positive charge of lysine. Multiple amino acid substitutions can in this way lead
to profound insights into the type of binding interactions between epitope and
antibody.
X-ray crystallography
X-ray crystallography is a powerful tool for analysis of protein interactions in
general. It has been used for detailed epitope mapping in studies of a large
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variety of antigens (Fischmann et al. 1991; Chitarra et al. 1993; Fleury et al.
2000; Mirza et al. 2000; Igonet et al. 2007). Before the determination of pro-
tein structure, different techniques are used for proteins to form crystals. This
step can be a limiting factor because some proteins are less crystallizable than
others, and the optimal conditions for crystallization can be difficult to reach.
When suitable crystals are obtained, these are irradiated with X-rays and the
resulting diffraction pattern can be transformed into a 3D electron density map,
which can be used to build a model of the protein structure (Branden and Tooze
1998). For analysis of antibody-antigen interactions, X-ray crystallography is
typically used to determine the structure of the antigen in complex with a Fab
fragment. Crystal structures of antibody-antigen complexes result in high qual-
ity epitope mapping, because information about antibody-antigen interactions
is obtained on the atomic level, in contrast to many other methods which only
assign interactions to amino acid residues. The level of information allows for
in-depth analysis of the interactions, thus obtaining more knowledge of shape
complementarity, types of interactions, and water molecules in the interface.
Information about the antigen structure alone is also useful. The mapping of
experimental results on the structure can allow for further analysis and bring one
dimensional (1D) sequence-based results into a 3D context. For instance, the
bioinformatic tools for mapping mimotopes identified by phage display (men-
tioned in above) use the 3D structure of the antigen. Also, the mapping of
linear epitopes identified by pepscan analysis can help to identify discontinuous
epitopes in the native protein (Hijnen et al. 2004).
1.7 B-cell epitope vaccines and diagnostic tools
The main goal of research in B-cell epitopes is to develop vaccines or diag-
nostic tools. Historically, vaccines have been based on responses to the entire
pathogen. Killed or attenuated organisms have been used for the vaccines to
raise the immunity while avoiding hazardous effects. These strategies have been
effective in diminishing the occurrence of major diseases, such as smallpox and
polio. However, there are several drawbacks of these types of vaccines. In
general, the practical use of killed or attenuated pathogens can be affected by
problems caused by producing of pathogen in sufficient amounts, safety, and
genetic evolution of pathogens (Arnon and Ben-Yedidia 2003).
Today the field is moving more toward “rational vaccine design”. The basic idea
of this approach is to use knowledge about the pathogen, the immune responses
against the pathogen, and general host-pathogen interactions in order to design
more efficient vaccines. However, even the rational approach to vaccine design
is still heavily dependent on experimental trials, since it is hard to predict
the response of a new vaccine in complex systems such as the human body
(Van Regenmortel 2007). Some of the problems in rational vaccine design are
mentioned in sections 1.7.1 and 1.7.2. One general approach of modern vaccine
design is the use of more simple vaccine formulations containing non-infecting
subunits of the pathogen (Ellis 1999). Subunit vaccines have shown to be useful
for vaccination. For instance, virus-like particles (VLPs) are assembled of the
human papilloma virus (HPV) proteins L1 and L2 (see Figure 1.3), and the
VLPs are used for HPV vaccines preventing viral infection and lowering the risk
of genital cancer (Ljubojevic 2006). One of the advantages of this approach is
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Figure 3. Surface-shaded representations of CRPV (top row) and HPV-1 (bottom row) reconstructions viewed along
a 2-fold symmetry axis. The CRPV capsid has an ‘‘open’’ form and the HPV-1 has a ‘‘closed’’ form. a, Outside view
of virions. b, Inside view of capsids (back half). Chromatin cores were computationally removed from the virion density
map (radii < 46 nm for CRPV and < 42 nm for HPV-1). c, Closeup stereo views. In CRPV (top), elongated holes lie
on opposite sides of the 2-fold axis. Triangular holes on the 3-fold axes can be seen at the top and bottom center, just
behind the protruding point of the capsomere. In HPV-1 (bottom), there is a single, small hole on the 2-fold axis. Bars
represent: a,b, 50 nm; c, 10 nm.
the pentavalent capsomeres of CRPV are slightly
larger (011 nm) and those of HPV-1 are slightly
smaller (09 nm). The subunits are packed tightly in
the closed HPV-1 capsid, as Baker et al. (1991)
observed. In contrast, the open CRPV capsid ex-
hibits much looser packing, as indicated by the
presence of large holes on the 3-fold axes and also
near the 2-fold axes.
Papovavirus sequence alignments
We used the program GAP (Genetics Computer
Group, Madison, Wisconsin) to compare the L1 and
L2 sequences of BPV-1, CRPV, and HPV-1 (Table 4).
The L1 sequences are more highly conserved
compared to the L2 sequences. Pairwise compari-
sons showed that CRPV and HPV-1 sequences have
the highest identity and similarity. Danos et al.
(1984) observed a similar trend in L1 sequences.
Comparison of the three L1 sequences to SV40 VP1
and the three L2 sequences to SV40 VP2/VP3
clearly demonstrated far less sequence similarity
between the two papovavirus genera (Table 4). The
program PILEUP (Genetics Computer Group,
Madison, Wisconsin) was used to align L1
sequences of CRPV, deer papillomavirus, European
elk papillomavirus, canine oral papillomavirus,
multimammate rat papillomavirus, pygmy chim-
panzee papillomavirus type 1, 3 types of BPV, and
47 types of HPV (data not shown). All these
papillomaviruses showed significant sequence iden-
tities and similarities. An analogous alignment of 26
L2 sequences demonstrated less agreement in
comparison to the L1 alignment.
Discussion
Conserved features in papovaviruses
The CRPV capsid exhibits several features in
common with all other papovavirus capsids
(Table 1). It consists solely of pentameric capsomeres
as do the capsids of murine polyomavirus, SV40,
BPV-1, and HPV-1 (Table 1, column 2). Seventy-two
capsomeres are arranged on a T = 7 icosahedral
lattice, as was observed previously in CRPV and
also in murine polyomavirus, SV40, K virus, HPV-1,
BPV-1, and human wart virus (Table 1, column 1).
Our results show that the CRPV capsomeres are
arranged on a T = 7dextro skew lattice, just like
murine polyomavirus, SV40, BPV-1, HPV-1, and
human wart virus (Table 1, column 4). Therefore,
the T = 7d, 72-pentamer capsid appears to be
conserved in all papovaviruses.
Capsomeres in open and closed CRPV capsids
have the same star-shaped morphology. This
morphology is conserved among the papillo-
maviruses (Baker et al., 1991; Hagensee et al., 1994),
but is not found in the polyomaviruses.
Open and closed papillomavirus capsids
Papillomavirus capsids exist in open and closed
forms. The open capsid has several large holes and
Figure 1.3: A model of a virus-like particle (VLP). The structure of a VLP
formed by the human papilloma virus proteins L1 and L2. (A) Outside view of the
VLP. (B) Inside view of the back half of a VLP. The bar represents 50 nm. The VLP
structure was investigated by using cryo-electron microscopy (cryo-EM) (Hagensee
et al. 1994) and 3D modeled by Belnap et al. (Belnap et al. 1996).
that these new vaccines should be more safe and not lead o infections.
Another example of a recombinant subunit vaccine, which has been approved
for human use, is the hepatitis B virus (HBV) DNA vaccine (Keating and Noble
2003). This vaccine is based on the HBV surface antigen (HBsAg) and produced
in genetically modified yeast.
Recently, one of the major research-topics in rational vaccine design has been
human immunodeficiency virus (HIV) vaccines. A vaccine, which elicits neu-
tralizing antibodies and effectively protects against HIV infection, has shown to
be extremely difficult to develop, and multiple approaches using modern vac-
cine design technologies are still used in the pursuit of an HIV vaccine (Douek
et al. 2006). Other examples of major research projects are B cell-based vac-
cines against infection of malaria parasites. The RTS,S subunit vaccine has
been an outcome of these malaria research projects. RTS,S vaccine is based on
a fusion-protein of a polypeptide from Plasmodium falciparum circumsporozoite
protein and HBsAg (Heppner et al. 2005) and clinical trials of the vaccine have
been promisi g (reviewed by (Matuschew ki 2006)). However, even though the
number of technologies for vaccine design i growing, developing a vaccine is a
complex task that is still m stly based on labor-intensive experimental studies.
B-cell epitope-based diagnostic tools also constitute a major research topic. In
the diagnosis of infectious diseases, B-cell epitope binding assays can be used
to detect humoral responses against pathogen-specific epitopes (Hsueh et al.
2004; Hamby et al. 2005). In addition, B-cell epitopes have a potential for
diagnosis of autoimmune diseases (Selak et al. 2003; Mahler et al. 2003),
allergy (Eigenmann 2004) and cancer (Valmori et al. 2005). The development
of effective B-cell epitope-based diagnostic tools is not trivial, however, because
non-specific antibody cross-reactivity and reactivity resulting from exposure,
but not infection, can affect the rate of false positives.
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1.7.1 Vaccines based on linear epitopes or peptides
Peptides containing linear epitopes are considered to have a high potential for
vaccines. In addition to the advantages of subunit vaccines mentioned above,
peptides are easily synthesized, purified, stored and handled. However, it has
become clear that efficient peptide-based vaccines in general are complex to
develop.
Peptides in vaccines must be immunogenic, i.e. have the ability to elicit anti-
bodies which cross-react with the native protein and protect against infection or
pathogenesis. Studies testing peptide epitopes are based on cross-reactive anti-
genicity: the ability for a peptide to be recognized by an antibody raised against
a native protein. However, antigenic peptides are usually not very immunogenic
and there can be several reasons for this lack of immunogenicity: Most peptide-
based vaccines would rely on CD4+ T-helper cell initiated immune responses,
and the B-cell epitope itself may not contain an MHC class II epitope. This can
be solved by fusing the peptide with residues containing an efficient MHC class
II epitope (Sabhnani et al. 2003).
Another major problem is that the binding of antibodies to continuous epitopes
is conformation-dependent. A peptide in solution may have a broad variety of
structural conformations, and the conformations to which antibodies are devel-
oped may not be similar to the conformation in the native protein. To solve
this problem, conformationally restricted peptides have been tested; for instance
disulphide bridges or other covalent links have been introduced in peptides to
stabilize loop conformations (Cabezas et al. 2000; Sabo et al. 2007). Confor-
mational restriction of peptides can also help to circumvent another problem
of short peptides, which is fast degradation by peptidases in the human body
(Hans et al. 2006).
Another problem in peptide-based vaccines is that the humoral immune response
is more efficiently initiated when the epitopes are repeatedly presented on larger
antigens. To circumvent this problem, a number of different adjuvant and carrier
systems have been studied. For instance, VLPs are used in development of a
foot-and-mouth disease virus vaccine to present continuous epitopes in a manner
that facilitates an immune response (Zhang et al. 2007).
1.7.2 Vaccines based on discontinuous epitopes
Discontinuous epitopes are more difficult than linear to use in general vaccine de-
sign. Because the epitope is composed of different parts of the protein sequence,
it is more complex to conserve the native conformation of the epitope in a re-
combinant protein or a peptide. The majority of natural epitopes are thought
to be discontinuous as mentioned in section 1.6. Therefore, much effort is put
into the development of vaccines based on discontinuous epitopes. Mimotopes
are considered to have a high potential in vaccines by mimicking discontinuous
epitopes (Untersmayr et al. 2006; Saphire et al. 2007). Recombinant proteins
are also considered useful for presentation of discontinuous epitopes in vaccines.
Koide et al. successfully applied structure-based design for a lyme disease vac-
cine candidate; the authors removed approximately 45% of the residues from
the OspA and stabilized the engineered protein by promoting hydrophobic in-
teractions. The engineered protein presented discontinuous epitopes and had an
affinity to monoclonal antibodies similar to the full-length OspA protein (Koide
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Feature Year Reference
Hydrophilicity 1981 (Hopp and Woods 1981)
Hydrophilicity 1986 (Parker et al. 1986)
Hydrophobicity 1982 (Kyte and Doolittle 1982)
Antigenicity 1985 (Welling et al. 1985)
Accessibility 1976 (Chothia 1976)
Surface probability 1978 (Janin and Wodak 1978)
Surface accessibility 1985 (Emini et al. 1985)
Backbone flexibility 1985 (Karplus and Schulz 1985)
Secondary structure 1978 (Chou and Fasman 1978)
Secondary structure 1978 (Garnier et al. 1978)
Turn prediction 1993 (Pellequer et al. 1993)
Table 1.1: A variety of propensity scales used for B-cell epitope prediction
et al. 2005). Recently, Zhou et al. investigated the binding of the neutraliz-
ing antibody b12 to stabilized protein constructs derived from the HIV protein
gp120 (Zhou et al. 2007), and such constructs have been suggested to have high
potential for HIV vaccine design (Douek et al. 2006).
However, the use of engineered proteins also has disadvantages. Recombinant
proteins for vaccines must be stable and easily produced in sufficient amounts;
for some proteins this is a limiting factor. In addition, the engineered proteins
may contain new epitopes on the surface which could be immunodominant and
lead to unwanted immune responses.
1.8 B-cell epitope prediction
Antibodies have been studied for many decades, and much effort has been put
into the delineation of interactions between antibodies and epitopes. Even
though “immunological bioinformatics” is a rather new term, computational
analysis and prediction of B-cell epitopes have been major areas of research for
more than 20 years (Hopp and Woods 1983; Barlow et al. 1986; Thornton et al.
1986). As the entire field of biotechnology has expanded tremendously within
the last two decades, development of new methods have led to more insight into
the antibody-antigen interactions as well as larger amounts of data. This, in
turn, allows for development of new bioinformatic tools and databases (Korber
et al. 2006).
Prediction of B-cell epitopes has mostly been based on analysis of protein se-
quences. However, these predictions are mostly limited to linear epitopes, be-
cause the prediction of discontinuous epitopes is thought to require knowledge
of the antigen structure.
1.8.1 Amino acid propensity scales
Sequence-based epitope prediction methods typically use propensity scales for
calculation of a prediction score. Propensity scales are composed by values
which describe intrinsic features for each of the 20 amino acids. No single
physico-chemical feature has been definitively used for epitope prediction, but
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Figure 1.4: A propensity score plot of the sperm whale myoglobulin sequence
as provided by the Immune Epitope Database and Analysis source (IEDB)
(Peters et al. 2005). The Parker hydrophilicity scale and a smoothing window
size of 7 residues was used for calculation of scores shown in black. The red line
corresponds to prediction threshold value as used in the IEDB. Blue lines indicate
experimentally identified continuous myoglobulin epitopes, which were compiled in a
data set by Pellequer et al. (Pellequer et al. 1993).
atoms which interact with the paratope have to be surface exposed. In B-
cell epitope prediction, the most successful features have been hydrophilicity,
accessibility, flexibility or loop/turn structures. In general, the predictions of
the propensity scales correlate with features of surface exposure. In Table 1.1
is listed a number of the different propensity scales which have been used for
epitope prediction.
Propensity scales are often used in combination with smoothing procedures. The
simplest type of smoothing is based on the sliding of a window through the pro-
tein sequence and averaging the propensities of the residues within the window.
The mean value of the window is then assigned to the residue in the middle of
the window. This simple type of smoothing has been used frequently for B-cell
epitope prediction, but more sophisticated methods using a weighted average,
or a Gaussian smoothing curve have also been applied (Pellequer et al. 1991).
The smoothing results in a scoring profile, where the high-scoring regions are
predicted to be antigenic. An example of a propensity scoring profile is shown
in Figure 1.4. Several tools for antigenicity prediction using combinations of
propensity scales have been developed (Jameson and Wolf 1988; Kolaskar and
Tongaonkar 1990; Maksyutov and Zagrebelnaya 1993; Pellequer and Westhof
1993; Alix 1999). However, the most extensive sequence-based study, involv-
ing 484 different propensity scale methods on a new data set of 50 proteins,
concluded that most propensity scales perform close to random and the use of
more sophisticated machine learning methods such as artificial neural networks
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(ANNs) was proposed (Blythe and Flower 2005).
1.8.2 New methods for prediction of continuous epitopes
In 2006, three different approaches using advanced machine learning methods
were published: Saha et al. proposed a prediction method based on recurrent
ANNs trained on data set of 700 continuous epitopes from the Bcipep data-
base (Saha and Raghava 2006; Saha et al. 2005). Larsen et al. published the
Bepipred method (Larsen et al. 2006) based on predictions of a hidden Markow
model (HMM) in combination with the Parker hydrophilicity scale (Parker et al.
1986). The method was trained on continuous epitopes of 127 proteins from the
AntiJen database (Toseland et al. 2005). Finally, Sollner et al. published a clas-
sification algorithm based on the combinations of propensities with sequential
residue neighborhood parameters (Sollner and Mayer 2006). The classification
algorithm was based on decision trees and nearest neighbor approaches, and
was trained on publicly available data sets from Bcipep and FIMM (Saha and
Raghava 2006; Schonbach et al. 2002) and a large amount of proprietary data.
In total 1211 epitopes and 1211 nonepitope sequences were used for training,
and the performance was shown to be greatly increased compared to single
propensity scale methods (Sollner and Mayer 2006). Although the performance
of these new methods is improved compared to the more simple propensity scale
methods, accurate prediction of continuous epitopes remains a challenge in the
field of immunological bioinformatics.
1.8.3 Prediction of B-cell epitopes based on protein struc-
ture
Protein 3D structures have also been used in the prediction of B-cell epitopes.
Particularly, the prediction of discontinuous epitopes is thought to require this
information. The first prediction methods based on protein structure were pub-
lished in 1986 by Thornton et al. and Novotny et al. (Thornton et al. 1986;
Novotny et al. 1986).
Early structure-based methods
The method proposed by Novotny et al. was based on the contacts of a large
sphere (called a probe) on the Van der Waals surface of the protein. A similar
method is used for calculating solvent accessible areas; here a 1.4 Å probe size,
corresponding to the van der Waals radius of a water molecule, is used in a
method first reported by Lee et al. (Lee and Richards 1971). Novotny et al.
found a probe size of 10 Å radius to correlate well with antigenic epitopes in
hen-egg-white lysozyme, sperm whale myoglobulin, cytochrome c and myohem-
erythrin. It was additionally observed that the contacting residues of the large
probe also had high solvent accessibility scores, as determined by using a probe
size of 1.4 Å.
Thornton et al. used ellipsoids with the same inertia moment as the protein
structure in order to model the overall shape of the protein. The sizes of the
ellipsoids were varied and chosen so that for protrusion index 9 (PI 9), 90% of
the atoms in the structure were inside the ellipsoid. The rest of the atoms (10%)
were protruding from (sticking out of) the structure. In general, it was found
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that antigenic peptides tend to protrude from the structures of the proteins
lysozyme, myoglobulin and myohemerythrin. In addition, it was found that
protruding residues had a tendency to be more flexible and accessible.
Recent structure-based methods
After the publication of studies by Novotny et al. and Thornton et al., only
little was reported of epitope prediction on the basis of protein structure. How-
ever, the number of available structures of both antigens and antibody-antigens
increased, and new approaches have recently been used for this type of epitope
prediction. In chapter 2, the DiscoTope method is presented. It was pub-
lished in 2006, and developed based on discontinuous epitopes in 76 structures
of antibody-antigen complexes. Other methods using protein structures have
been published recently as well. Some of these are mention below.
The server for Conformational Epitope Prediction (CEP) (Kulkarni-Kale et al.
2005) is based on the calculation of the relative surface accessibility (RSA).
Sequence fragments of surface-exposed residues are identified and condensed
with other proximal exposed fragments in the structure, this defines regions on
the 3D surface which are exposed and possibly act as antigenic regions.
The Epitope Mapping Tool (EMT) (Batori et al. 2006) is based on a sequence
library of epitopes in different proteins identified by phage display. In the pre-
diction method, the antigen structure is searched to find surface exposed regions
containing motifs of the library.
Rapberger et al. recently published a study of antigen-antibody interaction-site
prediction (Rapberger et al. 2007). Their method uses surface accessibility mea-
sured with a probe radius of 3Å, inspired by the results published by Novotny et
al. (Novotny et al. 1986). Additionally, the shape complementarity to paratopes
and interaction energies are included to identify residues with high probability
of being part of discontinuous epitopes. Similarly to the DiscoTope method,
the work was based on discontinuous epitopes derived from PDB structures of
antibody-antigen complexes. The method was tested using structures of free
antigens in unbound conformations. It was shown to have a moderate perfor-
mance and captured 3 of 8 residues in the 1F9 epitope of the apical membrane
antigen 1 (AMA1) of P. falciparum, which were identified by using phage display
(Coley et al. 2006).
As mentioned in section 1.6.2, a number of tools have been developed to facilitate
the mapping of epitopes on protein structures by using mimotopes. The methods
analyze the protein 3D structure to find regions which can be mimicked by
peptides.
In general, the increased number of publicly available methods for B-cell epi-
tope prediction shows that even though the performances are still quite low,
when compared to MHC class I epitope prediction, there is much optimism
among researchers in the field. Many research groups are continuously working
on improving methods, building databases, and evaluating the various methods
(Greenbaum et al. 2007). Thus, the field of B-cell epitope prediction is expected
to lead to further improved methods, which can aid experimental epitope map-
ping and vaccine design.
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Chapter2
DiscoTope, a prediction
method for B-cell epitopes
This chapter describes a new method for prediction of B-cell epitopes based on
protein 3D structures. The chapter is initiated by introductions to the methods
used in the presented paper. Following the introduction, my work is presented
in the paper “Prediction of residues in discontinuous B-cell epitopes based on
protein 3D structures”.
2.1 Performance measures
The concept of receiver operator characteristic (ROC) curves (Swets 1988) is
widely used to measure the performance of bioinformatic tools. A strength
of this method for evaluations of performances, is that the success rate for
finding the feature that is predicted for is taken into account, at the same time
accounting for the rates of non-successful predictions.
For general evaluation, and in calculation of ROC curves of epitope prediction
methods, the following six defined measures are used (Lund et al. 2005):
• True Positives TP is the number of residues that are predicted to be part
of epitopes and which are annotated as epitope residues in the data set.
• Actual positives AP , is the number of residues annotated epitopes in the
data set.
• True negatives TN , is the number of residues predicted to be non-epitopes
and which are annotated as non-epitopes in the data set.
• Actual negatives AN , is the number of residues in the data set which are
annotated as non-epitopes.
• Sensitivity is the fraction of actual positives which are correctly predicted.
It is defined as follows:
Sensitivity =
TP
AP
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Figure 2.1: An example of ROC curves for three different methods. The
areas under the curves (AUC) are noted in the legends. Based on the AUC values, the
method 1 has the highest performance, method 2 has the second highest performance,
and method 3 performs randomly. Note that the curves for method 1 and 2 are over-
lapping for sensitivity values >0.8. If only the thresholds corresponding to sensitivity
values >0.8 were used for comparing method 1 and 2, only a very minor difference in
performance would be observed.
• Specificity is the fraction of actual negatives which are correctly pre-
dicted:
Specificity =
TN
AN
For many prediction methods, the prediction outcome is a prediction score per
residue. A threshold is then used to distinguish predicted positives from pre-
dicted negatives. However, depending on the value of the threshold, the values
of sensitivity and specificity change. ROC curves are constructed by plotting
the Sensitivity as a function of 1 − specificity calculated with varied thresh-
olds (see Figure 2.1). The area under the curve (AUC) is used to evaluate the
overall performance of the methods. This has the advantage that methods are
compared on a more general basis than if only a single threshold is used for each
method. For a method predicting randomly, the AUC is 0.5, while the perfect
prediction method has an AUC of 1.
2.2 Measuring surface exposure
2.2.1 Contact numbers
Several methods can be used for measuring the surface exposure in protein
structures. A simple approach is based on the contact number of each residue
(Nishikawa and Ooi 1980). The contact number for a residue can be calculated
by summing the number of Cα atoms in other residues within a specific distance
from the Cα atom of the residue. The number of contacts correlates with surface
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A B
Figure 2.2: Contacts numbers correlate with surface exposure and structural
protrusion. The surface of a protein is marked here with a green line. Cα atoms in
the protein are shown in dots. Blue dots denote other residues and red dots denote
the residue for which contacts are counted. The area defined by a specific distance
threshold is shown as a black circle, and only residues with Cα atoms within the circle
are counted as contacts. (A) Contacts for a residue located close to the surface in
a protein structure, (B) Contacts for a residue located in the interior of a protein
structure.
exposure and structural protrusion, because residues with Cα atoms close to the
surface and in protruding areas have a low number of contacts (see Figure 2.2.)
2.2.2 NACCESS surface exposure
The surface exposure of residues in a protein is frequently measured by using
a method proposed by Lee and Richards (Lee and Richards 1971). In this ap-
proach, the area which is accessible for interaction with the solvent is calculated
for each residue. The program NACCESS (Hubbard and Thornton 1993) al-
lows for application of the method on protein structures. The accessible area
is calculated by using van der Waals radii of the atoms on the protein surface
and a probe of 1.4 Å, which is equal to the van der Waals radius of a water
molecule. Values of relative solvent accessibility (RSA) for residues are often
used to reflect the solvent accessibility. The RSA is calculated as follows:
RSA = 100%× SAmeasured
SAref,x
where the SAmeasured is the measured solvent accessible area of a particular
residue. SAref,x is the reference solvent accessible area for the specific amino
acid type X. The reference area is the solvent accessible area in a tripeptide
G-X-G, where the amino acid X is surrounded by the small amino acid glycine
(G) and therefore assumed to have maximum solvent accessibility.
2.3 Amino acid log-odds ratios
In prediction methods for protein sequences, log-odds ratios are often used to
reflect the probability that a given amino acid has the predicted property. For
example, log-odds ratios can be calculated for each amino acid to reflect how
likely for it to be part of a B-cell epitope. The probability of finding a given
type of amino acid in an epitope of a data set can be described as:
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paa =
naa
n
where paa is the probability for the amino acid, naa is the number of times the
amino acid is observed in epitopes of the data set, and n is the total number
amino acids in the data set. Because amino acids have different background fre-
quencies, qaa, the probabilities are often divided by the background frequencies
observed in a large database such as SwissProt (Bairoch and Apweiler 2000).
The resulting ratio is called the odds ratio.
The logarithm to the ratio is often used for practical reasons, so the final log-
odds ratio is calculated as:
L = logk
(
paa
qaa
)
where logk is the logarithm with base k. The epitope log-odds ratios presented
in the following paper are based on half-bit units using log2. In this example,
a high score indicates that the amino acid is more frequently observed in B-cell
epitopes than in the SwissProt database.
If a data set contains many similar examples for training, the log-odds ratios can
easily be biased toward the redundant examples. To avoid this problem, several
refinement techniques can be applied (Lund et al. 2005). For instance, sequence
weighting can be used; first the similar sequences are clustered, then weights
are assigned for each sequence to down-regulate the influence of highly similar
sequences. For data sets of limited size, pseudo-count correction is helpful for
types of amino acids which are observed rarely, or not at all. The strength of
this technique is that the frequency of rarely observed amino acids are adjusted
by using the frequencies of similar amino acids in the data set. The BLOSUM62
substitution matrix is widely used as a similarity measure (Nielsen et al. 2004).
In the paper presented in this chapter, log-odds ratios are calculated for both
epitope residues and non-epitope residues and then subtracted to get the final
epitope log-odds ratios:
Le−ne = Le − Lne
where Le is the log-odds ratio of a given amino acid type derived from epitope
residues, Le−ne is the log-odds ratio of a given amino acid type derived from
non-epitope residues and Le−ne is the final epitope log-odds ratio for the given
amino acid type.
2.4 Contributions to the paper
The following scientific paper was written in collaboration with Morten Nielsen
and Ole Lund. My part of the work included compilation and analysis of the
data set, development and evaluation of the method, set-up of the web-server,
producing all figures and writing the manuscript.
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Abstract
Discovery of discontinuous B-cell epitopes is a major challenge in vaccine de-
sign. Previous epitope prediction methods have mostly been based on protein
sequences and are not very effective. Here we present DiscoTope, a novel method
for discontinuous epitope prediction which uses protein three dimensional struc-
tural data. The method is based on amino acid statistics, spatial information
and surface accessibility in a compiled data set of discontinuous epitopes deter-
mined by X-ray crystallography of antibody/antigen protein complexes. Disco-
Tope is the first method to focus explicitly on discontinuous epitopes. We show
that the new structure based method has a better performance for predicting
residues of discontinuous epitopes than methods based solely on sequence in-
formation and that it can successfully predict epitope residues which have been
identified by different techniques. DiscoTope detects 15.5% of residues located
in discontinuous epitopes with a specificity of 95%. At this level of specificity,
the conventional Parker hydrophilicity scale for predicting linear B-cell epitopes
identifies only 11.0% of residues located in discontinuous epitopes. Predictions
by the DiscoTope method can guide experimental epitope mapping in both ra-
tional vaccine design and development of diagnostic tools and may lead to more
efficient epitope identification.
Keywords: Discontinuous epitopes; B-cell epitope; antibody; vaccine design;
protein structure; antigen; accessibility; hydrophilicity
Introduction
A major task in vaccine design is to select and design proteins containing an-
tibody binding epitopes (B-cell epitopes) able to induce an efficient immune
response. The selection can be aided by epitope prediction in relevant proteins
or regions of proteins. In addition, prediction of B-cell epitopes may help to iden-
tify epitopes in proteins that have been analysed using experimental techniques
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based on antibody affinity binding e.g. western blotting, immunohistochemistry,
radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA).
Most existing methods for prediction of B-cell epitopes exclusively use protein
sequences as input and are best suited to predict epitopes composed of a continu-
ous stretch of amino acids (linear epitopes) (Hopp and Woods 1981; Parker et al.
1986; Jameson and Wolf 1988; Debelle et al. 1992; Maksyutov and Zagrebelnaya
1993; Alix 1999; Odorico and Pellequer 2003). In general, these methods are
based on prediction of hydrophilicity, flexibility, beta-turns and surface accessi-
bility using a number of amino acid propensity scales. A large amount of data
exists on linear epitopes (Leitner et al. 2003; Saha et al. 2005; Toseland et al.
2005), since the annotation can be done by measuring the binding of antigen
peptide fragments to antibodies. However, this method of annotation may lead
to annotation errors, because a peptide can specifically bind an antibody even if
some residues of the peptide are not interacting with the antibody. Predicting
linear epitopes is still a non-trivial task and the obtainable prediction accuracy
is quite poor (Van Regenmortel and Pellequer 1994; Van Regenmortel 1996;
Blythe and Flower 2005). However, combination of a hidden Markow model
and a hydrophilicity scale constructed by Parker et al. (Parker et al. 1986) has
recently lead to some improvement in linear B-cell epitope prediction (Larsen
et al. 2006).
It has been estimated that more than 90% of B-cell epitopes are discontinuous,
i.e., consist of segments which are distantly separated in the pathogen pro-
tein sequence and brought into proximity by the folding of the protein (Barlow
et al. 1986; Van Regenmortel 1996). Identification of discontinuous epitopes is
difficult, since the complete analysis must be done in context of the native anti-
gen structure. The most informative and accurate method for identification of
discontinuous epitopes is determination of structures of antigen-antibody com-
plexes by X-ray crystallography (Fleury et al. 2000; Mirza et al. 2000). The
use of discontinuous epitopes derived from presently available X-ray structures
is complicated by two major problems: First, the available data on discontinu-
ous epitopes in different antigens is much reduced compared to linear epitopes.
Second, very few antigens have been studied to completely identify various dis-
continuous epitopes in the same antigen. The existence of undetected epitopes
which are not identified in the data set can make it harder to develop good pre-
diction algorithms because they influence on the measured performance. How-
ever, detailed structural knowledge on antibody-antigen complexes is growing
and allows for broader analysis of discontinuous epitopes in various antigens and
development of better prediction methods.
Correlation between surface exposure and B-cell epitopes has been known for
many years (Novotny et al. 1986; Thornton et al. 1986). Recently, two new
methods using protein structure and surface exposure for prediction of B-cell
epitopes have been published (Batori et al. 2006; Kulkarni-Kale et al. 2005).
However, none of these new methods using protein structure as input have the
primary focus on discontinuous epitopes.
Here we present a prediction method for residues located in discontinuous B-cell
epitopes. DiscoTope uses a combination of amino acid statistics, spatial infor-
mation and surface exposure. It is trained on a compiled data set of discontin-
uous epitopes from 76 X-ray structures of antibody/antigen protein complexes.
We present the performance of DiscoTope compared to the Parker hydrophilicity
scale (Parker et al. 1986) for a comparison to a classical, sequence based method
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Figure 2.3: Analysis of the complete dataset of discontinuous B-cell epitopes.
Analysis of the complete dataset of discontinuous B-cell epitopes. (A) Distribution of
the number of residues pr. epitope. (B) Distribution of the number of residues pr.
sequential stretch of epitopes. (C) Distribution of the maximum length of a sequential
stretch pr. epitope.
which has been shown recently to perform well for prediction of linear epitopes
(Larsen et al. 2006). In addition, we compare the performance with predictions
based on surface accessibility measured on antigen structures using the program
NACCESS (Hubbard and Thornton 1993). We demonstrate that DiscoTope is
generally the best performing of all methods described here. Finally we present
the delineation of epitopes in the malaria protein apical membrane antigen 1
(AMA1) where DiscoTope successfully predicts epitope residues that have been
identified using either various experimental or sequence analysis techniques.
Results
Properties of discontinuous B-cell epitopes
In order to get a well-established basis for development and evaluation of the
prediction method, we compiled a discontinuous epitope data set from 76 X-ray
structures of complexes between antibodies and protein antigens. We analyzed
the data set to find distributions for the number of residues per epitope, the
number of residues per sequential stretch in epitopes, and the longest sequential
stretch per epitope. These distributions are shown in Figure 2.3. The total
number of residues per epitope was ranging from 9-22 and more than 60% of
the epitopes consisted of 14-19 residues (Figure 2.3a). Segments with a single
epitope residue represented more than 45% of the 528 segments in the data set
(Figure 2.3b). The longest sequential stretch of identified residues per epitope
was ranging between 3-12 residues and more than 75% of epitopes comprised
a sequential stretch of a maximum length of 4-7 residues (Figure 2.3c). These
findings confirm that most epitopes in the data set are indeed discontinuous and
composed by small parts of the antigen sequence forming a binding region for
the antibody.
The data set was analyzed with respect to surface exposure by determining the
number of intra-molecular Cα atom contacts for each residue (Figure 2.4). A low
contact number correlates with localization close to the surface or in protruding
regions of antigen structures. A t-test showed that residues identified as part of
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Figure 2.4: Contact numbers of epitope residues in the dataset compared
to non-epitope residues. The curves show the distribution of contact numbers
for epitope residues (red curve) compared to non-epitope residues (black curve). The
vertical lines represent the mean value of contact numbers for the epitope residues (red
line) and for the non-epitope residues (black line).
epitopes in the data set had significantly lower numbers of contacts compared
to the non-epitope residues (P < 10-5). The average number of contacts and
standard error of mean for epitope residues was 15.7±0.12 and for non-epitope
residues the average contact number and standard error of mean was 19.2±0.05
(see Figure 2.4, vertical lines). The finding that epitopes are in exposed or
protruding regions is in agreement with previous analysis of B-cell epitopes
(Novotny et al. 1986; Thornton et al. 1986). As shown in Figure 2.4, the two
distributions are overlapping. This is most probably caused by the incomplete
annotation of the data set or because other factors than contact numbers are
important in defining an epitope.
For the development and evaluation of prediction methods, the 76 antigens in
the data set were grouped into 25 non-homologous groups (see Materials and
Methods for more details). From these 25 groups, 5 sets (of 5 groups each) were
constructed and used for 5 fold cross-validated training and evaluation to avoid
optimizing and evaluating on similar antigens.
Log-odds ratios calculated from the epitope data set
We analyzed the statistics of amino acids in epitopes and non-epitopes of the
data set by calculation of log-odds ratios from peptides of the data set. A
peptide-based approach of similarity reduction was chosen to avoid skewing log-
odds ratios toward highly redundant epitopes in the data set. Peptides with
high similarity in the data set were weighted lower than peptides with low
similarity and therefore the length of the peptides played an important role
in the derivation of log-odds ratios. We used raw log-odds ratios as epitope
propensities for prediction of epitopes in the training sets and found a peptide
length of 9 residues to be optimal.
Table 2.1 shows epitope log-odds ratios calculated from homology-reduced pep-
tides of the total data set of 76 proteins. Of the 20 amino acids, asparagines (N),
arginine (R), proline (P) and lysine (K) had the highest log-odds ratios, mean-
ing that they are over-represented in epitopes compared to non-epitopes of the
data set. Cysteine (C), alanine (A), leucine (L), valine (V) and phenylalanine
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Amino acid∗ Parker Log-odds ratios
D 2.460 0.691
E 1.860 0.346
N 1.640 1.242
S 1.500 -0.145
Q 1.370 1.082
G 1.280 0.189
K 1.260 1.136
T 1.150 -0.233
R 0.870 1.180
P 0.300 1.164
H 0.300 1.098
C 0.110 -3.519
A 0.030 -1.522
Y -0.780 0.030
V -1.270 -1.474
M -1.410 0.273
I -2.450 -0.713
F -2.780 -1.147
L -2.870 -1.836
W -3.000 -0.064
∗Amino acids are listed with descending hy-
drophilicity using the values of the Parker scale.
Table 2.1: The Parker hydrophilicity scale and epitope log-odds ratios
(F) had very low log-odds ratios and are correspondingly under-represented in
epitopes. Interestingly, we found several discrepancies between the Parker hy-
drophilicity scale and the log-odds ratios (Table 2.1). For example, the most
hydrophobic residue, tryptophan (W) did not have a particularly low log-odds
ratio. The most hydrophilic residues, aspartate (D) and glutamate (E) had
relatively moderate log-odds ratios. Arginine (R) and proline (P) had some of
the highest log-odds ratios but are ranked close to the middle of the Parker hy-
drophilicity scale. Cysteine (C) and alanine (A) are ranked close to the middle
of the Parker scale but had some of the lowest log-odds ratios.
Evaluation of uncombined methods for B-cell epitope prediction
To test the predictive strength of contact numbers and the epitope propensity
scale of log-odds ratios on discontinuous epitopes, we used the area under re-
ceiver operator curves (AUC) averages over different evaluation sets (see details
in Materials and Methods). We additionally tested a sequential average of log-
odds ratios as prediction score similar to the approach recommended for the
hydrophilicity scale by Parker et al. (Parker et al. 1986). The optimal win-
dow size for sequential averaging of log-odds ratios was found to be 9 residues
based on the predictive performance on the training sets (data not shown). We
found that the epitope log-odds ratios used with sequential averaging performed
better than the sequentially averaged Parker hydrophilicity scale on the discon-
tinuous epitopes (Figure 2.5a). The raw epitope log-odds propensity scale gave
an average performance of 0.604 on the evaluation sets. Smoothing of the log-
odds ratios using a sequential average of 9 residues improved the performance
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Figure 2.5: Evaluation of B-cell epitope prediction methods. The average AUC
of various methods on the 5 evaluation sets. Log e-ne denote raw log-odds ratios,
Parker denotes the Parker hydrophilicity scale, Win9 log e-ne denotes the log-odds
ratios used with a smoothing window of 9 residues, Contact denotes contact numbers
and Naccess denotes NACCESS RSA values. (A) The performance of single methods.
(B) The performance of simple combination methods using contact numbers. (C) The
performance of simple combination methods using NACCESS RSA values. (D) The
performance of the structural proximity sum methods.
to 0.636. The Parker scale was used with a smoothing window of 7 residues and
had a performance of 0.614. Compared to the methods based on propensity
scales, the methods based on contact numbers and NACCESS relative surface
area (RSA) values had considerably higher performances of 0.647 and 0.673 re-
spectively (Figure 2.5a).
Combination methods for epitope prediction
We additionally tested the prediction of epitope residues using surface localiza-
tion values based on contact numbers or NACCESS RSAs in combination with
Sequential average Structural proximity sum
Win 9 Win 9
Log-odds log-odds Parker Log-odds log-odds Parker
Contacts 1.5 0.25 1.75 -1.5 -0.5 -1.5
NACCESS 2.0 0.25 1.75
Win 9 denotes epitope log-odds ratios smoothed by a window of 9 sequential
residues
Table 2.2: Optimal weights on surface localization scores for combination
methods
2.5 Paper I 27
epitope log-odds ratios or the Parker hydrophilicity scale. One combination ap-
proach was to use a sum of weighted prediction scores from surface localization
measures and methods based on sequential information (log-odds ratios or hy-
drophilicity scores). A second approach was tested by summing log-odds ratios,
sequentially averaged log-odds ratios or Parker scale scores of residues in spa-
tial proximity and adding the contact numbers to give a prediction score. For
each combination, we estimated the relative weight on the surface localization
score by optimizing the predictive performance on the training sets measured
in average AUC. The optimized weights are listed in Table 2.2.
The predictive performances of the combination methods were tested by calcu-
lating the average AUC from predictions on the evaluation data sets (Figure
2.5b, c, d). Simple linear combinations of the Parker scale, raw log-odds ratios
and smoothed log-odds ratios with structure based methods (contact numbers
and NACCESS RSA values) in general improved the performance (Figure 2.5b,
c). Combination methods using raw log-odds ratios had a performance of 0.665
for the combinations with contact numbers and 0.676 for the combination with
NACCESS RSA values. The linear combinations with the Parker method had
performances of 0.674 for the contact number combination and 0.685 for the
NACCESS RSA combination. Using a combination of smoothed log-odds ra-
tios combined with contact numbers yielded a performance of 0.682. The best
performing method of the simple linear combinations was the combination of
smoothed log-odds ratios with NACCESS RSAs. This method had a perfor-
mance of 0.691 on the evaluation sets.
Methods based on a combination of structural proximity sums of propensity
scales with contact numbers gave the best performances on the evaluation sets
(Figure 2.5d). The performance of the structural proximity sum method based
on Parker predictive values combined with contact numbers had a performance
of 0.692. The corresponding structural proximity sum method using raw log-
odds ratios had a performance of 0.695. The best performing method on the
evaluation data sets was the structural proximity sum of sequentially smoothed
epitope log-odds ratios combined with contact numbers. This method was
shown to have a performance of 0.711, which is significantly better than the
method based on structural averaging using raw log-odds ratios (P = 0.040).
The method is also significantly better than the Parker method (P = 0.007) and
marginally better than the NACCESS RSA method (P = 0.105). We call this
method DiscoTope.
Analysis of the DiscoTope method for discontinuous B-cell epitope
prediction
We decided to further analyze the Parker hydrophilicity, NACCESS RSA and
DiscoTope predictions to get a more detailed comparison of the performances
of the methods. A comparison of the sensitivity of the three methods was done
based on a number of selected specificities (Table 2.3). In Table 2.3, we have
additionally listed prediction threshold values to facilitate general use of all three
methods for B-cell epitope prediction. For all five specificity levels, DiscoTope
had the highest sensitivity of the three methods. At a level of 95% specificity
(which means only 5% false positive predictions) DiscoTope detected 15% of
the epitopes. The Parker method had higher sensitivity than the NACCESS
RSA method for the 95% and 90% specificity levels. This is in contrast to the
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DiscoTope NACCESS RSA Parker
Specificity Sensitivity T∗ Sensitivity T∗ Sensitivity T∗
95% 15.5% -3.1 8.7% 88% 11.0% 1.07
90% 24,2% -4.7 18.9% 74% 19.6% 0.88
85% 32,3% -6.0 27,2% 67% 27.1% 0.74
80% 40,2% -6.9 37.3% 60% 36.0% 0.60
75% 47,3% -7.7 44.1% 55% 39.8% 0.50
∗ Residues with a prediction value above the thresholds (T) were pre-
dicted as parts of epitopes.
Table 2.3: Sensitivity of methods corresponding to a number of selected
specificity levels
Figure 2.6: Dot plots showing comparisons of performances of the Parker
method, the NACCESS RSA method and the DiscoTope method. Circles
indicate average AUC per group showed for the 25 groups of different antigens. The
dotted lines indicate points where the methods perform equally.
averaged AUC value on the 5 evaluation sets, which was found to be higher for
the NACCESS method than for the Parker method (Figure 2.5a).
In order to analyze the performances of the three methods on different groups of
antigens, we compared prediction AUC values for each of the 25 non-homologous
antigen groups (Figure 2.6). For the majority of the groups of antigens in the
data set, the DiscoTope method had a better performance than the Parker
method (Figure 2.6a). However, in 8 groups of antigens the epitope residues were
more accurately predicted using the Parker method. The same tendency was
observed for the NACCESS RSA method, where the Parker method performed
best for 12 groups (Figure 2.6b). Comparison of the DiscoTope and NACCESS
RSA methods showed that, even though the average AUC value for the 25 groups
was highest for the DiscoTope method, the NACCESS RSA method performed
best for 10 of the antigen groups (Figure 2.6c). We found that the DiscoTope
and the NACCESS RSA methods had 6 groups in common for which the Parker
method performed best. These groups were represented by the PDB antigen
entries 1JPS, 2JEL, 1TQB, 1AR1, 1OAZ, 1EO8. The fact that both surface
accessibility based methods had lower performance than the Parker scale method
suggests that the measured surface accessibility for single antigen chains is not
sufficient for epitope prediction in all types of antigens. Three of the six groups
(represented by antigens 1JPS, 1AR1 and 1EO8) contained antigens which have
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Figure 2.7: Structure of the 1AR1 antigen. The antigen is a subunit of the
cytochrome c oxidase (Ostermeier et al. 1997). (A) The 30% of residues with lowest
contact numbers are shown in green. In red is shown a residue which is part of the
30% with lowest contact numbers and of the epitope from the data set. The rest of the
epitope is shown in blue. (B) The structure mentioned above and rotated 90 degrees.
(C) The complex of the cytochrome c oxidase with antibody fragments. The 1AR1
antigen is color coded as in (A) and (B). Antibody fragments are shown in light blue.
The other subunit of the cytochrome c oxidase is shown in yellow. Membrane spanning
helices of the 1AR1 antigen are part of the lower half of the structure.
elongated structures. Furthermore, antigens of 1JPS, 1AR1 and 1EO8 are all
known as subunits of larger biological complexes associated with membranes
(Ostermeier et al. 1997; Fleury et al. 2000; Faelber et al. 2001). Perhaps not
surprising, the single antigen chain approach taken by the DiscoTope method
clearly could not correctly measure the surface accessibility of all residues in
such proteins. In Figure 2.7 is shown the structure of the antigen of 1AR1 as an
example. On the plot, most of the residues in the antigen that had the lowest
contact numbers are not in proximity of the epitope (Figure 2.7a and b). In
fact, only one residue of the epitope was among the 30% residues in the antigen
with lowest contact numbers. The antigen of 1AR1 is a subunit of a membrane
spanning cytocrome c oxidase (Figure 2.7c) and the largest continuous region of
residues with low contact numbers corresponds to a region of the protein which
is described as membrane-spanning (Ostermeier et al. 1997).
Prediction of B-cell epitope residues in Apical Membrane antigen 1
To evaluate our method on B-cell epitopes, which are mapped using other types
of methods than X-ray crystallography, we tested the predictions of DiscoTope
on the structure of the ectodomain from AMA1 (Bai et al. 2005; Pizarro et al.
2005). No AMA1 epitopes are included in the data set of discontinuous epitopes
derived from the PDB. However, two separate epitopes recognized by mono-
clonal antibodies Mab1F9 and Mab4G2 have been experimentally mapped on
the AMA1 ectodomain: The Mab1F9 epitope was mapped using phage-display
of peptides and point mutations of E197 (Coley et al. 2006). The discontinuous
Mab4G2 epitope was mapped in detail by point mutation of 9 residues (Pizarro
et al. 2005). In addition, Bai and coauthors have classified 5 residues (including
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Figure 2.8: Predicted epitope residues of the AMA1 ectodomain. Backbone
atoms of residues predicted by DiscoTope as parts of epitopes are highlighted in green.
Side chains of the residues mapped to the monoclonal antibodies 1F9 and 4G2 are
shown in black.
E197 and other residues in the same region of the structure) as highly polymor-
phic in Plasmodium falciparum AMA1 sequences. It has been suggested that
the polymorphism is caused by selection pressure on the antigen to avoid the
host immune system (Bai et al. 2005). We used a DiscoTope prediction thresh-
old of -4.7 which corresponds to a specificity of 90% and 24% sensitivity (Table
2.3). In AMA1, 43 of 311 residues were predicted as epitope residues. Most
of the predicted epitope residues cluster in three separate regions of the AMA1
structure (Figure 2.8). DiscoTope successfully identified 2 of the 8 residues in
the 1F9 epitope which were mapped using phage-display (D196 and E197). In
the discontinuous 4G2 epitope, all 9 residues except D348 were predicted to
be part of epitopes. All of the 5 highly polymorphic residues described by Bai
et al. were predicted to be located in epitopes. Thus, DiscoTope successfully
predicted epitope residues of AMA1 which have been mapped by using diverse
methods.
Discussion
In this paper we have presented DiscoTope, a novel method for prediction of
residues located in discontinuous B-cell epitopes. DiscoTope combines surface
localization and spatial properties of a protein structure with a novel epitope
propensity scale. The combination is defined in terms of a simple weighted sum
of the contact number and a sum of sequentially averaged epitope log-odds ratios
of spatially proximate residues. We propose to use DiscoTope for prediction of
discontinuous epitope residues for several reasons: First, we have shown on
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a data set of discontinuous epitopes that the average predictive performance
of the DiscoTope is significantly higher than the Parker propensity scale and
marginally higher than the surface localization score defined by the NACCESS
RSA score. Second, we have shown that DiscoTope correctly predicts residues
in epitopes which have been identified using different techniques such as phage-
display, point mutation and sequence analysis. Third, the DiscoTope prediction
method is publicly available on www.cbs.dtu.dk/services/DiscoTope and the
output of the method is easily interpreted.
The Parker hydrophilicity scale is often used for prediction of linear B-cell epi-
topes by smoothing values in a 7 residue window (Parker et al. 1986). Compared
to the epitope log-odds ratios smoothed over a window of 9 residues developed
here, the Parker scale was not as accurate for prediction of discontinuous B-
cell epitopes in the data set. The difference in ranking between the two scales
suggests that our log-odds ratios represent more characteristics of the epitopes
than only hydrophilicity. Possibly, this difference contributes to a better pre-
dictive performance on the data set since combinations of various propensity
scales including hydrophilicity, flexibility, accessibility and beta-turn prediction
are better than single propensity scales for epitope prediction (Pellequer et al.
1991). Our finding, that surface accessibility values improved the prediction of
residues in B-cell epitopes, is in agreement with recently reported results by Ba-
tori et al. (Batori et al. 2006). In addition, the combination of propensity scale
methods with structural information improved the performance considerably.
This suggests that both accessibility and chemical characteristics are important
in descriptors of discontinuous B-cell epitopes. Combination methods using a
number of propensity scales have been used for B-cell epitopes for more than 15
years (Pellequer et al. 1991). However, DiscoTope is the first reported method
combining a propensity scale with 3D structural information, such as spatial
proximity.
Van Regenmortel (Van Regenmortel 1996) has addressed the problem of using
protein sequences for prediction of B-cell epitopes which are in reality multi-
dimensional. He concluded that more input data such as the antigen three
dimensional structure is needed for accurate prediction. The requirement of
structural input for B-cell epitope prediction is a limiting factor for the general
use of the method. However, structural genomics projects help to increase the
number of X-ray crystallography structures determined of proteins in general,
and to cover larger areas of the structure space. Therefore, the requirement
of protein structures as input for prediction methods will become a decreas-
ing problem, because more structures will be determined and better homology
models can be obtained.
In general, methods based on structural information were shown to predict
residues in discontinuous B-cell epitopes with a higher performance measured
in average AUC, than propensity scale methods which only used sequential
information. In all methods of evaluation the DiscoTope method was shown to
have the highest performance. However, we found that the Parker hydrophilicity
scale had a higher sensitivity than the NACCESS RSA method on the 95% and
90% specificity levels. These results illustrate the importance of using other
measures of performance for evaluation in addition to the AUC.
We found that for antigen groups that contain antigens part of larger biologi-
cal complexes, the performances of both the NACCESS RSA method and the
DiscoTope method were relatively low. The low performances were due to an
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incorrect measure of surface accessibility of regions which are part of protein-
protein interaction sites or embedded in a membrane. Therefore, we believe that
the outcome of prediction methods for B-cell epitopes should be combined with
additional information about properties such as biological complex formation,
membrane interaction and glycosylation.
The accuracy of the described methods for B-cell epitope prediction was still
relatively moderate. This may partly be caused by the incomplete identification
of epitopes in the antigens of the data set. If the methods correctly predicted
an epitope that was not bound by the antibody in the corresponding complex
PDB file it counted as a false positive. However, since the same data set was
used in the evaluation of all methods described here, we assumed that incom-
plete identification had the same influence on the predictive performance of all
methods, and hence negligible influence on their relative ranking. The predic-
tive performance of the method developed by Batori et al. (Batori et al. 2006)
was evaluated on 6 epitopes of one single antigen. This evaluation approach,
using an antigen where all epitopes are more completely identified, possibly had
the effect that the false positive proportion was lower and the measured perfor-
mance was higher. In our approach of evaluation we chose to include as much
variation as possible and thereby avoid biasing the method towards a certain
type of antigens or epitopes. However, a future evaluation of our DiscoTope
method using a data set of antigens with more completely identified epitopes
would be of interest.
Recently, Schlessinger et al. have developed a sophisticated method for identi-
fication of epitopes in antibody/antigen complex structures (Schlessinger et al.
2006). The method is based on an analysis and identification of complementar-
ity determining regions (CDRs) of the antibody and a subsequent identification
of epitopes by mapping residues in the antigen in proximity to CDRs. The
identification described in this paper was simply based on antigen residues in
proximity to antibody residues in general and it is plausible that a future ap-
plication of the identification method developed by Schlessinger et al. could
improve the DiscoTope method.
Because of their non-linearity, discontinuous epitopes pose other problems than
linear epitopes in vaccine design. Not only must the new vaccine contain the
amino acids or atoms that are necessary for binding and eliciting specific an-
tibodies, but a conservation of the correct spatial conformation is also needed.
DiscoTope can predict residues that are likely to be part of discontinuous epi-
topes. Subsequently, antibody binding studies and site-directed mutagenesis
may help to group predicted epitope residues into epitopes and validate binding.
Analysis of the local conformations of epitope residues in the antigen structure
may also aid the design of vaccines, because a vaccine based on a discontinu-
ous epitope must have these conformations preserved. The preservation may be
obtained using native proteins, sub-domains of a protein, redesigned proteins
carrying the epitope or mimotope peptides in vaccines. Therefore we consider
discontinuous epitopes useful for rational vaccine design.
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Materials and methods
Preparation of the data set
A list of experimentally determined protein antigen-antibody structures was
obtained from the SACS database of antibody crystal structure information
(Allcorn and Martin 2002). The list was filtered to only contain structures de-
termined to a resolution < 3 Å with protein antigens of more than 25 amino
acids. Coordinate files corresponding to the filtered list were downloaded from
the Protein Data Bank (PDB, http://www.rcsb.org/pdb). The final data set
contained 76 complexes of antibody-antigen pairs. Epitope residues in the data
set were defined as antigen amino acids having atoms within a 4 Å distance
from antibody atoms. Comparisons based on a subset of five identified epitopes
with residues reported as antibody interacting (Padlan et al. 1989; Muller et al.
1998; Fleury et al. 2000; Mirza et al. 2000; Romijn et al. 2003) showed that a
distance threshold of 4 Å gave an annotation corresponding well to that made
by human experts. (92% of the epitope residues were correctly identified and
only 1% of the non-epitope residues were identified as epitope residues). Only a
single epitope was represented in each PDB file. All other epitopes that might
exist in a given antigen were treated as non-epitopes in our analysis. Cer-
tain antigens were represented multiple times in the data set (29 antigens are
variants of Lysozyme). Therefore we grouped the data set according to anti-
gen homology. Homology in the data set of 76 proteins was determined using
a BLAST search (Altschul et al. 1997) with the BLOSUM80 matrix against
all other antigens in the data set combined with a homology threshold as de-
scribed by Lund et al. (Lund et al. 1997). Antigens were then split into 25
groups with low homology between the groups (BLAST E-values >0.30 between
groups). The data set annotations and the groups of antigens are publicly avail-
able at http://www.cbs.dtu.dk/suppl/immunology/DiscoTope. Finally, the 25
non-homologous groups of antigens were divided into 5 data sets used for cross-
validated training and evaluation.
Use of the Parker hydrophilicity scale
The average Parker scale value over a window of 7 residues was used for the
per-residue epitope prediction value as proposed by Parker et al. (Parker et al.
1986).
Definition of surface residues
A combined measure of amino acid surface localization and structural protrusion
was obtained by using residue contact numbers. The residue contact number is
the number of Cα atoms in the antigen within a distance of 10 Å of the residue
Cα atom (Nishikawa and Ooi 1980). For a more direct measure of residue
solvent accessibility, the relative solvent accessible surface area per residue was
calculated for antigen chains extracted from each PDB file using the NACCESS
program (Hubbard and Thornton 1993). NACCESS default options were used
with a probe radius of 1.4 Å.
34 Chapter 2. DiscoTope, a prediction method for B-cell epitopes
Performance measures
The area under a receiver operator characteristics curve (AUC) (Swets 1988)
was used as performance measure. A receiver operator characteristics curve
is constructed by varying the prediction threshold and plot the false-positive
proportion, or 1-specificity, on the x-axis against the true positive proportion,
or sensitivity, on the y-axis (Swets 1988; Lund et al. 2005). We calculate the
AUC on a per protein basis. This ensures that a prediction where all residues
in a protein are predicted as only epitopes or only non-epitopes has an AUC
of 0.5 corresponding to a random prediction. The performance of each method
was measured as the average AUC, average specificity and average sensitivity
for the 25 antigen groups.
Statistical analysis
Mean values of contact numbers for epitope residues and non-epitope residues
were analyzed using a double sided t-test (standard deviation = 0.121, n = 1202
for epitope residues and standard deviation = 0.050, n = 13242 for non-epitope
residues.) A bootstrapping approach was used for pair-wise comparisons of the
average AUC values to determine the significance of the performances (Efron
and Tibshirani 1993). For each method, the 25 values of average AUC value
pr. antigen group were re-sampled 100,000 times in order to obtain a robust
estimate of the P-values.
Derivation of epitope log-odds ratios
Four of the five data sets (the training sets) were used for derivation of epitope
log-odds ratios. A series of peptides were produced by sliding an odd-sized
window through the sequences of antigens in the training sets. The peptides
were then sorted into an epitope group and a non-epitope group depending
on the identification of the residue in middle position as epitope residue, or
as non-epitope residue. Weight matrices were calculated from the peptides in
each group using the method described by Nielsen et al. (Nielsen et al. 2004),
including sequence clustering, sequence weighting and pseudo counts with a
weight of 200. Finally the log-odds ratios at the central matrix position for
each of the 20 amino acids in epitope group relative to non-epitope group were
calculated in half bits and used as an epitope propensity scale.
Using log-odds ratios for epitope prediction
For prediction of epitope residues, the raw log-odds ratios were used alone or
in combination with a smoothing window calculating the sequential average of
the epitope propensity scale values. The optimal length of peptides used for
the derivation of log-odds ratios and the optimal size of the smoothing window
were determined with respect to the predictive performance on the training
sets used for calculating the log-odds ratios. The performance reported is the
five-fold cross-validated performance on the data set. This reduces the risk of
overestimating the performance, since the calculation of the log-odds ratios and
optimization of other parameters, such as the peptide length and the smoothing
window size, are estimated on the training set and hence not biased by the
evaluation set data.
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Simple combinations of propensity scales with structure based meth-
ods
Contact numbers, NACCESS RSAs and Parker hydrophilicity values were nor-
malized by subtracting the mean and dividing with the standard deviation. The
normalized contact numbers were multiplied by -1 in order to correlate high val-
ues with surface localization. Subsequently, the different propensity scales were
combined with contact numbers or NACCESS RSAs using a linear combination
with a weight on the surface measure ranging from 0.001-100. Optimal weights
were determined using the training sets. Finally, the performance was evaluated
on evaluation sets.
Structural proximity sum of epitope log-odds ratios
Alternatively, the epitope log-odds ratios or the Parker hydrophilicity scale were
used by summing values for all residues with Cα atoms within a 10Å distance of
each residue. We tested a number of weighting schemes for the proximity sums,
for instance based on the distance to the central residue, the contact number for
the residue, and a combination of the two. However, the simple approach where
all residues carry equal weight gave the highest performance on the training sets
(data not shown).
Prediction of epitopes in AMA1
Chain A of the AMA1 ectodomain from P. falciparum (PDB code 1Z40) was
used for DiscoTope epitope prediction. We chose to use 1Z40 instead of a
full-length AMA1 ectodomain structure (1W8K) because the main part of the
residues in the 4G2 epitope was not observed in the latter. Residues 348, 351,
352, 354-356, 385 and 388-389 were counted as residues in the 4G2 epitope
(Pizarro et al. 2005), residues 191-199 were counted as part of the 1F9 epitope
(Coley et al. 2006) and residues 187, 197, 200, 230 and 243 were counted as
highly polymorphic residues (Bai et al. 2005).
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Chapter3
Identifications of B-cell
epitopes in the Plasmodium
falciparum protein VAR2CSA
This chapter is focused on research in B-cell epitopes with the final goal of
developing a pregnancy-associated malaria (PAM) vaccine. First I will give a
short introduction to malaria, PAM and to the vaccine-candidate; the Plasmod-
ium falciparum protein VAR2CSA. Subsequently, is given an introduction to
the methods used in this project: prediction of protein structure, affinity purifi-
cation, and depletion of antibodies combined with pepscan analysis. Following
the introduction, two papers present my work on the project, and finally the
chapter is ended by a short discussion of the results obtained in papers II and
III.
3.1 Pregnancy-associated malaria
Malaria is a major threat to public health in tropical and subtropical regions
of the world. The World Health Organization has estimated the occurrence
of 300-500 million cases of malaria per year, and more than 1 million deaths
from malaria annually (Korenromp et al. 2005). The disease is caused by
infection with parasites of the genus Plasmodium, which are transmitted by the
Anopheles mosquitoes. The species P. falciparum is the most lethal of the four
species which infect humans (Gardner et al. 2002). Several antimalarial drugs
have been developed, but the eradication of the disease has failed. One reason
for the failure is the development of drug resistance in Plasmodium species.
Additionally, because malaria is a disease of poverty, the availability of affordable
drugs play a major role (Kooij et al. 2006; Menendez et al. 2007). Several
approaches have been taken to develop malaria vaccines, but no effective malaria
vaccine has been developed yet (Epstein et al. 2007). However, the fact that
immunity to the disease can be acquired after natural infection suggests that a
malaria vaccine is attainable.
The P. falciparum parasite has a complex life cycle, and goes through many
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volunteers. This is essentially a modern-day version of
the empirical strategy mentioned earlier, and relies on
the technological capacity for rapid screening of a wide
range of peptide combinations, generated by synthetic
chemistry6 or in the form of a DNA vaccine.7 One of the
objectives of such a strategy is to mount a multipronged
attack on each stage of parasite development, and
another is to overcome the immunogenetic diversity of
the host. The genetic restriction of immune
responsiveness can be informative for vaccine
development, since HLA associations with disease
severity may shed light on epitopes that are critical for
protective immunity in a natural setting.8,9
Once candidate antigens have been identified, two
practical problems arise. The first is the question of
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antigenic diversity. Are the target epitopes conserved
and, if not, should the vaccine include several variants of
the same structure? The second question is the mode of
vaccine delivery. The ideal vaccine would be highly
immunogenic without causing side-effects; it would
provoke a type of immune response that is appropriate
for the stage of parasite being attacked; this response
would be long-lived and it would be boosted by
infectious challenge. Such features can be influenced, to
some extent, by manipulating the way in which the
candidate antigen is presented to the host. In this
respect malaria vaccine development has kept pace with
technology, and a range of different vaccine delivery
methods are under investigation. These include malaria
antigens linked to strong T-helper epitopes;10 synthetic
malarial peptides or recombinant proteins formulated
with adjuvant liposomes or other immunostimulatory
particles;11,12 malarial protein gene sequences
incorporated into live vectors such as salmonella13 or
vaccinia;14 and DNA vaccines.7,15 In the context of
malaria, DNA vaccines have two attractive features: they
allow many different permutations of candidate epitopes
to be tested in animal models and are gaining
acceptance for testing in human volunteers; and the
mode of antigen presentation by a DNA vaccine tends to
promote strong cytotoxic T-lymphocyte responses which
may be the key to a pre-erythrocytic vaccine.
Pre-erythrocytic vaccines
When an infected mosquito bites, malaria parasites are
inoculated into the bloodstream as sporozoites that
rapidly find their way to the liver and invade
hepatocytes. There follows an asymptomatic period of 1
or 2 weeks, during which parasites undergo massive
proliferation within the host hepatocytes. Finally, the
infected hepatocytes rupture to release many thousands
of merozoites which promptly invade erythrocytes. A
vaccine that successfully interfered with pre-erythrocytic
development would terminate infections before they had
any chance of causing clinical illness. It has been argued
that a pre-erythrocytic vaccine would be valuable even if
it did not completely protect against infection, as long as
it reduced the number of parasites entering the blood
stream and thereby lessened the risk of severe disease.
Much of the effort to develop a pre-erythrocytic vaccine
stems from the observation that human volunteers
inoculated with irradiated sporozoites can be protected
for up to 9 months against infectious challenge.16,17 Such
a form of immunisation could not be implemented in
practice, because of the logistical difficulty of generating
irradiated sporozoites, but this result indicates that
humans can mount a protective immune response
against pre-erythrocytic antigens.
A pre-erythrocytic vaccine can aim to prevent
sporozoites entering hepatocytes, or to inhibit parasite
development within the hepatocytes, or both. Some 20
years ago it emerged that malaria-exposed individuals
generate high titres of antibody against the
circumsporozoite protein which coats the surface of the
sporozoite. This antibody response became the focus of
intense interest when it was found that mice could be
rendered resistant to sporozoite challenge by passive
immunisation with monoclonal antibodies against
circumsporozoite protein.18 The cloning of
circumsporozoite protein for the monkey parasite
Figure 3.1: Stages of Plasmodium development in humans. The figure is
adapted from Kwiakowski et. al. (Kwiatkowski and Marsh 1997)
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stages of development (Kooij et al. 2006). It has been suggested that a malaria
vaccine should target parasites in several different stages of development to be
effective (Heppner et al. 2005). Here is summary of the different stages (see Fig-
ure 3.1). In the first stage, sporozoites enter the bloodstream of a human with
the saliva of a feeding mosquito. Then the sporozoites infect liver cells (hepato-
cytes), grow and replicate to produce many parasites of the next developmental
stage called merozoites. The merozoites invade red blood cells (erythocytes),
go through the ring, trophozoite and schizont stages and reproduce new mero-
zoites. These blood-stages are asexual and the major cause of the pathology of
malaria. When infected erythrocytes burst to release a number of newly devel-
oped merozoites, a number of toxins are released with the parasites and cause
fever, which is one of the most characteristic symptoms of malaria. Addition-
ally, the destruction of erythocytes can cause anaemia, another symptom of the
disease. A few merozoites develop into female or male gametocytes, and their
development is arrested until reactivation in the midgut of a female Anopheles
mosquito, which has been feeding on the infected human. Upon reactivation of
development in the mosquito, the gametocytes first develop into gametes that
are fertilized. These fertilized gametes develop into ookinetes, which traverses
the midgut wall and forms oocysts in the basolateral lamina. In these oocysts,
new sporozoites are developed and these migrate into the salivary glands of the
mosquitoes, ready for infection of a new victim (Kwiatkowski and Marsh 1997;
Kooij et al. 2006).
The spleen is a key site for removal of parasitized erythrocytes (Engwerda et al.
2005). However, the species P. falciparum has developed mechanisms for ad-
hesion of infected erythrocytes to human endothelium (sequestration), which
prevent the spleen-dependent clearance (Miller et al. 2002). This sequestration
contributes greatly to the severity of the disease. For instance, sequestration
of infected erythrocytes in capillaries of the brain results in cerebral malaria,
which is a life-threatening condition. Additionally, another form of malaria,
PAM, is critical in pregnant women. PAM is caused by the sequestration of
infected erythrocytes in the placenta. This results in a high risk of still birth,
low infant birth weight, and severe maternal anaemia. In sub-Saharan Africa,
where P. falciparum is widely spread, and the transmission of infection is stable,
approximately one in four pregnant women have evidence of placental infection
at the time of delivery. Malaria-associated low birth weight is estimated to cause
the deaths of 100,000 infants in Africa every year (Desai et al. 2007). Thus, a
PAM vaccine obstructing the placental sequestration could have a high impact
on the effects on P. falciparum infections, even if it would not directly prevent
infection. Since women in areas of stable transmission develop immunity to the
disease after a few pregnancies, a PAM vaccine would be most effective if given
to young women who have never been pregnant.
The adhesion properties are determined by the P. falciparum erythrocyte mem-
brane protein 1 (PfEMP1) family of proteins. These proteins are expressed on
the surface of the infected erythrocytes and are encoded by approximately 50-60
different var genes (Kraemer and Smith 2006). The proteins of the PfEMP1
family are capable of binding a variety of different receptors on the surface of
host endothelial cells. The extracellular part of PfEMP1 proteins have similar
compositions: all contain Duffy-binding like (DBL) domains and most contain
inter-domains called cysteine-rich domains (CIDR). Despite this similarity, the
sequence variability between different PfEMP1s and DBL domains within the
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same protein is extremely high (Smith et al. 2000). The sequestration of infected
erythrocytes to placenta during pregnancy is caused by adhesion to chondroitin
sulphate A (CSA) (Fried and Duffy 1996; Pouvelle et al. 1998; Scherf et al.
2001). Women in high transmission areas develop increasing resistance to PAM
over successive pregnancies (McGregor et al. 1983), and it has been shown that
maternal antibodies, which inhibit the binding to CSA, are associated with a
reduction in the symptoms of PAM (Duffy and Fried 2003; Fried et al. 1998).
VAR2CSA is the major protein of the PfEMP1 family, which is thought to
mediate this adhesion. Accordingly, VAR2CSA adhesion mechanisms and in-
teractions with the human immune system are major research topics in PAM
vaccine development projects (Oleinikov et al. 2007; Rogerson et al. 2007).
Recently, the first two structures of DBL domains from different Plasmodium
proteins were published (Tolia et al. 2005; Singh et al. 2006). The structure of
the P. falciparum erythrocyte binding antigen (EBA)-175 DBL domains F1 and
F2 revealed that the two DBL domains were very similar in structure, despite
sequence variations. Additionally the structure of the Plasmodium knowlesi
α-DBL domain showed that this DBL domain has a similar structure to the
EBA-175 DBL domains, even though the sequence variation between the do-
mains is high and functional residues were found to be located on the opposite
sides of the domain structures (Singh et al. 2006). The finding that DBL
domains from different proteins and species of Plasmodium share structural ho-
mology strengthens the hypothesis that DBL domains from other proteins can
be predicted by comparative modeling using the determined DBL domains as
templates. This modeling, and the interpretations of experimental data it al-
lows for, can potentially lead to new insight into the mechanisms of Plasmodium
infection and malaria disease (Tolia et al. 2005; Howell et al. 2006). Because
of that, we found it suitable to use comparative modeling in our research of
VAR2CSA and PAM.
3.2 Protein structure prediction
Knowledge of three-dimensional protein structure is essential for understand-
ing many biological questions. Much effort has been put into solving the 3D
structures of proteins, and the number of determined structures in the Pro-
tein Data Bank (PDB) has been remarkably increased during the last 20 years.
However, the number of sequenced genes is increasing even more rapidly, and
protein structure determination is still a time-consuming process. For some pro-
teins, the structure determination is still not within reach despite the progress
in improving technical methods. Protein structure prediction is a relatively fast
alternative to structure determination. A general observation in structure re-
search, is that evolutionary linked sequences often have similar 3D structures
(Chothia and Lesk 1986); and this is the basic assumption of protein struc-
ture prediction by comparative modeling. In comparative modeling, a model is
built from target protein sequence by using related proteins of known structure
(templates).
A comparative modeling process normally consists of the following steps (Dun-
brack 2006; Fiser and Sali 2003):
• Finding suitable template proteins which are related to the target protein
sequence
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• Aligning the target protein sequence to the sequences of templates
• Building coordinates of the 3D model
• Assessing the accuracy of the model
The correct identification of templates, and the alignment of target sequences
to template structures are the primary determinants of the quality of the final
model (Venclovas et al. 2003). In general, alignments are often close to opti-
mal for sequence identities higher than 30%, but for sequence identities below
30%, the general alignment quality is decreasing greatly and as many as 50%
of the residues may be misaligned when the sequence identity is below 20%
(Kryshtafovych et al. 2005). Therefore, it is important to select methods for
comparative modeling carefully, when modeling difficult targets with low se-
quence identity between target and template. For the comparative modeling
of protein structures presented in this chapter, the HHpred server has been
used (Soding 2005; Soding et al. 2005). The server has been chosen over other
methods because it is fast, user-friendly and optimized for remote homology
modeling. This makes it very suitable for the modeling of VAR2CSA domains.
Here is described an introduction to the methods used by the HHpred server.
3.2.1 Template finding and alignment
HHpred is based on three methods: sequence profiles, HMM-comparisons and
secondary structure prediction. These methods have been shown to greatly en-
hance the performance of comparative modeling for proteins which are remotely
related to available target sequences (Moult 2005). Firstly, these methods have
improved the detection of homology to identify a higher number of suitable tem-
plates. Secondly, the alignments between target protein sequence and template
structures have been improved.
Sequence profiles are based on iterative sequence searches and can be built using
the PSI-BLAST program (Altschul et al. 1997). Their main strength is that
they capture both sequence variation and conservation in positions of related
protein sequences. This can be used to identify farther related proteins with
similar structures, but different sequences. In the HHpred prediction method,
sequence profiles are build for both target protein sequences and template se-
quences, and these are compared to detect remote homologous proteins and
improve alignments (Soding 2005).
HMMs have additionally improved the comparative modeling performance greatly.
HMMs integrate probabilities of gaps and insertions at positions in the target
protein sequence compared to templates (Dunbrack 2006). This helps to iden-
tify correct template structures, because insertions and deletions tend to locate
at specific positions in profiles build from proteins of the same fold (Chothia
and Lesk 1986).
Secondary structure prediction is also used in the HHpred method to improve
the comparative modeling. The known and predicted template secondary struc-
ture is compared to secondary structure predictions of the target sequence. Be-
cause the performance of secondary structure prediction methods is relatively
high, this information of local structure improves the identification of templates
and alignments between target and template, for instance by shifting insertions
in the target sequence to loop areas of the template structure.
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The HHpred server first identifies template structures and generates alignments
of target sequences to template structures. These alignments are then used as
input for the MODELLER program (Sali and Blundell 1993), which is building
3D models based on the structures of the templates.
3.2.2 Building 3D coordinates
The MODELLER program is widely used for this purpose in protein prediction
protocols from many groups (Dunbrack 2006). Comparative modeling using
MODELLER is based on the extraction of a number of Cα-Cα distance re-
straints and dihedral angle restraints (both sidechain and mainchain) from the
template structure. In addition, the modeling method uses stereochemical re-
straints (i.e. chemical bonds, bond angles etc.) from the CHARMM molecular
mechanics force field (MacKerell et al. 1998), and a potential based on general
statistical preferences of amino acids from a data set of protein structures. The
different restraints are combined to result in an objective energy-function that
is optimized using molecular dynamics; in this way, 3D structure coordinates
are found which minimizes the energy of the model (Sali and Blundell 1993).
After the modeling of residues aligned to template structures, the insertions are
modeled using a loop modeling procedure. In general, loops are much more
difficult to model correctly than core protein structure, and the difficulty in-
creases with the loop length (Fiser et al. 2000). In loop regions, the number of
restraints obtained from template structures is low, and the prediction is mainly
based on energy functions derived from statistical energy potentials. Current
energy potentials do not describe protein structures accurately enough; in this
way loop modeling is closely related to the problem of ab initio protein struc-
ture prediction (Moult 2005). In the MODELLER loop modeling protocol the
rest of the model is kept unchanged, while the loops (insertions) are optimized.
Like in the protocol for modeling the general structure, the combination energy
function is optimized using molecular dynamics to get the loop conformations
with the lowest energy (Fiser et al. 2000).
3.2.3 Assessing model accuracy
The HHpred server has integrated model assessment and two of the integrated
methods are Verify3D and ANOLEA. These two methods for evaluation of mod-
els are based on general statistical preferences for amino acids in protein struc-
tures.
Verify3D is based on the preferences for each amino acid to be in specific environ-
ments (Luthy et al. 1992). In the Verify3D method, 18 different environments
are defined on the basis of solvent exposure, the degree of polarity of the amino
acid sidechain and the secondary structure. The statistical probability for each
type of amino acid to be found in each class is pre-calculated from determined
protein structures, and these probabilities are used to score the amino acids in
the models (Bowie et al. 1991).
The ANOLEA method is based on non-local interactions of residues which are
separated by more than 11 residues in the protein sequence (Melo and Feytmans
1998). Native, globular proteins have a high number of non-local interactions,
for instance between residues packing in the hydrophobic core of the protein.
Models of protein structures may not have the same degree of packing, and
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ANOLEA can be used to detect this lack of packing. In the ANOLEA method,
any given atom in a residue is scored by encountering all heavy atoms within a
distance of 7 Å and farther than 11 residues in the sequence (Melo and Feyt-
mans 1998). The heavy atoms are divided into 40 classes dependent on the
connectivity, chemical nature and location in sidechain or mainchain. Inter-
action probabilities for the different classes derived from structures of native
proteins are used to score observed interactions in the models (Melo and Feyt-
mans 1997). A surface exposure term based on the preferred total numbers of
heavy atoms within 7 Å from the atom is further included in the scoring (Melo
and Feytmans 1998).
3.3 Antibody affinity purification and depletion
studies
As mentioned in section 1.6.2, pepscan analysis is a useful technique for iden-
tification of peptide fragments which cross-react with antiprotein antibodies.
In the following two papers presented here, we have used pepscan analysis for
identifying epitopes of antibodies binding the P. falciparum VAR2CSA protein.
In our approach, we have combined pepscan analysis with antibody depletion
and affinity purification techniques. These are useful for identification of sur-
face exposed regions, and for detection of cross-reactivity between variants of a
protein from different lines.
In the first paper presented in this chapter (see section 3.5), we have used
affinity purification studies based on the heterologously expressed VAR2CSA
DBL3X domain. Here, antibodies binding the heterologously expressed DBL3X
domain are purified and analyzed by pepscan; antibodies which remain after the
purification are assumed to bind on the surface of the folded DBL3X domain
as opposed to non-surface exposed linear epitopes. However, because only the
heterologously expressed DBL3X domain is used, it is possible that the reactive
regions identified using this approach are not surface exposed in the native
VAR2CSA protein.
Depletion studies were carried out by incubating human serum pools with in-
fected erythrocytes expressing VAR2CSA. In infected erythrocytes, the whole
VAR2CSA protein is expressed in an environment that is considered to be close
to the native environment during a natural infection. Thus, the peaks of reactive
antibodies, which bind surface-exposed epitopes of native-like VAR2CSA, are
diminished after incubation. In the depletion studies presented in the second pa-
per (see section 3.6), we have used erythrocytes infected with two different lines
of P. falciparum, 3d7 and FCR3, to investigate if naturally acquired antibodies
bind VAR2CSA regions of both lines.
Finally, we have analyzed the binding of rabbit antibodies raised against the
VAR2CSA protein. Epitopes of rabbit antibodies may not be directly relevant
for vaccine design, but are used here to map which regions are surface exposed
in the VAR2CSA protein or the DBL3X domain alone.
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3.4 Contributions to the papers
The following papers present the results of my work on the VAR2CSA PAM-
vaccine project. In the first paper of this chapter, “Epitope mapping and topo-
graphic analysis of VAR2CSA DBL3X involved in P. falciparum placental se-
questration”, my work consisted of prediction of the DBL3X structure, analysis
of the structure model, mapping of identified B-cell epitopes and sequence vari-
ance analysis results on the structure model, preparation of figures including
the structure model and writing part of the manuscript. In the second paper
of this chapter, “Structural insight into epitopes in the pregnancy-associated
malaria protein”, my work included prediction of structure models, analysis of
these models, analysis of the pepscan data, mapping of identified B-cell epitopes
on the structure models, preparation of all figures and writing the main part of
the manuscript.
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Pregnancy-associated malaria (PAM) is a major health problem, which
mainly affects primigravidae living in malaria endemic areas. The
syndrome is precipitated by accumulation of infected erythrocytes in
placental tissue through an interaction between chondroitin sulphate
A (CSA) on syncytiotrophoblasts and a parasite encoded protein
on the surface of infected erythrocytes, believed to be VAR2CSA.
VAR2CSA is a polymorphic protein of approximately 3000 amino
acids forming six Duffy-binding-like (DBL) domains. For vaccine de-
velopment it is important to define the antigenic targets for pro-
tective antibodies and to characterize the consequences of sequence
variation. In this study, we used a combination of in silico tools, pep-
tide arrays and structural modeling to show that sequence variation
mainly occurs in regions under strong diversifying selection, predicted
to form flexible loops. These regions are the main targets of natu-
rally acquired IgG and accessible for antibodies reacting with native
VAR2CSA on infected erythrocytes. Interestingly, surface reactive
anti-VAR2CSA antibodies also target a conserved DBL3X region pre-
dicted to form an α-helix. Finally, we could identify DBL3X sequence
motifs that were more likely to occur in parasites isolated from primi-
and multigravidae, respectively. These findings strengthen the vac-
cine candidacy of VAR2CSA and will be important for choosing epi-
topes and variants of DBL3X to be included in a vaccine protecting
women against PAM.
Keywords: VAR2CSA, Malaria, Pregnancy, Vaccine, PfEMP1, DBL, Positive
selection, Recombination, PepScan, Epitope.
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Synopsis
Pregnancy-associated malaria caused by Plasmodium falciparum is
characterized by the accumulation of parasite-infected red blood cells in the
placenta and is a major health problem in Africa. VAR2CSA is a parasite
protein expressed on the surface of malaria-infected red blood cells and
mediates the binding to the placental receptor, chondroitin sulphate A. It
is believed that a vaccine based on VAR2CSA will protect pregnant women
against the adverse effects of pregnancy-associated malaria. However,
due to the size and polymorphism of VAR2CSA it is required to define
smaller regions that can be included in a vaccine and to analyze the degree
and consequences of sequence variation to ensure a broadly protective
immune response. The authors have characterized the chondroitin sulphate
A-binding DBL3X domain of VAR2CSA with regard to epitopes targeted
by naturally acquired antibodies and the influence of sequence variation
by bioinformatics and experimental data based on a VAR2CSA peptide
array. They identify both variable and conserved surface-exposed epitopes
that are targets of naturally acquired immunoglobulin gamma in pregnant
women with placental malaria. These findings will be imperative for
choosing epitopes and variants of DBL3X to be included in a vaccine
protecting pregnant women against malaria.
Introduction
Individuals living in areas with high P. falciparum transmission acquire im-
munity to malaria over time and adults have markedly reduced risk of getting
severe disease (Christophers 1924). Pregnant women constitute an important
exception to this rule and this has severe consequences for both mother and
child (Brabin 1983). Pregnancy-associated malaria (PAM) is characterized by
selective accumulation of P. falciparum in the intervillous blood spaces of the
placenta (Walter et al. 1982; Bray and Anderson 1979). The main pathophysio-
logical consequences of PAM are delivery of low birth weight (LBW) babies and
maternal anaemia (McGregor et al. 1983). In areas of high parasite transmis-
sion PAM affects mainly primigravidae as immunity is acquired as a function
of parity (Brabin 1983). Parasite sequestration in the placenta is mediated by
an interaction between chondroitin sulphate proteoglycans (CSA) on the syncy-
tiotrophoblasts and proteins expressed on the surface of infected erythrocytes
(Fried and Duffy 1996). VAR2CSA, a single and uniquely structured mole-
cule belonging to the Plasmodium falciparum Erythrocyte Membrane Protein
1 (PfEMP1) family, is currently believed to be the main parasite ligand for
placental binding (Salanti et al. 2003). Var2csa is markedly up-regulated in
P. falciparum selected in vitro to bind to CSA (Salanti et al. 2003) and in
parasites isolated from the placenta (Tuikue Ndam et al. 2005). Antibodies
to the surface-expressed VAR2CSA are acquired by women exposed to malaria
during pregnancy (Salanti et al. 2004; Tuikue Ndam et al. 2006) and high
levels of anti-VAR2CSA antibodies at delivery are associated with protection
from LBW (Salanti et al. 2004). Furthermore, it has been demonstrated that
targeted disruption of var2csa results in the loss of (Viebig et al. 2005), or a
marked reduction (Duffy et al. 2006) in the ability of parasites to adhere to CSA.
Based on these findings VAR2CSA is recognized as the leading PAM vaccine
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candidate, however var2csa is a polymorphic gene and the sequence variation
between genes from different parasites ranges from 10 to 30%, at the nucleic acid
level (Salanti et al. 2003; Trimnell et al. 2006). It is thus a major challenge for
vaccine development to characterize the importance of the sequence variation
and to define smaller epitopes that can be used in a vaccine to protect women
against PAM. This study had two objectives. Firstly, to characterize the epi-
topes of the CSA binding Duffy-binding-like (DBL) 3X domain of VAR2CSA,
which are recognised by naturally acquired antibodies. Secondly, to analyze the
degree and consequences of sequence variation and selection pressure within the
var2csa subfamily, using the var2csa cDNA sequences of a large number of fresh
placental parasite isolates. These studies would also test the validity of B-cell
epitope predictions and structural modelling of the DBL3X domain.
Results and Discussion
Recombinant VAR2CSA DBL3X binds CSA and the affinity depends
on the primary amino acid sequence
It has previously been shown that DBL3X expressed on the surface of CHO cells
binds CSA in vitro (Gamain et al. 2005). However it is important to test the
CSA binding properties of secreted VAR2CSA proteins produced in expression
systems that could allow for larger scale production of a vaccine. For this study
recombinant HIS-tagged proteins were produced in Baculovirus-transfected in-
sect cells and binding to CSA was determined in an ELISA system. It has
previously been suggested that the FCR3 DBL3X domain binds CSA, whereas
the 3D7 DBL3X domain does not (Gamain et al. 2005). We found that both
variants had affinity to CSA and that the 3D7 variant exhibited the strongest
binding. Binding of both FCR3 and 3D7 DBL3X was concentration depen-
dent (Figure 3.2A) and could be inhibited by soluble CSA in a dose dependent
manner (Figure 3.2B).
The structure of the VAR2CSA DBL3X domain can be modeled on
the basis of the structure of the DBL domains of Erythrocyte Binding
protein (EBA)-175
Recently, the structures of the two DBL domains (F1 and F2) of EBA-175 and a
DBL domain in Plasmodium knowlesi (Pk)α-DBL were solved (Tolia et al. 2005;
Singh et al. 2006). Using the crystal structure of EBA-175 F1 (PDB code 1ZRO)
as template, a three-dimensional model of DBL3X VAR2CSA was constructed
by comparative modeling on the basis of the 3D7 sequence (Figure 3.2C). The
sequence identity between DBL3X and EBA-175 F1 was 28%. From sequence
alignments of DBL3X, Pkα-DBL and EBA-175 (Supplementary figure 3.9) it
was apparent that a number of cysteines were conserved and 10 of these from
DBL3X aligned with cysteines which form disulfide bridges in the determined
structures of EBA-175 (Tolia et al. 2005) and Pkα-DBL (Singh et al. 2006). In
addition, we identified 34 buried hydrophobic residues in EBA-175 F1, EBA-175
F2 and Pkα-DBL, which corresponded to hydrophobic residues buried in the
DBL3X model (Supplementary figure 3.9). Compared to EBA-175 F1, a number
of insertions were found in DBL3X and the majority of these were predicted to
have coil secondary structure (Figure 3.2C). One of the insertions in DBL3X (L1:
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V3 were part of ﬂexible loops, whereas V2 included another
ﬂexible loop but also extended into a helical region. The
length of V1 and V3 varied between sequences and the 3D7
sequence was relatively short in both regions.
VAR2CSA Sequence Motifs Can Be Linked to the Parity of
the Infected Women
We have previously shown that the expression of certain
var genes is associated with severe malaria in young children
[22] and suggested that var gene expression is hierarchically
structured. This could occur because the progeny of parasites
expressing var gene products that mediate the most efﬁcient
sequestration outgrow the progeny of parasites expressing a
molecule mediating less efﬁcient binding [22–24]. A similar
process could shape the expression of molecules mediating
binding in the placenta. If that was the case, it would be
predicted that a systematic difference between molecules
mediating binding in primigravidae and multigravidae
women could be detected in areas of high P. falciparum
transmission where women are exposed to several parasite
clones during pregnancy [25]. This was addressed by
calculating the Kullback-Leibler distance between 21 VAR2-
CSA sequences originating from primigravidae and 21
sequences from multigravidae. The overall cumulated Kull-
back-Leibler distance (DKL) between sequences from the
primigravidae and the multigravidae was higher than for
Figure 1. Recombinant DBL3X VAR2CSA Binds CSA and the Structure of the Domain Can Be Modeled on the Basis of the Structure of the DBL Domains
of EBA-175
(A) Binding assay. DBL3X binds to CSA in a protein concentration-specific manner. ELISA plates were coated with soluble CSA and binding of
recombinant proteins at different concentrations was determined. DBL3X from 3D7 shows better binding compared to DBL3X from FCR3. The non-CSA
binding VAR2CSA DBL4e was included as a control. Results are the mean of three binding assays and the error bars indicate the standard deviation.
(B) Inhibition assay. Recombinant DBL3X proteins (7 lg/ml) were preincubated with increasing amounts of soluble CSA, and binding to CSA-coated
plates was determined. Binding of DBL3X is dose-dependently inhibited by soluble CSA. Results are the mean of four inhibition binding assays and error
bars indicate the standard deviation.
(C) Model of DBL3X using EBA-175 as template. The figure shows a superposition of the EBA-175 F1 domain in light blue and the DBL3X (PFL0030c
amino acids 1,217–1,559) model in yellow with insertions highlighted in red. Arrows indicate insertions, which align with flexible loop regions in Pka-
DBL (L1) and EBA-175 F1 (L2). Side chains of glycan-binding residues in EBA-175 F1 are shown in black. Arrow 3 indicates the corresponding Pka-DBL
Duffy antigen receptor for chemokine-binding site.
doi:10.1371/journal.ppat.0020124.g001
PLoS Pathogens | www.plospathogens.org November 2006 | Volume 2 | Issue 11 | e1241071
Mapping of Surface Epitopes on VAR2CSA
Figure 3.2: Recombinant DBL3X VAR2CSA binds CSA and the structure
of the domain can be model d on the basis of the struc ure f the DBL
doma ns of EBA-175. (A) Binding assay. DBL3X binds to CSA in a protein on-
centration pecific manner. ELISA plates were coated with soluble CSA and binding
of recombinant proteins a different concent ations we e determined. DBL3X from
3 7 shows better bindi g compared to DBL3X from FCR3. The non-CSA binding
VAR2CSA DBL4 was included as a control. Results are the mean of three binding
assays and the err r bars indicate the standard d viation. (B) I hibition assay. Re-
combinant DBL3X proteins (7µg/ml) were pre-incubated with increasing amounts of
soluble CSA and binding to CSA coated plates were determined. Bi ding of DBL3X
is dose dependently inhibited by soluble CSA. Results are the mean of four inhibition
binding assays and error bars indicate the standard deviation. (C) Model of DBL3X
using EBA-175 as template. The figure shows a superposition of t e EBA-175 F1
domain in light blue and the DBL3X (PFL0030c amino acids 1217 - 1559) model
in yellow with inse tion highlighted in red. Arrows indicate inserti ns, which align
with flexible loop regions in Pkα-DBL (L1) and EBA-175 F1 (L2). Side chains of
glycan binding residues in EBA-175 F1 are shown in black. Arrow 3 indicates the
corresponding Pkα-DBL DARC binding site.
R56-I63) was found to align structurally next to a region in Pkα-DBL, which
is described as a flexible linker with an experimentally determined proteolytic
cleavage site (Singh et al. 2006). A second insertion (L2: N1417-E1430) was
aligned in a loop region where two residues were missing structural information
in the structure of EBA-175 F1 (Tolia et al. 2005), which also indicates high
flexibility. Thus, the alignment of DBL3X to the solved DBL domain structures
seems to match characteristics such as disulfide-bridges, stabilizing hydrophobic
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interactions and flexible loop regions. These findings suggests that VAR2CSA
DBL3X has the same basic structure as the solved DBL structures (Tolia et al.
2005; Singh et al. 2006; Howell et al. 2006) in spite of the extensive sequence
variation. The ability of proteins to form similar structures despite marked
sequence variation has also been described for the VSG molecules covering the
surface of Trypanosomes (Blum et al. 1993; Carrington and Boothroyd 1996).
Sequence variation within the var2csa family is present as small hy-
pervariable blocks and parasite diversity is similar on a local and
global scale
Var2csa is a relatively conserved var gene carried by all P. falciparum genomes,
however sequence polymorphisms are present in the gene. In a previous study,
it was established that var2csa is transcribed at high levels by placental par-
asites isolated at delivery from Senegalese women (Tuikue Ndam et al. 2005;
Tuikue Ndam et al. 2004). Using cDNA from 24 placentas from that study,
the region encoding DBL3X of var2csa was cloned and sequenced. A multi-
ple alignment of 43 sequences showed that the average nucleotide diversity was
low (pi = 8.48% ± 0.37%, see materials and methods for details) reflecting a
limited inter-parasite diversity in these isolates collected from a geographically
small and well-defined area of West Africa. To test whether the Senegalese pla-
cental DBL3X sequences represented a monophyletic group compared to non-
Senegalese DBL3X sequences, a phylogenetic tree, which included VAR2CSA
DBL3X sequences available in GenBank, was constructed (Figure 3.3). These
non-Senegalese sequences included four lab-strains parasites with different geo-
graphic origin (DD2 from Laos, MC from Thailand, IT4 from Brazil and 3D7
with unknown origin) and 21 sequences from a sequencing study from Malawi
(Duffy et al. 2006). The four database sequences and the Malawi sequences
were scattered evenly in the tree indicating that the Senegalese sequences were
representative for the var2csa repertoire in general and that parasite nucleotide
diversity is similar on a local and global scale. It is also apparent that there is
no clear subgrouping within the DBL3X sequences. The protein alignment of
the DBL3X sequences (Figure 3.4A and Appendix II) suggested that DBL3X
could be divided into four relatively conserved regions (C1-4) separated by three
shorter variable regions (V1-3). When the variable regions were mapped to the
three-dimensional model (Figure 3.4B), V1 and V3 were part of flexible loops,
whereas V2 included another flexible loop but also extended into a helical re-
gion. The length of V1 and V3 varied between sequences and the 3D7 sequence
was relatively short in both regions.
VAR2CSA sequence motifs can be linked to the parity of the infected
woman
We have previously shown that the expression of certain var genes is associ-
ated with severe malaria in young children (Jensen et al. 2004) and suggested
that var gene expression is hierarchically structured. This could occur because
the progeny of parasites expressing var gene products that mediate the most
effective sequestration outgrow the progeny of parasites expressing a molecule
mediating less effective binding (Jensen et al. 2004; Hviid and Staalsoe 2004;
Lavstsen et al. 2005). A similar process could shape the expression of mole-
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Figure 3.3: Phylogentic relationship between different VAR2CSA DBL3X
sequences. Bayesian inference tree of 43 placental cDNA sequences from Senegal
(blue), 21 Malawian sequences (orange) and database sequences from four isolates
(green) of different geographic origin. The posterior probability of the clades is shown
at the branches.
cules mediating binding in the placenta. If that was the case, it would be
predicted that a systematic difference between molecules mediating binding in
primigravidae and multigravidae women could be detected in areas of high P.
falciparum transmission where women are exposed to several parasite clones
during pregnancy (Jafari-Guemouri et al. 2006). This was addressed by cal-
culating the Kullback-Leibler distance between 21 VAR2CSA sequences origi-
nating from primigravidae and 21 sequences from multigravidae. The overall
cumulated Kullback-Leibler distance (DKL) between sequences from the primi-
gravidae and the multigravidae was higher than for randomly chosen groupings
of the sequences (p=0.0075). The DKL was also calculated for each position in
the alignment to determine which polymorphisms contributed to the difference
between the sequence of parasites from primi- and multigravidae women and
visualized in a Kullback-Leibler sequence logo (Figure 3.5A). This implicated
two stretches of amino acids in positions 135-175 and 233-245 located in the V2
and V3 regions, respectively. The region from position 158 to 162 was of special
interest since the motif "EIEKD" was mainly found in primigravidae and the
motif "GIEGE" mainly in the multigravidae (Table 3.1). Intermediate motifs
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Figure 3.4: Multiple alignment of VAR2CSA DBL3X sequences. (A) cDNA
from 43 placental parasite samples were amplified with conserved DBL3X primers and
sequenced. Sequences were curated for primer sequence, translated and aligned. The
text to the left indicate the identity of the samples. The DBL3X domain can be
divided into four regions, which are highly conserved, C1-C4, and three regions, which
are polymorphic and/or harbour deletions V1-V3. A larger version of the alignment
can be found in the Appendix II of this thesis. (B) Model of DBL3X showing the
position of V1 (red), V2 (green) and V3 (orange).
like "(G/E)IERE" where the fourth position had changed from lysine to argi-
nine were also found, implying that the following evolutionary pathway may have
been operating: lysine (AAA or AAG) ↔ arginine (AGG) ↔ glycine (GGG).
The change from glutamate and lysine/arginine, which have large charged side
chains into glycine without a side chain could result in marked functional and
antigenic changes. Thus, it was interesting that positions 1, 4, and 5 in the motif
(position 158, 161 and 162) were predicted to be surface exposed in the struc-
tural model, which was also the case for all of the other amino acid positions in
V2 that differed significantly in the Kullback-Leibler sequence logo (Figure 3.5B
and 3.5C). The finding that parasites expressing the EIEKD motif were more
prevalent in primigravidae than in multigravidae women (Table 1, Chi-square
test: p<0.001) could indicate that these parasites have a biological advantage
in women experiencing their first pregnancy and that parasites expressing the
other motifs (G/EIERE or GIEGE) have an advantage in women who have been
pregnant before. This could arise because parasites carrying the EIEKD motif
are the most effective mediators of binding and therefore dominate in women
with limited immunity against PAM. As immunity develops against these para-
site forms, parasites expressing other motifs that are less effective in binding but
not serologically cross-reactive take over. Interestingly a monoclonal Ghanaian
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Figure 3.5: Sequence differences in infections with different parity. (A)
Kullback-Leibler sequence logo based on a multiple alignment of the DBL3X region
(Figure 3.4). The sequences in the alignment were split into two groups of equal size: 21
sequences obtained from primigravidae and 21 sequences from multigravidae women.
The x-axis shows amino acid positions in the alignment. The height of a position
indicates the amount of difference between the two groups according to the symmetric
Kullback-Leibler distance, and the letters indicate the amino acids contributing to this
difference. The letter "O" has been chosen to signify gaps in the alignment. Polar
amino acids are green, basic are blue, acidic are red and hydrophobic amino acids
are black. P-values indicating the significance of DKL based on the parity grouping
compared to random groupings are shown below positions where p<0.05. (B) DBL3X
model showing the position of amino acids that were differentially found in primi-
gravidae and multigravidae women. Residues in the region 135-175 of moderately
significant difference are shown in orange and highly significant residues (positions
158, 161, and 162) are shown in red. (C) The model (B) rotated 180 degrees so it is
positioned similar to Figure 3.2C.
field isolate undergoing full genome sequencing at the Sanger institute has two
copies of var2csa, one with the EIEKD motif and one with the GIEGE. Al-
though the functional background for the observed phenomenon is presently
not clear, the systematic sequence variation at positions predicted to be surface
exposed between parasites from primi- and multigravidae women strengthen the
concept that VAR2CSA is the main parasite ligand for sequestration of malaria
parasites in the placenta.
VAR2CSA is under both positive and purifying selection
A recent study has suggested that sequence polymorphisms in a region of VAR2CSA
upstream to DBL3X largely are due to positive natural selection pressure (Trim-
nell et al. 2006). To further investigate the nature of sequence diversity in
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Sequence motif in DBL3X Primigravidae (n=21) Multigravidae (n=21)
EIEKD 16a 4
EIERD/EIEGE/GIERE 1 6
GEIGE 4 10
Gap 0 1
aSignificantly higher represented in primigravidae, p<0.001, Chi-square.
Table 3.1: Sequence signature in DBL3X positions 158-162 of VAR2CSA ex-
pressed by 42 parasites infecting either primigravidae or multigravidae. The
motif “EIEKD” is overrepresented iin primigravidae and underrepresented in multi-
gravidae. The intermediate motifs and “GEIGE” are mainly present in multigravidae.
One of the sequences from multigravidae contains a gap in the region
var2csa, the dN/dS ratios (dN: rate of non-synonymous mutations per non-
synonymous site and dS: the rate of synonymous mutations per synonymous
site) for DBL3X were calculated on the basis of the sequenced DBL3X domains.
A dN/dS less than 1 indicates that the position is under negative or purify-
ing selection pressure leading to conservation of the residue, while dN/dS>1
suggests positive or diversifying selection pressure, and suggest that amino acid
changes are evolutionarily advantageous at the position. Purifying selection was
mainly found in the conserved regions C1-4 and it was especially pronounced
in the C2 and C4 regions, although single sites were observed to be under di-
versifying selection (Figure 3.6A). Several blocks appeared to be under strong
diversifying selection and these appeared most prominently in regions V1, V2,
and V3. It is interesting to note that residues under diversifying selection mainly
were situated in regions predicted to be surface exposed and concentrated on
one side of the molecule (Figure 3.6D and 3.6E). The two DBL domains of
EBA-175 are predicted to form a reverse handshake dimer with the F1 domain
of each molecule interacting with F2 of the other (Tolia et al. 2005). In this
four-domain DBL structure, we replaced one of the EBA-175 F1 domains with
our VAR2CSA DBL3X model (Figure 3.6F). It was noticeable that the largely
conserved C2 and C4 regions of DBL3X were predicted to take part in the lining
of the central cavity of the four-domain structure and form the region next to
the cavity facing the membrane in native configuration. The model presented
here is unlikely to fatefully reflect the structure of the native molecule, but the
positioning of conserved DBL3X regions in the model makes biological sense,
and the finding underscores the need to obtain knowledge about possible in-
teractions between VAR2CSA DBL domains. The lack of amino acid positions
under diversifying selection in the regions adjacent to the cavity might be due
to that these sites are involved in ligand binding and thus functional constraint.
Another explanation could be that the regions forming the predicted cavity and
the area predicted to face the membrane are not accessible for antibodies in
natively folded molecules.
Recombination is a factor in the generation of var2csa sequence vari-
ation
Previous studies have reported that frequent recombination events generate se-
quence diversity in the PfEMP1 family (Taylor et al. 2000; Freitas-Junior et al.
2000; Mu et al. 2005). To determine the role of recombination for DBL3X se-
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Figure 3.6: Sequence variation and B-cell epitopes in DBL3X. (A) dN/dS ratio
per amino acid based on an alignment of 47 DBL3X sequences. dN/dS ratio higher
than the dashed line indicate that the position is under positive selection. V1-V3 and
C1-C4 are indicated with solid bars. It should be noted that the inference of selection
pressure is less reliable in positions with gaps, which are mainly found in the variable
regions (see Figure 3.4). (B) The population recombination rate ρ = 2Ner(1 − f)
estimated per base pair across DBL3X. Circles indicate the single nucleotide polymor-
phisms (SNPs) for which ρ is estimated, linear interpolation is shown between SNPs.
Two hotspots corresponding to a local raise in r are observed in association with the
variable regions V1 and V3. (C) B-cell epitope predictions of the 3D7 sequence per-
formed by the BepiPred server. DD2 and IT-4 were used to fill 3D7 sequence gaps.
(D) Cartoon representation of the DBL3X model showing amino acid positions un-
der diversifying selection in red (dN/dS ratios >1). (E) DBL3X model with surface
topography prediction showing amino acid positions under diversifying selection in red
(dN/dS ratios >1). (F) The homo-dimer of the two domains of RII of EBA-175 has
been shown to form a handshake structure with F1 of one molecule dimerizing with F2
of another molecule and vice-versa. Here VAR2CSA DBL3X has been superimposed
on the F1 domain of one of the EBA-175 molecules in the dimer. The F1 domain is
shown in green; F2 domains are blue and the linker regions are gold. Amino acids
under diversifying selection in DBL3X are shown in red (dN/dS ratios >1). It is clear
that most residues inwards of the dimer are not under positive selection. (G) DBL3X
model showing residues with BepiPred scores higher than 0.9 in green. Locations of
V1-V3 are indicated on the model. GB indicates the glycan binding site of EBA-175.
quence variation, we estimated the population recombination rate ρ defined for
partially inbreeding haploid species by the compound parameter 2Ner(1 − f),
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where Ne represents the effective population size, r is the per-generation cross-
over recombination rate per base pair (bp) and f is the inbreeding coefficient.
Variations in ρ across DBL3X correspond to variations in the recombination
rate r, as Ne and f are constant for the data set. Two recombinational hotspots
were observed at bp positions 138-178 and 704-730 (Figure 3.6B). The two best
defined recombination breakpoints were present in the C1/V1 borderline at bp
177-179 and within V3 at bp 728-730. Both the V1 and V3 region harboured
major deletions/insertions in several of the sequences, which may have arisen
as a consequence of unequal cross-over during recombination at the hotspots.
Unequal cross-over results in either deletions or insertions of variable number
of tandem repeats (VNTR), and the DBL3X V1 region did indeed contain a
high amount of VNTR. The loop region of V2 contained a small VNTR in-
sert in some sequences, while VNTR were less obvious in the V3 region. In
a recent study of the P. falciparum chromosome 3, high recombination rates
were found in sub-telomeric regions, and African P. falciparum strains showed
a much higher population recombination rate than strains from other regions
of the world (Yang et al. 2003). The overall population recombination rate
for the DBL3X region was estimated to ρ = 0.54 per bp (95% CI: 0.41-0.90).
This is in accordance with a recent report for a VAR2CSA region upstream to
DBL3X in interdomain 1, where the rate was estimated to 0.71 per bp (Trimnell
et al. 2006), and in agreement with recombination rates in chromosome 3 of
African parasite lines summarized as ρ > 0.1 per bp (Mu et al. 2005). The high
population recombination rate in DBL3X combined with the observed sequence
variation adjacent to the detected recombination hotspots, suggests that recom-
bination is an important factor in generating sequence variation. The V1 region
which seems to be most strongly affected by recombination is predicted to form
a structurally unrestricted flexible loop allowing for sequence variation, and it
is possible that the whole V1 region is under diversifying selection pressure ex-
erted by the immune system, even though this could not be predicted by the
dN/dS method due to gaps. This notion is supported by the findings discussed
below, showing that this region is part of a major B-cell epitope.
VAR2CSA DBL3X B-cell epitope prediction
VAR2CSA epitopes exposed on the surface of the protein and accessible for IgG
binding could be under diversifying selection resulting in escape mutations and
high dN/dS ratios, whereas residues involved in protein folding, stability and
anchoring could be under purifying selection with low dN/dS ratios. To predict
linear B-cell epitopes the 3D7 sequence was submitted to the BepiPred server
(Larsen et al. 2006) and seven epitopes were predicted within the DBL3X
sequence (Figure 3.6C). Some of these epitopes were located in areas with
high dN/dS ratios and there was a weak but statistically significant associa-
tion between the BepiPred score and the dN/dS ratio (Pearson’s r=0.18 and
p = 2.5 × 10−9). The reason for this weak association could be that antibody
epitopes are situated in regions that are functionally constrained or that pos-
itive selection pressure is also driven by other forces like MHC-2 binding and
T-helper cell activation as found for HIV-1 (Yang et al. 2003). Furthermore,
the BepiPred algorithm predicts linear epitopes and some of these could be lo-
cated in parts of the molecule that are not accessible to antibodies in the native
folded molecule. Nevertheless, most of the predicted epitopes (Figure 3.6G)
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were situated in surface exposed loop regions of the model, and one of the high-
est scoring epitopes was in the V1 region. Residues that align directly to the
glycan-binding residues of EBA-175 F1 and to the Duffy antigen receptor for
chemokines (DARC) binding site in Pkα-DBL were not predicted to be part of
epitopes. However, a part of the V2 region in proximity to the putative glycan-
binding loop was predicted to be targeted by antibodies and had high dN/dS
values.
Fine epitope mapping of VAR2CSA antibodies acquired during preg-
nancy
To verify the above mentioned bioinformatical predictions we evaluated the
fine specificity of naturally acquired human antibodies to VAR2CSA DBL3X
in a peptide array consisting of 442 overlapping 31mer peptides covering exon
I of VAR2CSA of the 3D7 sequence. Antibody reactivity to individual amino
acids was assigned on the basis of an algorithm based on the observation that
a major part of antibody binding motifs in a set of conformational epitopes
are from 2 to 7 amino acids long, containing either 2 or 3 defined residues
spaced by undefined amino acids (Haste Andersen et al. 2006). The VAR2CSA
of 3D7 contains 31149 such motifs and each was assigned an average pepscan
value by adding the measured reactivity from the 31mers in which the motif
was present and dividing with the number of times the motif occurred. The
method, described in the material and methods section, was validated by testing
serum from rabbits immunized with a VAR2CSA construct, which showed that
both the measurements based on individual peptide readings and the algorithm
described above, mapped antibody responses to regions present in the antigen
used for immunization (Supplementary figure 3.10). Furthermore, there was
a high concurrence between antibody peaks defined by the reactivity of the
individual peptides and the peaks defined by the algorithm defining single amino
acid scores (Supplementary figure 3.10).
Plasma from individuals not exposed to malaria did not react with any of the
peptides in the array (data not shown). The IgG reactivity in the plasma of
eight Ghanaian women with a known history of a placental malaria infection
was analyzed and the peptide array data was visualized on the DBL3X model
(Figure 3.7). The regions with the highest reactivity were on the side of the
domain where glycan-binding is found in EBA-175 F1 (Figure 3.7A and 3.7B)
and therefore IgG reactivity was visualized on a model positioned with this
side in the front (Figure 3.7A and 3.7C - I). It was clear that the majority of
the individuals had specific IgG against the variable regions, V1 or V2. V3
is partly deleted in 3D7 and IgG reactivity could thus not be measured in
the peptide array based on the 3D7 sequence. Remarkably, a short α-helix
(Figure 3.7A-arrow 1) in proximity to the loop for glycan-binding in EBA-175
F1 showed the highest antibody reactivity in all serum samples, despite the fact
that this region had very low dN/dS ratios (Figure 3.6A, positions 120-132).
Another α-helix was also often recognized by antibodies (Figure 3.7A-arrow 2).
This helix was predicted to contain a B-cell epitope by the BepiPred algorithm
and had polymorphic residues (Figure 3.6A and 3.6C, positions 251-281). The
region corresponding to the loops containing the EBA-175 F1 glycan-binding
sites was not recognized by any of the serum samples. Conserved regions (Figure
3.7A-arrow 1) targeted by naturally acquired IgG are of considerable interest in
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Figure 3.7: Defining targets of antibodies on DBL3X. Models of DBL3X in
which the intensity of the grey and blue indicates reactivity of plasma tested on a
peptide array (pepscan scores). Grey indicates lowest scores and dark blue indicates
highest scores. (A and C-I) represent reactivity in eight individual plasma samples.
(B) shows the reactivity in the same plasma as tested in (A), but the model has been
rotated 180 degrees. Arrow 1 indicates a highly recognized α-helix region, which was
not predicted to be an epitope by BepiPred and was characterized by low dN/dS
ratios and high sequence variation. Arrow 2 indicates an α-helix with a predicted
B-cell epitope containing residues with high sequence variation. Variable regions V1
and V2 are fairly well recognized by most of the serum samples. GB indicates the
glycan binding site of EBA-175.
the search for vaccine constructs which could elicit a broad protective immune
response.
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Pepscan analysis of affinity purified antibodies
During infection VAR2CSA will be degraded and antibodies will be acquired
against epitopes that are not accessible for antibodies when the protein is in
its natural conformation. It is therefore possible that some of the antibody
reactivities measured in the peptide array were directed against such epitopes.
To address this question, analysis was performed on plasma, which had been
affinity purified on recombinant DBL3X or antibody-depleted by incubation
with erythrocytes infected with VAR2CSA expressing parasites.
Plasma from a rabbit immunized with recombinant DBL3X and plasma from
women who had suffered a placental infection were affinity purified on the recom-
binant CSA binding DBL3X protein and analyzed by the peptide array. Before
affinity purification, the plasma pool from Ghanaian women showed reactivity
corresponding to eight peaks distributed throughout the domain (Figure 3.8A).
By contrast, the reactivity of the affinity-purified IgG was concentrated to three
peaks (SE1-SE3) in the C1, V1, and C2/V2 regions. The immunized rabbit had
strong IgG reactivity against the epitope in the C2/V2, which was also affin-
ity purified from the female plasma pool (Figure 3.8B), but the rabbit had not
raised an IgG response against the epitopes in C1 and V1. A plasma pool from
Tanzanian women was also analyzed and in this case surface reactive antibodies
were depleted from the pool by incubation with VAR2CSA expressing infected
erythrocytes. In this pool the main reactivity was against the surface exposed
epitopes (SE1-SE3) defined in the Ghanaian plasma, and the depletion exper-
iment indicated that absorption with infected erythrocytes caused a marked
reduction in the reactivity against these epitopes (Figure 3.8C). These findings
indicate that the three identified regions were accessible to antibodies on the
native protein and that the folding of the Baculovirus produced recombinant
protein was close to the natural configuration. SE2 and SE3 corresponded to
loop regions V1 and V2, which are both protruding from the structure of the
DBL3X model (Figure 3.8D). Interestingly SE1 and SE3, which are located in
separate parts of the primary structure of the domain, form a continuous region
on the surface of the predicted DBL3X protein structure (Figure 3.8E). The
model also predicts that all surface exposed sites are located on one part of
the domain indicating that the other parts are buried or engaged in the intact
PfEMP1 molecule expressed on the surface of the infected erythrocyte (Figure
3.8E). Unexpectedly, the highly conserved part of C2, which was well recognized
in the peptide array by all women, corresponded to a part of the surface exposed
epitope SE3.
When exchanging the F1 domain of one of the EBA-175 molecules in the EBA-
175 dimer with VAR2CSA DBL3X and mapping SE1-SE3 to the model, it is
apparent that the surface exposed regions are on the opposite side of the central
cavity of the dimer (Figure 3.8F). However, the part of DBL3X that may be di-
rectly involved in the dimerization extends into the SE3 region (shown in green),
indicating that in this model the potential dimerization motifs are accessible for
antibodies. EBA-175 is suggested to dimerize upon ligand interaction and it
could be that SE3 was "unengaged" due to the lack of CSA during antibody
depletion. If several domains need to interact to form a buried CSA binding
site, antibodies targeting conserved residues like the region in C2 that forms
parts of SE3 could function by inhibiting the dimerization of domains.
Our results demonstrate that both conserved and polymorphic surface exposed
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Figure 3.8: Reactivity of plasma affinity purified on recombinant DBL3X
and human IgG depleted for surface reactivity by incubation with infected
erythrocytes expressing VAR2CSA. (A) pepscan IgG reactivity in a Ghanaian
pool of pregnancy plasma before (red) and after (blue) affinity purification on recom-
binant DBL3X protein. Variable regions V1 and V2 are indicated with a black line.
Arrows indicates 3 surface exposed regions (SE). The X-axis is amino acid position
in 3D7 VAR2CSA. (B) Pepscan IgG reactivity in plasma from a rabbit immunized
with DBL3X before (red) and after (blue) affinity purification on recombinant DBL3X
protein. Arrow indicates the surface exposed region. N and C-terminal parts of the
recombinant proteins did also appear to be surface exposed; this could be due to im-
proper folding of the N and C terminal parts of the protein. (C) Pepscan IgG reactivity
in a Tanzanian pool of pregnancy plasma before (red) and after (blue) depletion of
antibodies directed against surfaced exposed VAR2CSA regions by incubation with
infected erythrocytes expressing VAR2CSA on the surface. Arrows indicates three re-
gions where the reactivity was markedly reduced after depletion largely corresponding
to SE1, SE2 and SE3 on panel A. (D) DBL3X model showing the location of surface
exposed epitopes, SE1 (blue), SE2 (red) and SE3 (green). (E) DBL3X surface topog-
raphy showing SE1-SE3. From the model it is apparent that the SE1 and SE3 form
a discontinuous epitope. (F) VAR2CSA DBL3X superimposed on the F1 domain of
one of the molecules in the EBA-175 dimer. The F1 domain is shown in green; F2
domains are blue and the linker regions are gold. On the DBL3X domain the three
experimentally verified surface exposed regions are shown in similar colouring as (D
and E). The three regions are mainly predicted to be on the opposite side of the cen-
tral cavity of the dimer, and parts of SE3 correspond to amino acid positions directly
involved in the dimerization of EBA-175.
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regions are targets for VAR2CSA DBL3X antibodies acquired during pregnancy
by malaria-infected women. This opens for vaccine strategies similar to those
being pursued for the polymorphic Merozoite Surface Protein (MSP) 1 (Holder
et al. 1999). The proteolytic processing of MSP1 is a prerequisite for success-
ful parasite invasion of erythrocytes and one vaccine strategy is based on the
induction of antibodies against the conserved C-terminal part of the molecule
that inhibit processing (Blackman et al. 1994). Another MSP1 vaccine strategy
employs chimeric vaccine constructs designed to induce antibodies targeting the
polymorphic types present in the N-terminal part of the molecule (Tetteh et al.
2005). In a similar fashion VAR2CSA vaccine constructs could target conserved
epitopes like those identified in SE3 or alternatively constructs should induce
antibodies targeting different serological variants like those predicted to be gen-
erated by the sequence polymorphisms present in regions, SE1 and SE2. The
human antibody pools used in this study to identify surface exposed antigenic
targets inhibit parasite binding to CSA in vitro (data not shown). However,
the molecular targets of the inhibitory antibodies have not been identified and
knowledge is required about the antigenic targets for antibodies on the other
VAR2CSA DBL domains. The high similarity between the DBL structures of
EBA-175 (Tolia et al. 2005), Pkα-DBL (Singh et al. 2006) and the VAR2CSA
DBL3X model suggests that the DBL structures in Plasmodium are relatively
conserved and that the antigenic characteristics of the DBL3X might be com-
parable to those of the remaining VAR2CSA DBL domains. However, a more
comprehensive analysis of sequence variation, antibody epitopes and structure
of the VAR2CSA DBL domains not belonging to DBL3X is needed to establish
the extent of the structural conservation between the domains.
Development of PAM vaccines requires a much better understanding about the
molecular interaction between placental parasites and the ligand on the syncy-
tiotrophoblasts, as well as knowledge about the fine specificity of the targets for
antibodies inhibiting binding. Native PfEMP1 molecules are difficult to isolate
and with current technologies it is difficult to produce correctly folded recom-
binant material in quantities allowing structure elucidation by crystallography.
In this paper, we have combined in silico methods such as model building and
sequence analysis and the analysis of antibody reactivity to obtain new infor-
mation and generate hypotheses about the structure and functional relationship
of VAR2CSA.
Materials and methods
Cloning and expression of VAR2CSA domains
DBL3X and DBL4 of VAR2CSA was amplified from FCR3 and 3D7 genomic
DNA with the following primers: FCR3 DBL3X - 5’ CG GAA TTC ACC AAT
ATT AAT AAA AGT GAA and 3’ ATT TGC GGC CGC CAG CAT TAT
TAT ATT TGT A, 3D7 DBL3X - 5’CG GAA TTC AAG ATG AAG TCC TCC
GAG and 3’ATT TGC GGC CGC CAA AAC AGC CAA GCT GGA, 3D7
DBL4 - 5’CG GAA TTC CAG GTG AAG TAC TAC GAA and 3’CTG TTC
CTC CAC GTG CTC CAG. PCR products were digested with EcoRI and NotI
for cloning into the Baculovirus vector, pAcGP67-A (BD Biosciences), which
was modified to contain the V5 epitope upstream of a histidine tag in the C-
terminal end of the constructs. Linearised Bakpak6 Baculovirus DNA (BD
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Biosciences Clontech) was co-transfected with pAcGP67-A into Sf9 insect cells
for generation of recombinant virus particles. Recombinant protein was purified
on Co2+ metal-chelate agarose columns as secreted histidine-tagged proteins
from the supernatant of infected High-Five insect cells.
CSA binding assay
Binding to CSA (C9819 Sigma-Aldrich, Brøndby, Denmark) was determined in
an ELISA system. ELISA plates (Falcon 351172) were coated overnight with
CSA (50 µg/ml) in PBS at 4◦C. Coating with 1% BSA in PBS (blocking buffer)
was used as negative control. Plates were incubated with blocking buffer for 1
hour at room temperature (RT) to inhibit non-specific adsorption to the plate.
The VAR2CSA proteins were diluted in blocking buffer (1-10 µg/ml protein),
added to the wells and incubated for 1 hour at RT. For the inhibition assays,
proteins (7µg/ml) were pre-incubated with different concentrations of soluble
CSA for 30 min. Plates were washed 4× in PBS in between the different steps.
Specific binding was visualized by adding an HRP-conjugated antibody (R960-
25, Invitrogen, Taastrup, Denmark) targeting the V5 epitope of the constructs.
Plates were incubated for 1 hour with the anti-V5 antibody diluted 1:3000 in
blocking buffer. The color reactions were developed for 15 min by the addition
of o-phenylenediamine substrate and stopped by adding 2.5 M H2SO4. The
optical density (OD) was measured at 490 nm.
Cloning and sequencing of placental var2csa genes
All DBL3X sequences were obtained from cDNA, whereas DBL2X and the over-
lapping region of DBL4 and DBL5 of var2csa were cloned from genomic DNA
of placental parasites. In brief, parasites were dissolved in Trizol LS (Invitro-
gen) and RNA was prepared according to the manufacturer’s instruction. RNA
pellets were dissolved in 10 µl of RNase-free water and treated with DNaseI
(Sigma-Aldrich, Brøndby, Denmark) for 25 min at RT, followed by 10 min heat
inactivation at 65◦C. All RNA samples were subsequently tested in real-time
PCR for contamination with genomic DNA using a primer set for the house-
keeping gene, seryl-tRNA synthetase. DNA-free RNA samples were used for
synthesis of cDNA by reverse transcriptase (Superscript II, Invitrogen) and ran-
dom hexamer primers as described by the manufacturer. Following primer sets
were used for cloning DBL3X from cDNA into either the Baculovirus vector,
pAcGP67-A (BD Biosciences) or the pCR2.1-TOPO R© vector (Invitrogen): p509
5’ CG GAA TTC GAT ACA AAT GGT GCC TGT and p510 3’ ATT TGC
GGC CGC ATA TAC TGC TAT AAT CTC C, p508 5’ CG GAA TTC ACA
CAA AAT TTA TGT GTT and p510, p503 5’ GAG ATA CAA ATG GTG
CCT GT and p505 3’ AAA TTT GCT GAT ATA CAT TCA G. PCR products
aimed for the Baculovirus vector were digested with EcoRI and NotI before
ligation. Three to six colonies of each cloning and corresponding plasmids were
sequenced by Macrogen (Seoul, Korea). Genomic DNA was extracted from fil-
ter paper using a chelex based method (Pearce et al. 2003). Briefly, filter spots
were dissolved in 0.5% saponin in PBS using a microtiter plate and incubated
overnight on a shaker at RT. After washing the filter spots twice in PBS, a solu-
tion of 50 µl of H2O and 100 µl of 10% chelex mixture was added to each well.
The plate was boiled for 8 min and subsequently cooled down for 10 min at RT.
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A PCR reaction was run with primers for the seryl-tRNA synthetase gene to
control for the DNA content. Around 1-3 µl of DNA was used for the PCR re-
actions amplifying the different var2csa regions. All PCR products were cloned
into the pCR2.1-TOPO R© vector and the inserts sequenced on a 3100-Avant
Genetic Analyzer (Applied Biosystems). The origin of parasites are described
in (Tuikue Ndam et al. 2004). All sequence data are available at GenBank
accession numbers DQ995590-DQ995632.
Phylogenetic reconstruction
The alignment of 43 placental and 4 database VAR2CSA DBL3X sequences,
covering the 3D7 amino acid positions 1256 to 1549, was constructed using the
software RevTrans (Wernersson and Pedersen 2003), and subsequently manually
corrected for errors. To cover more of the DBL3X domain, an alignment of 17
database sequences was constructed in the same way, covering the 3D7 positions
1217 to 1255. For the phylogenetic tree, 21 Malawian sequences (Duffy et al.
2006) were aligned with the sequences mentioned above, again using RevTrans
and manual correction, resulting in a 609 bp alignment. The program Mr-
Modeltest version 2.2 (Nylander 2006) was used to find the most appropriate
nucleotide substitution model based on the Akaike information criterion (Posada
and Buckley 2004). Phylogenetic trees based on the above alignments were con-
structed by Bayesian inference using the program MrBayes version 3.1.1 (Ron-
quist and Huelsenbeck 2003). In all cases Markov chain Monte Carlo (MCMC)
sampling was performed for 10,000,000 generations with 8 chains. Convergence
was confirmed by comparing the results of two independent runs. Burn-in was
determined using Tracer (Rambaut and Drummond 2006) and 50 % majority
rule consensus trees were constructed.
Model fitting and Akaike weighted dN/dS average
The program codeml from the PAML package version 3.14 (Yang 1997) was
used to fit a range of codon-based evolutionary models to the VAR2CSA DBL3X
region using the alignments and Bayesian trees mentioned above. Eleven codon-
based models were tested using codeml: M0, M1a, M2a, M3 (with either 3, 4,
5, 6, or 7 site categories), M5, M7 and M8 (Goldman and Yang 1994; Nielsen
and Yang 1998; Yang et al. 1998). All 11 models were fitted using the F3x4
(different nucleotide frequencies for each codon position) approach for estimating
codon frequencies. Convergence was confirmed by comparing the results of
several independent runs started with different parameter vectors. The Akaike
information criterion (AIC) was used to assess model fits (Posada and Buckley
2004; Akaike 1973; Burnham and Anderson 2002). Briefly, AIC estimates the
expected relative Kullback-Leibler distance (i.e. AIC is an estimate of the
amount of information that is lost when a given model is used to approximate
the full truth). AIC is a function of the maximized log-likelihood (lnL) and the
number of estimated parameters (K) for a model. Specifically, AIC = −2lnL+
2K where lower AIC values indicate better models. From AIC it was possible to
compute Akaike weights, which can be interpreted as the conditional probability
of the model given the data and the set of initial models (Posada and Buckley
2004; Burnham and Anderson 2002). On this basis, dN/dS ratios for codon
positions were calculated as an average of the dN/dS ratios estimated from
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each of the eleven models, weighted by the Akaike weights for the corresponding
model.
Recombination and mutation rates, diversity and sequence logo cre-
ation
The population recombination rate ρ was estimated for the VAR2CSA DBL3X
domain in LDhat version 2.0 (McVean et al. 2004), which based on population
genetics uses coalescent methods specially adapted to account for the possi-
bility of recurrent or back mutation and for an AT-rich genome such as that
of P. falciparum (McVean et al. 2002). As argued by Mu et al. (Mu et al.
2005), the coalescent recombination estimate can for partially inbreeding hap-
loid species such as P. falciparum, be interpreted as the compound parameter
ρ = 2Ner(1−f), where Ne represents the effective population size of the DBL3X
population, r denotes the rate of recombination cross-over events per genera-
tion per bp and f is the inbreeding coefficient. The effective population size
should be thought of as the size of an ideal population (McVean et al. 2002;
Hudson 2001) with the same magnitude of random genetic drift as the actual
population with size N (Hartl and Clark 1997). To test if the placental DBL3X
sequence data showed evidence for deviation from the neutral model of evo-
lution assumed by the coalescent method, we calculated Tajima’s D statistic
(Tajima 1989) and Fu and Li’s D* and F* statistic (Fu and Li 1993). All three
statistics were insignificantly different from zero (p>0.1 in all cases), indicating
that the coalescent approach could be applied. The hypothesis of no recombi-
nation was rejected using the likelihood permutation test (McVean et al. 2002)
with 1000 permutations of segregating sites, of which none produced a higher
maximum composite likelihood than for the DBL3X data. The hypothesis of a
constant recombination rate across the analyzed region was also rejected (p =
0.048 with 10,000 simulations) using the method described in (McVean et al.
2004), indicating significance in the recombination rate variations over DBL3X.
For calculation of the population recombination rate ρ, we used the Bayesian
reversible-jump Markov chain Monte Carlo (RJMCMC) method with a block
penalty of 10, running for 10,000,000 iterations with 2,000 iterations per sample
and a burn in of 50 samples. The overall region estimate was converted to base
pair units using the average length of the analyzed sequences. Recombination
hotspots were defined as intervals containing SNPs where the population recom-
bination rate mean was above the upper limit of the 95% confidence interval
for the overall region estimate of 2Ner(1 − f). Fu and Li’s D were calculated
using DnaSP version 4.10.6 (Rozas et al. 2003). The average nucleotide diver-
sity and its variance were calculated according to Nei (Nei 1997) equation 10.5
and 10.7, respectively (gapped columns were included). The Kullback-Leibler
sequence logo was created by calculating the distance between the two groups
of sequences for each amino acid position in the alignment using the symmetric
Kullback-Leibler distance:
DKL =
∑
AA
(p− p′)× log
(
p
p′
)
where p and p′ are the frequencies of an amino acid type in each of the two
groups, and AA indicates that the sum is over all the amino acid types. The
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cumulated Kullback-Leibler distance was calculated as the sum of DKL for all
positions in the alignment. Gaps in the alignment were in this analysis assigned
the letter "O" and treated as an amino acid class. To test if the mentioned
grouping according to parity gave two significantly different sequence groups,
we created 10,000 random groupings and for each of these summed the DKL over
all amino acid positions. Similarly for the individual positions in the logo, the
distribution of DKL for 10,000 random shuﬄes of sequence grouping was noted
specifically for each position, and the p-values were based on these distributions.
Pepscan motif analysis
442 overlapping 31mer peptides covering the exon1 of 3D7 VAR2CSA were syn-
thesized as Solid Phase Peptide Synthesis (SPPS) with a stepwise addition of the
different amino acids attached to a solid resin. The long peptides were synthe-
sized with a cysteine at aa position 15 allowing some secondary structure. This
approach allows identification of antigenic sites that cannot be mapped using
short, linear peptides (Pepscan systems, the Netherlands). The raw data from
a pepscan experiment consists of figures measuring the amount of IgG bound
to each of the overlapping 31 mer peptides. We used the overlap in primary
sequence to determine more specifically what the antibodies have affinity for.
The motif analysis is based on the concept that polyclonal IgG response consists
of subpopulations of monoclonal antibodies each binding a certain set of amino
acid sequence motifs. We then made a list of all possible binding motifs and
transferred the information from the peptide array to these, giving each motif
a score indicating the IgG affinity for the motif. The pepscan assay is designed
primarily to determine linear epitopes, and thus we are mainly interested in
short binding motifs and gaps. On this basis we performed the pepscan motif
analysis, using motifs containing either 2 or 3 defined residues spaced by un-
defined amino acids up to a certain maximal length of 5, 7, 10, 15, 20 or 25
residues. We found that the different maximal motif lengths gave similar re-
sults, but with different detail resolutions (long motifs had a smoothing effect),
and a binding motif with a maximal length of 7 residues was selected as being
most informative. Thus, the presented results are based on the assumption that
motifs are 2 - 7 amino acids long, and contain either 2 or 3 defined residues
spaced by undefined amino acids, e.g. a possible motif could be "WXXXDXE"
or simply "KN". The method was validated by comparison to the raw data,
where rabbit serum from a rabbit immunized with a DBL5 construct was used
in the pepscan assay (Supplementary figure 3.10). The figure shows that the
motif analysis produces peaks approximately at the same positions as in the raw
data, and that the analysis does not introduce bias in the other regions of the
protein. As control for the human IgG used in Figure 6 we used non-immune
Dutch serum as well as a malaria exposed nulliparous woman.
Affinity purification of antibodies and depletion of serum on parasites
Affinity purification of antibodies was done according to manufacturers in-
structions. In brief, 1 mg of recombinant protein was dialyzed against 0.2 M
NaHCO3, 0.5 M NaCl, pH 8.3 and applied to a NHS-activated HiTrap 1 ml
column (GE Healthcare) that had been equilibrated with 3×2 ml 4◦C 1 mM
HCl. After coupling the columns were washed with 0.5 M ethanolamine 0.5
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M NaCl, pH 8 and 0.1 M acetate, 0.5 M NaCl, pH 4 and a final wash with
PBS pH 7.4. One ml of a plasma pool (28 women from Ghana) was then ap-
plied to the column. After washing in 10 ml PBS, affinity bound antibodies
were eluted by CH3COONH4, pH 3 and neutralized in 1 M Tris pH 7.5. The
specificity of the purified antibodies was tested in ELISA against 1) the domain
used for affinity purification, 2) other VAR2CSA domains, and 3) glutamine
rich protein (GLURP) (Dodoo et al. 2000). Affinity purified antibodies used
for pepscan analysis were all negative in ELISA against control proteins and
positive against the homologous domain (data not shown). Surface reactive an-
tibodies in a pool of pregnancy plasma (from 15 pregnant women from Korogwe,
Tanzania) were depleted using a parasite line selected for VAR2CSA expression
using VAR2CSA specific antibodies (Salanti et al. 2004). In brief, 40 µl of
the plasma pool were incubated with 2.0×108 MACS purified intact late stage
trophozoite and schizont infected erythrocytes for 20 min at 4 ◦C. Hereafter, the
cells were centrifuged at 800 g for 8 min, and the supernatant used to suspend
a new pellet of 2.0×108 infected erythrocytes. This procedure was repeated
four times. The depletion of surface reactive antibodies from the plasma pool
was confirmed using a flow cytometry assay (Salanti et al. 2004) after the final
depletion.
3D modelling of the 3D7 DBL3X domain
The three-dimensional structure of the 3D7 sequence (PFL0030c aa 1217 to
1559) was modeled using the HHpred server with default settings (Soding et al.
2005). Briefly, the HHpred method is specialized in remote homology detection
using hidden Markow models (HMMs) build from PSI-BLAST profiles and sec-
ondary structure. The crystal structure of EBA-175 F1 (PDB code 1ZRO chain
A, (Tolia et al. 2005)) was used as template and had the highest sequence and
secondary structure alignment scores. The HHpred alignment was corrected in
a short template loop sequence (Supplementary figure 3.9, positions 215-219)
positioned next to a gap. The correction shifted the position of the gap and
allowed for the modeling of a disulfide bridge in DBL3X, which was conserved
in the EBA-175 F1, F2 and Pkα-DBL domains. HHpred HMMs for DBL3X and
the template continued to match. Finally the corrected alignment was used to
generate a three-dimensional model using MODELLER (Sali et al. 1995) with
the protocol setup in the HHpred server toolkit. A superimposition of the EBA-
175 F1 structure and the DBL3X model was obtained by the HHpred toolkit.
NACCESS (Hubbard and Thornton 1993) was used to calculate relative surface
exposed areas (RSAs) in single chains of EBA-175 F1, F2 and the Pkα-DBL
domain (Singh et al. 2006). The MAMMOTH-mult alignment server (Lupyan
et al. 2005) was used to make a multiple structure superimposition of DBL3X
model on the EBA-175 F1 and F2 DBL domains (Tolia et al. 2005) and the
Pkα-DBL domain (Singh et al. 2006). The resulting alignment was inspected to
identify conserved positions of cysteines and buried hydrophobic residues (RSA
< 30%). Structural visualizations were made using PyMol (DeLano 2002).
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Supplementary figures to Paper II
Figure 3.9: Multiple Structural Alignment of VAR2CSA DBL3X, EBA-175
F1, EBA-175 F2, and Pkα-DBL. Cysteines in conserved disulfide bonds are high-
lighted in blue, conserved tryptophans buried in the structures are shown in red, and
other conserved, buried, and hydrophobic positions are shown in green.
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Figure 3.10: Pepscan Analysis of Rabbit Serum Immunized with a DBL5
Recombinant Construct. (A) Plasma from a rabbit immunized with a DBL5 con-
struct was tested in 1:1000 on the VAR2CSA pepscan array. The upper diagram is
the raw pepscan values with the pepscan score (y-axis) for each of the 420 peptides
(x-axis). (B) The same PepScan scores as (A) but calculated using a motif algorithm
assigning a value to each amino acid.
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Abstract
Pregnancy associated malaria is caused by P. falciparum malaria
parasites binding specifically to chondroitin sulfate A (CSA) in the
placenta. This sequestration of parasites is a major cause of low
birth weight in infants and anemia in the mothers. VAR2CSA is
the main parasite ligand for CSA-binding, and identifying epitopes
of protective antibodies is essential for VAR2CSA vaccine develop-
ment. VAR2CSA is a multi-domain protein and vaccine research has
mainly focused on individual domains. In this study we propose 3D
models for each of the VAR2CSA DBL domains. Additionally, we
show that regions of ID2 and a PfEMP1 CIDR domain could be ho-
mologous to the EBA-175 and Pkα-DBL fold, indicating that ID2
could be a functional domain. We identified regions of VAR2CSA
present on the surface of the native VAR2CSA by comparing reac-
tivity of plasma containing anti-VAR2CSA antibodies in peptide ar-
ray experiments before and after incubation with native VAR2CSA.
When these data were mapped onto the DBL models it was clear
that the S1+S2 DBL sub-domains were surface-exposed in most do-
mains, whereas sub-domains S3 seemed to be less exposed in native
VAR2CSA. These results comprise an important step towards under-
standing the structure of VAR2CSA on the surface of CSA binding
infected erythrocytes.
Keywords: VAR2CSA, DBL, PfEMP1 Malaria, Pepscan, Pregnancy, Struc-
ture modeling
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Introduction
The invasion of erythrocytes and the subsequent adhesion of parasite-infected
erythrocytes (IE) to vascular endothelium or placenta are key events in the
asexual lifecycle of Plasmodium falciparum and thus of major importance for
virulence of this parasite. Erythrocyte invasion is mediated by proteins be-
longing to the Erythrocyte Binding Ligand family (EBL) and in P. falciparum
the Erythrocyte Binding Antigen (EBA)-175 is the best described EBL protein.
EBA-175 contains two Duffy binding like (DBL) domains (called F1 and F2)
which binds to the heavly sialated glycophorin A on the erythrocyte surface
(Orlandi et al. 1992). The monomeric structure of EBA-175 was determined by
X-ray crystallography and the primary feature of the two DBL domains were
α-helices and an anti-parallel β-hairpin (Tolia et al. 2005). EBA-175 also crys-
tallized as a dimer, and the structure of this complex showed that the DBL
domains of EBA-175 interacted in a reverse handshake orientation (Tolia et al.
2005). The simian malaria parasite, Plasmodium knowlesi invade erythrocytes
through the host receptor "Duffy antigen receptor for chemokines" (DARC)
(Miller et al. 1975). This interaction is also mediated by a parasite-encoded
DBL containing protein, Pkα-DBL, and the crystal structure of Pkα-DBL has
been shown to be very similar to PfEBA-175 despite of extensive sequence vari-
ation (Singh et al. 2006). Based on the structure of Pkα-DBL the DBL domain
could be divided into three sub-domains named S1-S3 which are connected by
short linkers. Both glycan binding and DARC binding are predominantly lo-
cated in S1 and S2 (Tolia et al. 2005; Singh et al. 2006).
Adhesion of IE to the vascular bed is thought to be a mechanism developed by
the parasite to avoid being filtered through the spleen, where erythrocytes in-
fected with late stage asexual parasites are removed from the circulation (Weiss
1990). The adhesion is mediated by P. falciparum erythrocyte membrane pro-
tein 1 (PfEMP1), which interacts specifically with receptors on the vascular
endothelium or placenta (Baruch et al. 1995; Salanti et al. 2004). Antibodies
targeting PfEMP1 and abrogating binding are believed to be important media-
tors of acquired malaria immunity (reviewed in (Kraemer and Smith 2006).
Pregnancy-associated malaria (PAM) is caused by P. falciparum sequestering in
the placenta by binding to chondroitin sulfate A (CSA) on syncytiotrophoblasts
(Fried and Duffy 1996). Women suffering from PAM develop antibodies which
protect them and their offspring during subsequent pregnancies (Duffy and Fried
2003). These protective antibodies are thought to recognize a relatively con-
served antigen as plasma and parasites from pregnant women from different
malaria areas cross-react (Fried et al. 1998). The PfEMP1 variant mediat-
ing placental binding was recently discovered and named VAR2CSA (Salanti
et al. 2003; Salanti et al. 2004). The extra-cellular part of VAR2CSA consists
of six Duffy Binding Like (DBL) domains, a large inter-domain (ID2) and a
C-terminal region predicted to be cytoplasmic. Most PfEMP1 molecules, but
not VAR2CSA, contain two cysteine-rich interdomain regions (CIDR domains)
(Gardner et al. 2002; Smith et al. 2000). Some CIDR domains bind to CD36
(Smith et al. 1998) and they have been described as degenerated DBL domains
(Su et al. 1995).
With the aim of making a vaccine that can reverse or inhibit parasite bind-
ing in the placenta, much effort is put into defining the specific part/parts of
VAR2CSA that bind to CSA (reviewed in (Gamain et al. 2007)). The best way
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of determining this interaction would be to produce the extra-cellular part of
VAR2CSA and co-crystallize this multidomain protein with CSA. However, it
is very difficult to express such a large protein and previous attempts to crys-
tallize even single VAR2CSA DBL domains have failed. Thus, novel methods
are required to generate models and hypotheses on the 3D structure of PfEMP1
molecules. The DBL domains of PfEMP1 are often illustrated as pearls on a
string, and vaccine development strategies are focusing on the VAR2CSA DBL
domains as single entities in a larger protein. We have recently published data
showing a structural model of VAR2CSA DBL3X and mapped areas of DBL3X
that are surface exposed on the native protein (Dahlback et al. 2006).
In this study, we modelled the remaining five VAR2CSA DBL domains, the
VAR2CSA inter-domain 2 (ID2) and a number of CIDR domains from different
PfEMP1 molecules. The models indicate that DBL domains contain features
that are structurally conserved. Furthermore it appears that there is homology
between the ID2, CIDR and part of the resolved structures of the DBL fold. By
absorbing antibodies on native VAR2CSA on the surface of infected erythrocytes
and comparing antibody reactivity on a VAR2CSA peptide array before and
after absorption, we define which areas of the VAR2CSA molecule are accessible
to antibodies in the native protein. Interestingly, the surface exposed epitopes
on the six VAR2CSA domains are largely found within S1 and S2, whereas S3
appears to be hidden in the complete VAR2CSA structure. Based on these
data we discuss the domain architecture of VAR2CSA and suggest a model
where the protein is surface-exposed as a globular or multimerized structured
protein stabilized by long α-helices in the S3 region.
Results and Discussion
Modeling of the VAR2CSA DBL domains
The 3D structures of the 3D7 VAR2CSA DBL domains (Figure 3.11) were mod-
eled using the HHpred server (Soding et al. 2005) developed for low-homology
modeling. HHpred template searches confirmed that the determined structures
of the P. falciparum EBA-175 DBL domains F1 and F2 and the P. knowlesi
DBL domain Pkα-DBL (Singh et al. 2006; Tolia et al. 2005) could be used
VAR2CSA Modeling Template Insertions Missing Gaps
DBL template sequence relative to info relative to
domain identity template inserts∗ template
DBL1 Pka-DBL 16.4% 10 4 2
DBL2 EBA-175 F1 17.2% 10 1 0
DBL3 EBA-175 F1 20.7% 6 1 1
DBL4 Pka-DBL 17.8% 9 4 1
DBL5 EBA-175 F1 18.8% 8 1 2
DBL6 Pka-DBL 18.7% 8 4 1
∗Inserts in regions with missing structural information in the template structure.
Table 3.2: Modeling details of the VAR2CSA DBL domains
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Figure 3.11: Structure models of the VAR2CSA DBL domains The experimen-
tal structures of the template EBA-175 and Pkα-DBL domains are shown in the first
row, and DBL models are shown in the middle and last rows. Sub-domains 1-3 of Pkα-
DBL (Pka-DBL) are colored in blue, green and yellow, respectively. Cysteines in all
domains are highlighted in red. Disulfide bonds in templates are numbered according
to occurrence in the sequences. Cysteine pairs in the models which are aligned with
disulfide bonding cysteines in templates are numbered with respect to the templates.
3.6 Paper III 73
as templates for modeling (HHpred probability scores were all 100%), although
the sequence identity between the VAR2CSA DBL domains and templates was
between 16-20% (see modeling details in Table 3.2). The determined struc-
tures of the two EBA-175 DBL domains each contain a region where structural
information is missing and the structure of Pkα-DBL has four such regions
(Table 3.2 and Figure 3.12). In crystallographic experiments, the local occur-
rence of missing structural information indicates regions of flexibility and loosely
defined secondary structure. In Pkα-DBL, regions of missing structural infor-
mation were used to divide the DBL fold into the subdomains S1-S3 (Tolia et al.
2005) and we adapted a similar classification for the VAR2CSA DBL domains
(Figure 3.11 and 3.12). VAR2CSA residues corresponding to regions of miss-
ing structural information in the templates were modeled as insertions relative
to the template structure. The structure of such inserted regions is difficult
to predict correctly (Ginalski 2006). Secondary structure predictions using the
PSIPRED method (Jones 1999) is part of the HHpred modeling protocol. The
prediction results are divided into helix, strand and coil, where the coil class
consists of secondary structure types mostly found in loops. Interestingly, the
template regions of missing structural information aligned with VAR2CSA DBL
sequences predicted to have coil secondary structure. In general, the VAR2CSA
sequence variation is high within these regions (Figure 3.12). Taken together,
this suggests that these VAR2CSA DBL regions form a variety of flexible loops
of different structures.
Evaluation of the VAR2CSA DBL structure models
The quality of a structure model obviously has a pronounced effect on the infor-
mation that can be deduced from the model. We used the automated structure
analysis tool ANOLEA (Melo and Feytmans 1998) for evaluation, and Z-scores
ranging from 5.00 to 9.61 with 52-68% high-energy residues were obtained. The
results indicated that the quality was lowest in the loop regions. Analysis us-
ing Verify3d (Eisenberg et al. 1997) resulted in a similar conclusion (data not
shown). Since these results did not convince us that the models were correct,
we decided to further investigate the quality of the models by inspecting them
for conserved residues stabilizing the determined structures of EBA-175 and
Pkα-DBL domains.
Structural alignment of the EBA-175 and Pkα-DBL domains identified a number
of positions, which can be assumed to be important for the stabilization of the
DBL fold. Thirty-four buried conserved positions of hydrophobic residues, 10
buried conserved positions of polar/charged residues, four helix-capping residues
and 12 conserved cysteines which form six disulfide bridges were identified. The
positions of these residues were distributed throughout the domains in blocks.
We then made a multiple structural alignment including the six VAR2CSA DBL
models and the EBA-175 and Pkα-DBL structure to identify VAR2CSA residues
at the positions corresponding to the positions identified as conserved and sta-
bilizing EBA-175 and Pkα-DBL (Figure 3.12). We found that the models have
preserved a high number of buried hydrophobic positions, which help to form
a hydrophobic core of the DBL domain structure (Table 3.3 and Figure 3.12).
The buried polar and charged amino acids, which stabilize template structures
by forming hydrogen bonding networks or salt bridges, were also conserved.
The models also had conserved helix-capping residues, which stabilize the ends
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S1
S2
S3
Figure 3.12: A structural alignment of the template structures EBA-175 F1
and F2 and Pkα-DBL and the six VAR2CSA DBL models. Vertical color bars
denote positions of stabilizing residues in template structures. Blue bars denote cys-
teines forming disulfide bonds, green bars denote buried hydrophobic residues, orange
bars denote helix capping residues and red bars denote buried polar/charged residues.
The location of sub-domains S1-S3 are marked by horizontal black bars, and regions of
missing structural information in the template structures are marked by black arrow
heads. Residues involved in glycosaminglycan (GAG) binding of EBA-175 DBL do-
mains or DARC receptor binding of Pkα-DBL are marked with red letters. EBA-175
residues involved in dimerization are marked in blue letters.
of helices in the template structures. This conservation of stabilizing positions
indicates that the alignments of the model sequences to the template sequences
are correct in regions surrounding these positions.
The structural alignment and sequence alignments used by HHpred for model-
ing were analyzed for conservation of cysteines forming disulfide bonds in the
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VAR2CSA Buried Buried Helix Cysteines
DBL hydrophobic polar/ capping in positions
domain charged of disulfide bridges∗
Templates 34 11 4 12(14)
DBL1 33 10 4 6
DBL2 32 8 3 10
DBL3 31 9 4 13
DBL4 33 11 4 8
DBL5 33 9 3 6
DBL6 32 11 4 6
∗Counted in HHpred alignments used for modeling.
The parenthesis denotes EBA175 F2.
Table 3.3: Summary of conserved stabilizing positions in models of
VAR2CSA DBL domains
template DBL structures. The models of the VAR2CSA DBL domains all con-
tain conserved cysteine positions likely to form disulfide bonds (Figure 3.11 and
3.12). The disulfide bonds were numbered according to the occurrence of the
cysteines in the sequence. Cysteines of disulfide bond 1 are conserved in all
models except DBL6. Likewise, the cysteines of disulfide bond 5 are conserved
in all models except DBL1. DBL3 is the model with the highest number of con-
served cysteines forming disulfide bonds. DBL1 has a high number of conserved
cysteines, but many of them lack the partner cysteine to make the disulfide
bond. An example is disulfide bond 2, where only one cysteine is conserved
(Figure 3.12, positions 38 and 63). A number of cysteines in the models are
in close proximity to a disulfide bond-forming template cysteine. This suggests
that the local alignments used for the modeling are sub-optimal or that alter-
native disulfide bonds are formed in the VAR2CSA DBL domains. An example
of an alternative bond is the disulfide bond 4 (Figure 3.11, number 4) which
is only found in the EBA-175 F2 DBL (Figure 3.12, positions 316 and 407).
All VAR2CSA DBL domains except DBL1 have cysteines aligned in position
316. Only VAR2CSA DBL3 has a cysteine aligned to 407, but the models of
DBL2 and DBL6 have cysteines in the proximity and it is likely that they form
disulfide bonds with the conserved cysteine in the native structure. Therefore
we suggest that this disulfide bond is common among VAR2CSA DBL domains,
although not present in EBA-175 F1 and Pkα-DBL. Another interesting exam-
ple is the disulfide bond 2 (Figure 3.11, number 2 and Figure 3.12, positions 38
and 64). The disulfide bond is proximal to a region containing glycan binding
amino acids in the EBA-175 F1 and F2 domains (Figure 3.12, positions 44, 48,
and 50-53) and it may play a role for the function of these domains. Among the
VAR2CSA DBL domains, only DBL3 has both cysteines conserved. None of the
other VAR2CSA DBL sequences have two cysteines in the proximity, and it is
thus unlikely that the apparent variation stems from incorrect alignments. The
lack of the disulfide bonds in some regions of the VAR2CSA DBL domains may
suggest higher flexibility and a more dynamic structure than in DBL domains
stabilized by a higher number of disulfide bonds.
The analysis of different types of stabilizing characteristics shows that these to
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Figure 3.13: Modeled regions of ID2 and CIDR domains. The S3 domain of
the template EBA-175 F2 is shown in white. Cysteines in the models are highlighted
in red. (A) The model of the VAR2CSA ID2 domain superimposed in yellow on the
EBA-175 F2. (B) Similar to (A) except showing only the S3 domain. (C) Model of a
CIDR domain.
a large extent are conserved between the template and the VAR2CSA models.
Since our aim was to map experimental data onto the DBL models, rather than
analyzing the structural conformations in detail, we concluded that the models
were of sufficient quality for mapping of these data.
Modeling of VAR2CSA inter-domain 2
The extra-cellular part of VAR2CSA consists of six DBL domains and a sequence
stretch consisting of 337 amino acids named inter-domain 2 (ID2) (Gardner
et al. 2002). This part of the molecule has attracted little attention and has
been viewed as an inter-domain spacer sequence. We analyzed the ID2 sequence
(PFL0030c positions 879-1216) for homology to other proteins using the HHpred
search and alignment tool. Interestingly, the EBA-175 and Pkα-DBL domains
were all identified as homologous to the ID2 domain with very high HHpred
probability scores (Probabilities = 98.3-99.9%). The similarity was pronounced
in a region of 100 residues (PFL0030c positions 1017-1116), which aligned to the
first two α-helices in S3 with a sequence identity of 19.8%. Using the EBA-175
F2 DBL domain as template, we modeled the structure of ID2 positions 1017-
1116 (Figure 3.13A and B). The secondary structure of the whole ID2 domain
was then predicted using PSIPRED (data not shown). The ID2 region subse-
quent to the DBL-homologous region was predicted to consist of a short β-sheet
and four α-helices interspersed with loop regions. In the EBA-175 and Pkα-
DBL structures, these sequences consist of α-helices interspersed with a loop
region. The ID2 region preceding the DBL homologous region was predicted to
contain six β-strands and two α-helices. These data suggest that the C-terminal
part of ID2 form a structure similar to DBL S3, but does not support the notion
that the N-terminal part of ID2 has a fold similar fold to DBL S1 and S2.
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In most PfEMP1 molecules the first DBL domains are separated by a cysteine-
rich inter-domain region (CIDR1) on which there is no structural data available.
Since VAR2CSA ID2 and CIDR1 domains are placed at the same position in the
sequence, we examined CIDR1 sequences representative for the three subgroups
CIDR-α, β and γ. Using the HHpred server, homology between all CIDRs
and EBA-175 was identified. Similarly to the ID2 domain, the homology was
detected in the first two helices of the DBL S3 and a structure model was
made using the EBA-175 F2 DBL as template structure (Figure 3.13B). The
homologous region was part of the CIDR M2 region defined by Smith et. al
(Smith et al. 2000). The secondary structure of the CIDR region preceding
the DBL homologous region was predicted to contain three β-strands and four
α-helices; the subsequent region was predicted to contain six α-helices (data not
shown). These predictions suggest that like ID2, the C-terminal part of CIDR1
forms a structure similar to that of the DBL S3.
Mapping surface-expressed continuous epitopes on VAR2CSA
In rational PAM vaccine design, it is important to establish which parts of native
VAR2CSA are accessible to antibodies acquired by women who have developed
immunity to pregnancy-associated malaria. To gain such information we ab-
sorbed anti-VAR2CSA IgG from pools of plasma using VAR2CSA-expressing
infected erythrocytes and compared the antibody reactivity of the pools in a
VAR2CSA peptide array before and after absorption. Based on prior knowl-
edge of high levels of anti-VARCSA IgG two pools were made using plasma from
32 and 10 Tanzanian pregnant women, respectively. One of the plasma pools
(Human serum pool 1) was depleted using erythrocytes infected with 3D7 par-
asites. From the other pool (Human serum pool 2), two depleted plasma pools
were generated by depleting one part with erythrocytes infected with 3D7, and
depleting the other part on erythrocytes infected with the FCR3 parasite line.
The antibody assays were performed on an array containing 442 overlapping
31mer peptides corresponding to the extra-cellular part of VAR2CSA based on
the sequence of 3D7.
Before absorption, the two pools contained antibodies targeting all the peptides
(data not shown) but some regions distributed in different parts of the domains
showed high reactivity, which can be seen as peaks in Supplementary figure 3.17
-3.22. The antibody reactivity toward most of the peptides was not affected by
the depletion, but depletion on native VAR2CSA consistently removed antibody
reactivity against some peptides (Supplementary figure 3.17 -3.22).
In addition to the human plasma pool, a pool of plasma from six rabbits each
immunized by a different VAR2CSA DBL domain was absorbed and tested.
The pattern of reactivity in the peptide array with this pool before absorption
was slightly different from the reactivity obtained with the human plasma pools
and this difference was also reflected in the absorption experiments.
These results indicated that all domains including the N-terminal segment con-
tained continuous peptides sequences accessible to antibodies, when the VAR2CSA
protein was expressed on the surface of CSA-binding infected erythrocytes. It
was difficult however, to detect a pattern for this reactivity between the domains
when depicting the reactivity on a string of residues. We therefore went on to
visualize the reactivity on the DBL models.
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Figure 3.14: Mapping of surface exposed antibody reactive regions onto the
model of the DBL6 domain. The color intensity denotes the level of antibody
depletion when VAR2CSA containing plasma is incubated with parasites expressing
native VAR2CSA. The following plasma and parasite combinations were used for the
depletion experiments: (A) Human serum pool 1 depleted with 3D7 parasites. (B)
Human serum pool 2 depleted with 3D7 parasites. (C) Human serum pool 2 depleted
with FCR3 parasites. (D) Rabbit serum pool depleted with 3D7 parasites.
3D aspects of surface exposed epitopes in VAR2CSA DBL domains
To assign a value reflecting the accessibility to antibodies of a residue in the
native protein we subtracted the depleted reactivity from the non-depleted re-
activity. These values, Depletion values (DV) were calculated for each of the
four depletion experiments (human pool 1 vs. 3D7 or FCR3, human pool 2 vs.
3D7, rabbit pool vs. 3D7) and mapped onto the six structural DBL models
(Supplementary figure 3.23 -3.27). Figure 3.14 shows the results for DBL6 and
it is apparent that the depletion experiments using the two human plasma pools
identified essentially the same regions as target for surface reactive antibodies
(Figure 3.14A versus 3.14B). The results obtained in the absorption experiment
using FCR3-infected erythrocytes gave essentially the same results as the exper-
iment using 3D7-infected cells (Figure 3.14A versus 3.14C). Since the peptide
array was based on the 3D7 sequence, this indicates that the surface-exposed epi-
topes on the 3D7 and FCR3 versions of VAR2CSA are cross-reactive or target-
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conserved epitopes. The absorption experiment using the rabbit plasma pool
only showed depletion of antibodies targeting peptides residing in S1 and S2
(Figure 3.14D). There was no indication of depletion of antibodies targeting S3
in any of the experiments.
To facilitate a comparison between DBL domains, we created consensus DVs
for each domain by calculating a sum of normalized DVs from each of the four
absorption experiments and scoring the residue as positive if the value was
above a fixed threshold (Figure 3.15). Overall there was a reasonable agreement
between the models based on the individual absorption experiments and the
consensus DVs (Figure 3.14A and B versus Fig. 3.15, DBL6). The results
for DBL3 were also in agreement with the surface exposed epitopes identified
previously (Dahlback et al. 2006). When evaluating the consensus models
it should be kept in mind that surface-exposed VAR2CSA regions can only
be detected if the plasma pool contains antibodies against the region and if
the antibodies can be detected in the peptide array assay. Thus, regions not
targeted by antibodies or targeted by antibodies, which cannot be detected in
the peptide array experiment because they either target non-linear sequences or
polymorphic sequences not represented in 3D7 VAR2CSA, will not be scored as
surface reactive. Likewise, residues buried in the native molecule but residing
close to a region representing a surface exposed epitope on the peptides will
score as positive.
When comparing the consensus models for the six DBL domains, it was evident
that the pattern of reactivity was comparable in DBL domains 1, 2, 3, 5 and 6,
whereas the pattern in DBL4 was unique (Figure 3.15). For the former domains
the targets of surface reactive antibodies were mainly located in S1 and S2,
whereas little reactivity was found in S3, which is located on the lower left
side of the models in Figure 3.15. In S1 and S2 both loops and α-helices were
targets of surface reactive antibodies. The loop between S1 and S2 (Figure
3.12, positions 81-87 and appearing most prominently in the upper left corner
of the DBL2 model on Figure 3.15) is flexible in the Pkα-DBL structure and
we observe a high sequence variation between the DBL domains in the region,
suggesting that the corresponding loops in the VAR2CSA DBL domains are
correspondingly flexible, reinforcing the possibility that VAR2CSA domains can
be divided into sub-domains. In DBL domains 2, 3, 5 and 6, a loop in S2
(appearing most prominently in the lower right corner of DBL3 on Figure 3.15)
was also targeted by surface reactive antibodies. A loop region in S1 (Figure
3.12, positions 44-52, appearing most prominently in the center of DBL6 on
Figure 3.15) was recognized in DBL domains 1, 2, 3, and 6. Interestingly, the
corresponding regions in EBA-175 contain glycan-binding residues. The S2 α-
helix appearing in the upper right on all models was recognized in all domains
but DBL4, whereas some of the α-helices in S1 and S2 were recognized to a
varying degree.
The regions of DBL4 targeted by surface reactive antibodies differed markedly
from the other domains. Relatively more reactivity was detected against S3
and the reactivity against S2 was mainly against regions on opposite site of the
domain compared to the other domains (Figure 3.15 and Figure 3.16). The
possibility that DBL4 is positioned different from the other domains in the
quaternary VAR2CSA structure is in agreement with the finding that the DBL4
specific rabbit antibodies are not reacting with the native VAR2CSA on IE
(Nielsen et al. 2007, and unpublished data).
80 Chapter 3. Identifications of B-cell epitopes in the Plasmodium falciparum protein VAR2CSA
Figure 3.15: Areas predicted to be targeted by surface reactive antibodies
on the six VAR2CSA DBL domains. The highlighted regions were defined on
the basis of the results of several experiments where anti-VAR2CSA antibody contain-
ing plasma was incubated with parasites expressing native VAR2CSA. Residues with
consensus DVs>1 which are conserved in sequences of VAR2CSA are highlighted in
blue and variable residues with consensus DVs>1 are highlighted in green. See text
for details.
Using a multiple sequence alignment of seven full-length VAR2CSA sequences,
residues were classified as conserved if they were all identical and as polymorphic
if any of the sequences showed variation in the particular position. It is appar-
ent from Figure 3.14 and 3.15 that all domains contained both conserved and
polymorphic regions targeted by surface reactive antibodies, but the conserved
regions were most prominent in DBL3 and DBL5. This is in agreement with
data showing that antibodies raised against recombinant proteins representing
DBL3 and DBL5 are more likely to cross react with heterologous parasites,
than antibodies raised against the other domains (Nielsen et al. 2007). The
data is also in agreement with the reactivity of human monoclonal antibodies
produced by immortalized B cells from malaria-exposed pregnant women which
are directed predominantly against these two domains (Barfod et al. 2007).
Conserved surface-exposed epitopes appear to be attractive vaccine targets.
However, protective immunity is acquired through successive pregnancies (Duffy
and Fried 2003; Staalsoe et al. 2004), and is a function of transmission intensity
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Figure 3.16: VAR2CSA DBL4 regions predicted to be targeted by surface
reactive antibodies. The plot is similar to Figure 3.14, except viewed from the
reverse side.
(McGregor et al. 1983). Natural acquired protection could therefore depend on
the ability to recognize several polymorphic VAR2CSA variants. This is con-
sistent with the finding that some targets of naturally acquired antibodies are
under diversifying selection (Dahlback et al. 2006). The levels of antibodies
against pregnancy-associated parasite-encoded antigens on the surface of the
erythrocyte increase with the number of pregnancies, and are correlated to the
adhesion inhibitory capacity (Fried et al. 1998; Ricke et al. 2000). Therefore, it
is also possible that protective adhesion-blocking antibodies against conserved
epitopes only appear after a number of infections, and that the antibodies ap-
pearing after the first infection have less protective value.
VAR2CSA, a globular protein?
So far, little is known about the overall structure of VAR2CSA or any other
PfEMP1. It has been suggested that the PfEMP1 protein architecture is com-
prised by a compact conserved head structure which defines the binding affinity
and a number of variable C-terminal domains (Su et al. 1995). Previous data
have indicated that the general DBL fold is relatively conserved (Dahlback et al.
2006; Howell et al. 2006; Singh et al. 2006; Tolia et al. 2005) and that DBL
domains can interact with each other as building block to form binding sites
(Tolia et al. 2005). The data presented here indicates that DBL S3 is less
surface-exposed than S1 and S2. Sub-domain 3 contains two long α-helices
which are conserved in the template structures. A number of multimeric pro-
tein complexes have been reported to be stabilized by interactions between long
α-helices; a well-studied example is the trimer of influenza virus hemagglutinin
(Gamblin et al. 2004). The data presented here does not lend support to the
idea of a compact conserved head structure in VAR2CSA. Rather it is tempt-
ing to propose models of VAR2CSA where α-helices of different DBL domains
interact to bury a considerable part of S3 in the interface between the domains.
The interaction could be formed between DBL domains of a single VAR2CSA
molecule to form a more globular shape of VAR2CSA. Another possibility is
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that several VAR2CSA molecules form dimers or multimers with S3 buried in
the middle. The possibility that VAR2CSA is present as a globular protein
opens up for the possibility that the CSA binding site is comprised of regions
from different DBL domains, like the glycan binding sites of EBA-175 (Tolia
et al. 2005). Further exploration of the quaternary structure of VAR2CSA is
therefore of the utmost importance.
Experimental procedures:
Modeling the structure of the VAR2CSA domains
Structures of the CIDR domains and the 3D7 VAR2CSA DBL and ID2 do-
mains were modeled using the HHpred server with default settings (Soding et al.
2005). The HHpred method is based on comparisons and alignments of hidden
Markow models (HMMs), which include gaps and insertion probabilities. The
modeling of the DBL3 domain was done as described previously (Dahlback et al.
2006). VAR2CSA domains were modeled separately by splitting the PFL0030c
sequence into separate domains (DBL1 aa 57-400, DBL2 aa 531-879, DBL4
aa 1575-1911, DBL5 aa 1999-2283, DBL6 aa 2340-2633, ID2 aa 879-1216). All
HMM databases available in web-server were used for template structure search,
including the Protein Data Bank (PDB). For all the VAR2CSA DBL domains
described, the structures of the EBA-175 DBL domains (Tolia et al. 2005) and
the Pkα-DBL domain (Singh et al. 2006) had HHpred probability scores sig-
nificantly higher than other structures detected. The DBL structure with the
highest sequence and secondary structure alignment scores were chosen as tem-
plate for each domain. Template alignments proposed by the HHpred method
were used to generate 3D models by using a HHpred server toolkit protocol for
MODELLER (Sali and Blundell 1993). Models were evaluated using Verify3d
(Eisenberg et al. 1997) and ANOLEA (Melo and Feytmans 1998), available in
the HHpred server toolkit.
Superimpositions of EBA-175 F1, F2, Pkα-DBL and VAR2CSA domains were
made using the MAMMOTH-mult alignment server (Lupyan et al. 2005). NAC-
CESS version 2.1.1 (Hubbard and Thornton 1993) was used for analysis of rel-
ative accessible surface areas (RSAs) in the template structures. Residues with
RSA<30% were considerer buried. Separate secondary structure predictions of
CIDR and ID2 were made using the PSIPRED (Jones 1999). All structural
visualizations were produced using PyMol (DeLano 2002).
Selection and depletion of plasma samples on parasites
Plasma levels of DBL1-DBL6 VAR2CSA specific IgG were measured in standard
ELISA assays (Dodoo et al. 2000). Plasma samples positive against more than
two domains were used to make two pools of plasma samples. No single plasma
sample was used in both pools. Rabbits were immunized with DBL1-DBL6 and
ID2 recombinant protein as described (Barfod et al. 2006) and the seven serum
samples were pooled to create the VAR2CSA rabbit pool.
3D7 and FCR3 parasites were panned on BeWo cells to create CSA adhering
parasite lines. Using real time PCR and flow cytometry with VAR2CSA specific
reagents as well as plasma from Tanzania, we verified that the parasites were
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gender-specifically recognized and expressing high levels of VAR2CSA on the
surface of the infected erythrocyte (Haase et al. 2006).
For the parasite IgG depletion 40 µl of the plasma pool were incubated with
2.0 × 108 MACS purified intact late stage trophozoite- and schizont-infected
erythrocytes for 20 min at 4 ◦C. Hereafter, the cells were centrifuged at 800
g for 8 min, and the supernatant used to suspend a new pellet of 2.0 × 108
infected erythrocytes. This procedure was repeated four times. The depletion
of surface reactive antibodies from the plasma pool was confirmed using a flow
cytometry assay after the final depletion.
Analysis of Pepcan data
All raw pepscan data were analyzed for short motifs as described previously
(Dahlback et al. 2006). For each of the four depletion studies, DVs were cal-
culated by subtracting depleted pepscan data points from non depleted points.
Positive DVs of each individual experiment was split into five equally sized in-
tervals ranging from the highest to the lowest data points and with increasing
color intensity. The five intervals were then plotted on the models. For consen-
sus DVs, the DVs for each depletion study on individual DBL domain were first
normalized by subtracting the mean and dividing with the standard deviation.
Subsequently, the consensus DVs was calculated by summing the normalized
values for each position in the DBL domains. Consensus DVs >1 were plotted
on the DBL models.
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Supplementary figures to Paper III
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Figure 3.17: Plots of pepscan analysis results for the DBL1 domain. The top
figure represent results from anti-VAR2CSA antibody human plasma pool 1 before and
after depletion with infected parasites. The middle figure represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and the bottom
figure represents similar results obtained by using a rabbit anti-VAR2CSA antibody
plasma pool. All data presented here was analyzed for short motifs.
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Figure 3.18: Plots of pepscan analysis results for the DBL2 domain. The top
figure represent results from anti-VAR2CSA antibody human plasma pool 1 before and
after depletion with infected parasites. The middle figure represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and the bottom
figure represents similar results obtained by using a rabbit anti-VAR2CSA antibody
plasma pool. All data shown in this figure was analyzed for short motifs.
86 Chapter 3. Identifications of B-cell epitopes in the Plasmodium falciparum protein VAR2CSA
1250 1300 1350 1400 1450 1500 1550
100
150
200
250
Non-depleted human pool 1
3d7 depleted human pool 1
VAR2CSA DBL3 Pepscan data
1250 1300 1350 1400 1450 1500 1550
100
150
200
250
Non-depleted human pool 2
3d7 depleted human pool 2
FCR3 depleted human pool 2
1250 1300 1350 1400 1450 1500 1550
PFL0030c residue number
100
150
200
250
Non-depleted rabbit pool
3d7 depleted rabbit pool
Figure 3.19: Plots of pepscan analysis results for the DBL3 domain. The top
figure represent results from anti-VAR2CSA antibody human plasma pool 1 before and
after depletion with infected parasites. The middle figure represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and the bottom
figure represents similar results obtained by using a rabbit anti-VAR2CSA antibody
plasma pool. All data shown in this figure was analyzed for short motifs.
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Figure 3.20: Plots of pepscan analysis results for the DBL4 domain. The top
figure represent results from anti-VAR2CSA antibody human plasma pool 1 before and
after depletion with infected parasites. The middle figure represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and the bottom
figure represents similar results obtained by using a rabbit anti-VAR2CSA antibody
plasma pool. All data shown in this figure was analyzed for short motifs.
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Figure 3.21: Plots of pepscan analysis results for the DBL5 domain. The top
figure represent results from anti-VAR2CSA antibody human plasma pool 1 before and
after depletion with infected parasites. The middle figure represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and the bottom
figure represents similar results obtained by using a rabbit anti-VAR2CSA antibody
plasma pool. All data shown in this figure was analyzed for short motifs.
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Figure 3.22: Plots of pepscan analysis results for the DBL6 domain. The top
figure represent results from anti-VAR2CSA antibody human plasma pool 1 before and
after depletion with infected parasites. The middle figure represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and the bottom
figure represents similar results obtained by using a rabbit anti-VAR2CSA antibody
plasma pool. All data shown in this figure was analyzed for short motifs.
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Figure 3.23: Mapping surface exposed antibody reactive regions on the
model of the DBL1 domain. The color intensity denotes the values of positive
depletion values. (A) Human serum pool 1 depleted with 3D7 parasites. (B) Human
serum pool 2 depleted with 3D7 parasites. (C) Human serum pool 2 depleted with
FCR3 parasites. (D) Rabbit serum pool depleted with 3D7 parasites.
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Figure 3.24: Mapping surface exposed antibody reactive regions on the
model of the DBL2 domain. The color intensity denotes the values of positive
depletion values. (A) Human serum pool 1 depleted with 3D7 parasites. (B) Human
serum pool 2 depleted with 3D7 parasites. (C) Human serum pool 2 depleted with
FCR3 parasites. (D) Rabbit serum pool depleted with 3D7 parasites.
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Figure 3.25: Mapping surface exposed antibody reactive regions on the
model of the DBL3 domain. The color intensity denotes the values of positive
depletion values. (A) Human serum pool 1 depleted with 3D7 parasites. (B) Human
serum pool 2 depleted with 3D7 parasites. (C) Human serum pool 2 depleted with
FCR3 parasites. (D) Rabbit serum pool depleted with 3D7 parasites.
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Figure 3.26: Mapping surface exposed antibody reactive regions on the
model of the DBL4 domain. The color intensity denotes the values of positive
depletion values. (A) Human serum pool 1 depleted with 3D7 parasites. (B) Human
serum pool 2 depleted with 3D7 parasites. (C) Human serum pool 2 depleted with
FCR3 parasites. (D) Rabbit serum pool depleted with 3D7 parasites.
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Figure 3.27: Mapping surface exposed antibody reactive regions on the
model of the DBL5 domain. The color intensity denotes the values of positive
depletion values. (A) Human serum pool 1 depleted with 3D7 parasites. (B) Human
serum pool 2 depleted with 3D7 parasites. (C) Human serum pool 2 depleted with
FCR3 parasites. (D) Rabbit serum pool depleted with 3D7 parasites.
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3.7 Discussion of results in papers II and III
In the two papers presented in this chapter, we identified peptides from VAR2CSA
DBL domains, which cross-bind to antibodies binding the native VAR2CSA pro-
tein in conformations found on the surface of infected erythrocytes. The results
based on the peptide arrays were then mapped on the 3D models of DBL do-
main structures, and this suggested that S1 and S2 are generally more targeted
by antibodies from women immune to PAM, than S3. As mentioned in the
papers, it is important to realize that these peptide array experiments do not
identify all epitopes of these domains. There is two reasons for this: First, the
peptide arrays only identify linear epitopes. In general, many natural epitopes
are discontinuous and conformation-dependent; therefore all residues of these
epitopes cannot be expected to be identified by using peptide arrays. Second,
the identified peptides are restricted to only cross-react to antibodies in the
serum pools used. Because the sequence variability of VAR2CSA is high, it is
possible that the serum pools contain antibodies which cannot bind the 3d7 line,
but bind surface exposed epitopes in VAR2CSA DBL domains from other lines
with high affinity.
It is important to note that the DBL3X residues which were found to vary
significantly with the parity of women, are not found to be highly reactive in
the pepscan experiments. This can be seen in figure 3.7, where only the data
shown in figure 3.7G-I have notable pepscan scores in that region. In the results
of paper III, which are based on other serum pools, the region is not seen to be
reactive either (see figure 3.25). Also, we observed a difference in reactivity of
depletion studies between different serum samples in papers II and III. One of
the depletion studies (figure 3.25A) showed similar reactive regions to the SE1-
SE3 regions identified in paper II (figure 3.8D and E), but the other depletion
studies of DBL3X (figure 3.25B and C) showed different reactive regions, and
only the SE2 region was found to be have reactivity. Taken together, these
results suggest that more epitopes remain to be identified. However, all of the
DBL domains except DBL4 have little reactivity in the S3 part of the DBL
structure and this strengthens the hypothesis that the S3 part is less prone to
targeting by neutralizing antibodies.
The final aim of the PAM research projects is to develop vaccines which can
prevent the effects of PAM. However, little is known about the mechanisms of
VAR2CSA function and host interaction. For the development of a vaccine, it
is useful to gain more knowledge of these mechanisms because epitopes used
in a vaccine should elicit neutralizing antibodies which abrupt binding of CSA.
The results presented in the papers II and III provide more insight in antibody
reactive regions, and future experiments should investigate whether the epitopes
of these regions can elicit neutralizing antibodies.
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Chapter4
Concluding remarks and
perspectives
The chapters of this thesis have described my work on different research projects
in the fields of B-cell epitope prediction and identification. In this chapter
is a final summary of some findings of the projects and a discussion of the
perspectives of the results.
4.1 Concluding remarks
Prediction of B-cell epitopes
In the development of a B-cell epitope prediction method, 3D structures of
antibody-antigen complexes provided detailed information of binding interac-
tions which were used to derive a data set of discontinuous B-cell epitopes. The
data set was used to develop a method for prediction of discontinuous B-cell
epitopes, which uses protein 3D structures to measure surface exposure and de-
termine spatial proximity. We have shown that the method performs better than
a classical sequence-based method, and that it can predict residues in epitopes
which have been identified on the basis of different experimental techniques.
Thus, in the B-cell epitope prediction project, 3D protein structures were useful
both for definition of epitopes in the data set, and for providing information
about proteins which can be used for prediction of epitope residues.
Identification of B-cell epitopes in the PAM-related protein VAR2CSA
The experimentally determined structures of the EBA-175 and Pkα DBL do-
mains were essential for this project, as structure predictions showed that the
VAR2CSA DBL domains have similar folds to the EBA-175 and Pkα DBL do-
mains, despite a high sequence variation between the domains. Furthermore,
3D structure prediction of the VAR2CSA ID2 and various CIDR domains indi-
cated that parts of these domains have similar folds to the S3 region of the DBL
domains. Secondary structure prediction showed that other parts of the ID2
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and CIDR domains are less likely to fold as DBL sub-domains 1 and 2. The ho-
mology modeling of the VAR2CSA gave some indications about the structures
of several domains of the VAR2CSA protein, which can be used for mapping of
experimental data. B-cell epitopes in VAR2CSA were identified using pepscan
peptide-arrays. The study showed that all DBL domains in the VAR2CSA pro-
tein contain peptides that can cross-react with naturally acquired antibodies.
The identified VAR2CSA B-cell epitopes were analyzed in the context of the
predicted structures, and this showed that these epitopes are mostly located
on one side of the DBL domain structures and primarily in sub-domains 1 and
2. Furthermore, the mapping of identified linear epitopes on the 3D structures
showed that many of the epitopes are proximal in space and may together form
discontinuous epitopes. In the VAR2CSA DBL3X domain, it was shown that
residues with high sequence variability were mostly located on one side of the
domain, in a region which is not aligned to the dimer interfaces of EBA-175
DBL domains. In addition, it was found that both positions of high recombina-
tion rates, and surface-exposed epitopes were located in predicted loop regions
which were suggested to be flexible.
4.2 Perspectives
The developed method and findings presented in this thesis may contribute in
many ways to vaccine design. It has been shown that the DiscoTope method
has a reasonable performance, and hopefully the server will be applied broadly
among researchers for prediction studies previous to experimental identification
studies.
However, the method could be improved further. For instance, more sophisti-
cated surface accessibility measures would probably improve the method. Ad-
ditionally, protein structure information could be useful for allocating predicted
B-cell epitope residues into groups representing whole B-cell epitope entities.
The server could be improved by integrating the DiscoTope predictions with
information of glycosylation or trans-membrane regions; and plots of sequence
variability could also be used to help identify predicted epitopes located in con-
served areas of the structure. Finally, the prediction of protein 3D structure
could be part of the server; this would be useful for a number of pathogen
proteins with no determined structure.
The presented results of the VAR2CSA PAM-vaccine project gave more insight
in the locations of B-cell epitopes of naturally acquired human antibodies. Be-
cause B-cell epitopes of naturally acquired antibodies were identified in all DBL
domains, it is probable that a PAM vaccine would have to present epitopes from
several of these DBL domains to be effective.
In further investigation and modeling of the native VAR2CSA quaternary struc-
ture, the modeled DBL structures may be useful in combination with cryo-EM
experiments. These studies could give more insight in the native conformation of
VAR2CSA and indicate whether the overall shape of the molecule is like a string
of pearls (where the DBL domains represent pearls), or if the VAR2CSA protein
folds into specific quaternary structures by interactions between DBL domains.
Cryo-EM is also useful for improving comparative models, because shapes ob-
served in the structures can be used as restraints in comparative modeling (Topf
and Sali 2005). In this way, it is likely that the DBL domain models could be
4.2 Perspectives 97
further improved by combination with cryo-EM structures of the VAR2CSA
protein.
The mapping of functional, CSA-binding residues in VAR2CSA could lead to
identify which of the identified B-cell epitopes are overlapping, or proximal, to
the functional site; when used in a vaccine, such epitopes could more probably
elicit neutralizing antibodies protecting against sequestration. ELISA exper-
iments using peptides shown to bind naturally acquired antibodies could be
used to investigate for CSA binding. Similarly, mutant DBL domains could
be used to test antibody reactive regions for CSA binding properties. Another
approach could be to immunize mice or rabbits with reactive peptides identified
in the pepscan experiments, and test the serum for antibodies which inhibit the
binding of CSA. Additionally, the serum could be affinity purified on infected
erythrocytes, to identify peptides which elicit antibodies that bind native-like
VAR2CSA.
The X-ray structures of the EBA-175 DBL domains suggested that the dimer-
ization of this protein is important for GAG binding. If dimerization (or multi-
merization) of VAR2CSA DBL domains is similarly important for CSA binding,
it would be interesting to determine if the binding of antibodies to epitopes that
are overlapping the dimerization site can prevent CSA binding. Thus, investi-
gation of dimerization properties of VAR2CSA domains also have a potential
for providing valuable knowledge which can be useful in vaccine design.
The sequencing of more var2csa genes is essential in the investigation of se-
quence variability in the rest of the VAR2CSA DBL domains; this would help
to determine which epitopes are more conserved than others. Conserved epi-
topes may be more effective if used in a vaccine, because the vaccine has a
potential to protect from infections of several P. falciparum lines.
We found that naturally acquired antibodies are directed against all the DBL
domains of VAR2CSA. This suggests that a PAM vaccine must present epitopes
from several DBL domains to be effective. In contrast, the finding, that most
epitopes are located in sub-domains 1 and 2, suggests that a VAR2CSA-based
vaccine may only contain these sub-domains expressed as recombinant, stable
proteins. The exclusion of sub-domain 3 could potentially prevent unwanted im-
mune responses, which are directed against irrelevant epitopes and do not lead
to protection against PAM. Energy potentials and protein structure prediction
could probably contribute to the design of a vaccine including only sub-domains
1 and 2 by prediction of stable constructs that can be expressed as recombinant
proteins. However, these constructs would need to be tested intensively in ex-
perimental studies to identify which constructs present relevant epitopes that
elicit protecting antibodies, and at the same time are not leading to unwanted
side-effects.
At present, both B-cell epitope prediction, and PAM vaccines are subjects of re-
search for many different groups which are working on interesting projects. The
outcome of this research has potential to impact the health of many individuals
on a global scale. In this thesis I have presented results contributing to research
in both subjects, and I am very interested in seeing how these contributions
may facilitate future research in vaccine development.
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Appendix I, Data sets used in
Paper I
DiscoTope data set 1
Each entry is marked with the PDB code. For each entry the antigen sequence
is shown first. The next lines mark the identification status of the residues: “.”
marks non-epitope residue and epitopes are marked with capital letters accord-
ing to the identifier of the contacting antibody chain.
200 1JPS.T
NTVAAYNLTWKSTNFKTILEWEPKPVNQVYTVQISTKSGDWKSKCFYTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVE
PLYENSPEFTPYLETNLGQPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFGKDLIYTLYYWKSSSSGKKTAKTN
TNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDSPVECMG
................................................................................
............................................................H.H.H.......HHLLLLLL
..................H.H.H..HHHHH.HH.......
95 1JRH.I
SVPTPTNVTIESYNMNPIVYWEYQIMPQVPVFTVEVKNYGVKNSEWIDACINISHHYCNISDHVGDPSNSLWVRVKARVG
QKESAYAKSEEFAVS
....................................L.LHHHHLLL...................H.HH..L.L......
.......L.......
91 1XIW.A
QTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYL
YLRARVCENCM
.......................D........DDDDDD......DD....................D.DCDCDCC.....
...........
251 1FJ1.F
SLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLELKGTSDKNNGSGVLEGVKADKCKVKLTISDDLGQTTLEVF
KEDGKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKGYVLEGTLTAEKTTLVVKE
GTVTLSKNISKSGEVSVELNDTDSSAATKKTAAWNSGTSTLTITVNSKKTKDLVFTKENTITVQQYDSNGTKLEGSAVEI
TKLDEIKNALK
................................................................................
................................................................................
.......................AAAB.A.AAA..........A.BAB..................BBBAB.........
...........
251 1OSP.O
SLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLELKGTSDKNNGSGVLEGVKADKCKVKLTISDDLGQTTLEVF
KEDGKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKGYVLEGTLTAEKTTLVVKE
119
GTVTLSKNISKSGEVSVELNDTDSSAATKKTAAWNSGTSTLTITVNSKKTKDLVFTKENTITVQQYDSNGTKLEGSAVEI
TKLDEIKNALK
.......L..HHH......LLLLL.....L................LLH....................HHHH.......
..............HHH...............................................................
................................................................................
...........
196 1FNS.A
MYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRVSQKWVRVAVVEYHDGSHAYIGLKDRKRPSELRRIASQVKY
AGSQVASTSEVLKYTLFQIFSKIDRPEASRIALLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIE
KQAPENKAFVLSSVDELEQQRDEIVSYLCDLAPEAP
................................................................................
........................................HHH.HHHHHL.......................HH..H..
....................................
196 1OAK.A
MYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVEYHDGSHAYIGLKDRKRPSELRRIASQVKY
AGSQVASTSEVLKYTLFQIFSKIDRPEASRIALLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIE
KQAPENKAFVLSSVDELEQQRDEIVSYLCDLAPEAP
................................................................................
........................................HHH.HLHHHL.....................H.HH..H..
....................................
186 1FE8.A
PDCSQPLDVILLLDGSSSFPASYFDEKSFAKAFISKANIGPRLTQVSVLQYGSITTIDVPWNVVPEKAHLLSLVDVQREG
GPSQIGDALGFAVRYLTSEHGARPGASKAVVILVTDVSVDSVDAAADAARSNRVTVFPIGIGDRYDAAQLRILAGPAGDS
NVVKLQRIEDLPTVTLGNSFLHKLCS
........................................LL..L..............HHHHHLL.HH..HH.HH....
...................LL.L.........................................................
..........................
184 1MHP.A
TQLDIVIVLDGSNSIYPWESVIAFLNDLLKRMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEVLVAANKIVQRGGRQT
MTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNYRLKQVIQDCEDENIQRFSIAILGTEKFVEEIKSIASEPTE
KHFFNVSDELALVTIVKALGERIF
...........HHH.H...............................L.........................HHHHHHH
..................................L.H.LL........................................
........................
94 1TZH.V
VVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGE
MSFLQHNKCECRPK
...............................H.................................H..HLHLLLHHHHH.
..............
94 1CZ8.W
VVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGE
MSFLQHNKCECRPK
...............................H..H..............................HHHHH..HHHHHHHH
H.............
94 1BJ1.W
VVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGE
MSFLQHNKCECRPK
...............................H..H..............................HHHHH..HHHHHHHH
H.............
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DiscoTope data set 2
Each entry is marked with the PDB code. For each entry the antigen sequence
is shown first. The next lines mark the identification status of the residues: “.”
marks non-epitope residue and epitopes are marked with capital letters accord-
ing to the identifier of the contacting antibody chain.
129 1A2Y.C
KVFGRCELAAAMKRHGLANYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
..................A..BBB..B.....................................................
.....................BB............BBBBBB..AA....
129 1BVK.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.................AA..BBB..B.....................................................
.....................BB............BBBBBB..AA....
129 3HFL.Y
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
........................................H.HLLLLLL...H.............HHHH..........
...H.............................................
129 1IC4.Y
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
..............LL..LLL........................................HH.........H.H.....
........L...L..LHH.HHHH..........................
129 1FDL.Y
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.................LL..HHH..H.....................................................
...................................HHHHHL..LL....
129 1IC5.Y
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
..............LL..LLL.........................................H.........H.H.....
........L...L..LHH.HHH...........................
129 1C08.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
..............AA..AAA.........................................B.........B.B.....
........A...A..ABB.BBBB..........................
129 1NDM.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
..............AA.AAAA.........................................B.........B.B.....
........A...A..ABB.ABBB..........................
129 1IC7.Y
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
..............LL..LLL.........................................H.........H.H.....
........L...L..LHH.HHHH..........................
129 1MLC.E
121
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
........................................B.B.BAAAAAA.B.............BA.A........B.
B..B.............................................
129 1KIP.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.................AA..BBB..B.....................................................
.....................B.............BBBBBB..AA....
129 1G7L.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.................AA..BBB..B.....................................................
.....................B.............BBBBBA..AA....
129 1DQJ.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.............AAA.AAAA........................................BB.........B.B.B...
........A...A..ABB.ABBB..........................
129 1KIR.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
..................A..BBB..B.....................................................
.....................BB............BBBBBB...A....
129 1G7M.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.................AA..BBB..B.....................................................
.....................BB............BBBBBA..A.....
129 1KIQ.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.................AA..BBB..B.....................................................
.....................B.............BBBBBA..AA....
129 1G7H.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.................AA..BBB..B.....................................................
.....................BB............BBBBBA..AA....
129 1J1X.Y
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
..............LL..LLL........................................HH.........H.H.H...
........L...L..LHH.LHHH..........................
129 1J1P.Y
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.............LLL..LLL........................................HH.........H.H.H...
........L...L..LHH.HHHH..........................
129 1J1O.Y
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
122
..............LL..LLL........................................HH.........H.H.H...
........L...L..HHH.HHHH..........................
129 1G7I.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.................AA..BBB..B.....................................................
.....................B.............BBBBBA..AA....
129 1G7J.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.................AA..BBB..B.....................................................
.....................B.............BBBBBA..AA....
129 1NBZ.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKAIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
..............AA.AAAA.........................................B.........B.B.B...
........A...A..ABB.BBBB..........................
129 1NBY.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAAKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
............AAAA..AAA.........................................B.........B.B.....
........A...A..ABB.ABBB..........................
129 1NDG.C
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSAWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
.............AAA..AAB........................................BB........BBBB.B...
........A...A..ABB.BBB...........................
127 1MEL.L
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNTQATNRNTDGSTDYGILQINSRWWCNDGRTPGSRNLCNIPC
SALLSSDITASVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGC
..................................A..........AAA...A....AAA.AAA.........A.A.....
.................A..A.A..AAAA..A...A...........
129 1BQL.Y
KVFGRCELAAAMKRHGLDNYRGYSLGNWVCAAKFESNFNSQATNRNTDGSTDYGVLQINSRWWCNDGKTPGSRNLCNIPC
SALLSSDITATVNCAKKIVSDGNGMNAWVAWRNRCKGTDVQAWIRGCRL
........................................H.HLLL.L....H.............HHHH..........
H..H.............................................
129 1DZB.X
KVYGRCELAAAMKRLGLDNYRGYSLGNWVCAAKFESNFNTHATNRNTDGSTDYGILQINSRWWCNDGRTPGSKNLCNIPC
SALLSSDITASVNCAKKIASGGNGMNAWVAWRNRCKGTDVHAWIRGCRL
....................A.A.....................................AAA.........A.A.....
...............AAA.AAAAA.A.....A...A.............
129 1JHL.A
KVYGRCELAAAMKRMGLDNYRGYSLGNWVCAAKFESNFNTGATNRNTDGSTDYGILQINSRWWCNDGRTPGSKNLCHIPC
SALLSSDITASVNCAKKIVSDGDGMNAWVAWRKHCKGTDVNVWIRGCRL
....................H.H.........................................................
......................H..H.....HH..HLLL.L........
132 1ORS.C
DVMEHPLVELGVSYAALLSVIVVVVEYTMQLSGEYLVRLYLVDLILVIILWADYAYRAYKSGDPAGYVKKTLYEIPALVP
AGLLALIEGHLAGLGLFRLVRLLRFLRILLIISRGSKFLSAIADAADKLVPR
................................................................................
.......B...BABBBBB.B...B............................
123
103 1K4D.C
SALHWRAAGAATVLLVIVLLAGSYLAVLAERGAPGAQLITYPRALWWSVETATTVGYGDLYPVTLWGRCVAVVVMVAGIT
SFGLVTAALATWFVGREQERRGH
.......................A...A..BBBBBBB.BAA.B.....................................
.......................
103 1K4C.C
SALHWRAAGAATVLLVIVLLAGSYLAVLAERGAPGAQLITYPRALWWSVETATTVGYGDLYPVTLWGRCVAVVVMVAGIT
SFGLVTAALATWFVGREQERRGH
.......................A...AA.BBBBBBB.BAA.B.....................................
.......................
136 1LK3.A
NMLRDLRDAFSRVKTFFQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKT
LRLRLRRCHRFLPCEKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMK
..................L...............................H..HH..HH..HH.................
.......................H..HHLLLLL.HL....................
85 2JEL.P
MFQQEVTITAPNGLHTRPAAQFVKEAKGFTSEITVTSNGKSASAKSLFKLQTLGLTQGTVVTISAEGEDEQKAVEHLVKL
MAELE
LHLH.............................L......L......................L.LHH.HHH..HH....
.....
581 1N8Z.C
TQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIV
RGTQLFEDNYALAVLDNGDPLSPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRA
CHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPAL
VTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTATQRCEKCSKPCARVCYGLGMEHLREVR
AVTSANIQEFAGCKKIFGSLAFLPESFDSNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHN
GAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARG
HCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVA
RCPSIWKFPDEEGACQPCPIN
................................................................................
................................................................................
................................................................................
................................................................................
................................................................................
................................................................................
............................................................BB.AB.......ABAAB...
....B.B..A.A.A.AAA...
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DiscoTope data set 3
Each entry is marked with the PDB code. For each entry the antigen sequence
is shown first. The next lines mark the identification status of the residues: “.”
marks non-epitope residue and epitopes are marked with capital letters accord-
ing to the identifier of the contacting antibody chain.
122 1H0D.C
DNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTC
KLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP
................................AAAAABBB........................................
.B.BBBBABB.B..............................
156 1IQD.C
CSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLT
SMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNCLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQ
......................AAAAB..............B....B.AA..........................BBBB
.B...........................................................AA.............
185 1KYO.E
KSTYRTPNFDDVLKENNDADKGRSYAYFMVGAMGLLSSAGAKSTVETFISSMTATADVLAMAKVEVNLAAIPLGKNVVVK
WQGKPVFIRHRTPHEIQEANSVDMSALKDPQTDADRVKDPQWLIMLGICTHLGCVPIGEAGDFGGWFCPCHGSHYDISGR
IRKGPAPLNLEIPAYEFDGDKVIVG
................................................................................
............K..KJ..JJ.JJ.......JJJ..JJKJK.......................................
.........................
185 1EZV.E
KSTYRTPNFDDVLKENNDADKGRSYAYFMVGAMGLLSSAGAKSTVETFISSMTATADVLAMAKVEVNLAAIPLGKNVVVK
WQGKPVFIRHRTPHEIQEANSVDMSALKDPQTDADRVKDPQWLIMLGICTHLGCVPIGEAGDFGGWFCPCHGSHYDISGR
IRKGPAPLNLEIPAYEFDGDKVIVG
................................................................................
............YY.YY..XXXXX.......XXX..XXYXY.......................................
.........................
389 1NCA.N
IRDFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTREPYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALIS
WPLSSPPTVYNSRVECIGWSSTSCHDGKTRMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCHNGVCPV
VFTDGSATGPAETRIYYFKEGKILKWEPLAGTAKHIEECSCYGERAEITCTCRDNWQGSNRPVIRIDPVAMTHTSQYICS
PVLTDNPRPNDPTVGKCNDPYPGNNNNGVKGFSYLDGVNTWLGRTISIASRSGYEMLKVPNALTDDKSKPTQGQTIVLNT
DWSGYSGSFMDYWAEGECYRACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWDWPDGAKIEYFL
................................................................................
................................................................................
................................................................................
......LLLL............LLL.L..................HHHLH.H.........................HHH
HH.............................LL....................................
388 1NMC.N
RDFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTREPYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALISW
PLSSPPTVYNSRVECIGWSSTSCHDGKTRMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCHNGVCPVV
FTDGSATGPAETRIYYFKEGKILKWEPLAGTAKHIEECSCYGERAEITCTCRDNWQGSNRPVIRIDPVAMTHTSQYICSP
VLTDNPRPNDPTVGKCNDPYPGNNNNGVKGFSYLDGVNTWLGRTISIASRSGYEMLKVPNALTDDKSKPTQGQTIVLNTD
WSGYSGSFMDYWAEGECYRACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWDWPDGAKIEYFL
................................................................................
................................................................................
................................................................................
.......LLLL..........LL.....................HHLHH............................HH.
H..............................H....................................
388 1A14.N
RDFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTREPYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALISW
PLSSPPTVYNSRVECIGWSSTSCHDGKTRMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCHNGVCPVV
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FTDGSATGPAETRIYYFKEGKILKWEPLAGTAKHIEECSCYGERAEITCTCRDNWQGSNRPVIRIDPVAMTHTSQYICSP
VLTDNPRPNDPTVGKCNDPYPGNNNNGVKGFSYLDGVNTWLGRTISIASRSGYEMLKVPNALTDDKSKPTQGQTIVLNTD
WSGYSGSFMDYWAEGECYRACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWDWPDGAKIEYFL
................................................................................
................................................................................
................................................................................
.......LLLL........LLLL.....................H.LHH.H..........................HH.
H..............................H....................................
389 1NCB.N
IRDFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTREPYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALIS
WPLSSPPTVYNSRVECIGWSSTSCHDGKTRMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCHNGVCPV
VFTDGSATGPAETRIYYFKEGKILKWEPLAGTAKHIEECSCYGERAEITCTCRDNWQGSNRPVIRIDPVAMTHTSQYICS
PVLTDNPRPDDPTVGKCNDPYPGNNNNGVKGFSYLDGVNTWLGRTISIASRSGYEMLKVPNALTDDKSKPTQGQTIVLNT
DWSGYSGSFMDYWAEGECYRACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWDWPDGAKIEYFL
................................................................................
................................................................................
................................................................................
......LLLL............LL..L..................HHHHH.H.........................HHH
HH.............................LL....................................
389 1NCC.N
IRDFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTREPYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALIS
WPLSSPPTVYNSRVECIGWSSTSCHDGKTRMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCHNGVCPV
VFTDGSATGPAETRIYYFKEGKILKWEPLAGTAKHIEECSCYGERAEITCTCRDNWQGSNRPVIRIDPVAMTHTSQYICS
PVLTDNPRPNDPTVGKCNDPYPGNNNNGVKGFSYLDGVNTWLGRTISRASRSGYEMLKVPNALTDDKSKPTQGQTIVLNT
DWSGYSGSFMDYWAEGECYRACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWDWPDGAKIEYFL
................................................................................
................................................................................
................................................................................
......LLLL............LLL.L..................HHHHH.H.........................HHH
HH.............................LL....................................
389 1NCD.N
IREFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTREPYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRDLIS
WPLSSPPTVYNSRVECIGWSSTSCHDGRARMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCQNGVCPV
VFTDGSATGPAETRIYYFKEGKILKWEPLTGTAKHIEECSCYGEQAGVTCTCRDNWQGSNRPVIQIDPVAMTHTSQYICS
PVLTDNPRPNDPTVGKCNDPYPGNNNNGVKGFSYLDGGNTWLGRTISIASRSGYEMLKVPNALTDDRSKPTQGQTIVLNT
DWSGYSGSFMDYWAEGECYRACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWNWPDGAKIEYFL
................................................................................
................................................................................
................................................................................
......LLLL............LL..L..................HHHLH.H.........................HHH
.H.............................LL....................................
444 1OTS.A
RRRQLIRQLLERDKTPLAILFMAAVVGTLVGLAAVAFDKGVAWLQNQRMGALVHTADNYPLLLTVAFLCSAVLAMFGYFL
VRKYAPEAGGSGIPEIEGALEDQRPVRWWRVLPVKFFGGLGTLGGGMVLGREGPTVQIGGNIGRMVLDIFRLKGDEARHT
LLATGAAAGLAAAFNAPLAGILFIIEEMRPQFRYTLISIKAVFIGVIMSTIMYRIFNHEVALIDVGKLSDAPLNTLWLYL
ILGIIFGIFGPIFNKWVLGMQDLLHRVHGGNITKWVLMGGAIGGLCGLLGFVAPATSGGGFNLIPIATAGNFSMGMLVFI
FVARVITTLLCFSSGAPGGIFAPMLALGTVLGTAFGMVAVELFPQYHLEAGTFAIAGMGALLAASIRAPLTGIILVLEMT
DNYQLILPMIITGLGATLLAQFTGGKPLYSAILARTLAKQEAEQ
................................................................................
................................................................................
..................................................................C..C.CCC......
................................................................................
...........................................DDCD.................................
............................................
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DiscoTope data set 4
Each entry is marked with the PDB code. For each entry the antigen sequence
is shown first. The next lines mark the identification status of the residues: “.”
marks non-epitope residue and epitopes are marked with capital letters accord-
ing to the identifier of the contacting antibody chain.
305 1RZJ.G
EVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVGAGSCNTSVITQACPKVSFEPIPIHYCAPAGFAIL
KCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTGAGHCNISR
AKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNGSDTITLPCRIKQIINMW
QKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIE
....................................LH.H...............LL.......................
................................................................................
.......................................................................H.HHH....
......H..H.......................................................
305 1G9M.G
EVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVGAGSCNTSVITQACPKVSFEPIPIHYCAPAGFAIL
KCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTGAGHCNISR
AKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNGSDTITLPCRIKQIINMW
QKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIE
....................................LH.H.............H.LL.......................
................................................................................
.......................................................................H.HHH....
......L..H.......................................................
297 1GC1.G
TENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVGAGSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTF
NGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTGAGHCNISRAKWNNTL
KQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFGSDTITLPCRIKQIINMWQKVGKAMY
APPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIE
.............................L.H..............H.LL..............................
................................................................................
...............................................................H.HHH..........L.
.H.......................................................
306 1RZK.G
LENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVGAGSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCN
DKKFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEIVIRSENFTNNAKTIIVQLNESVVINCTGAGHCNLSKTQW
ENTLEQIAIKLKEQFGNNKTIIFNPSSGGDPEIVTHSFNCGGEFFYCNSTQLFTWNDTRKLNNTGRNITLPCRIKQIINM
WQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGKDTNGTEIFRPGGGDMRDNWRSELYKYKVVKIE
.................................LH.H.............H.LL..........................
................................................................................
........................................................................H.HHH...
.......H..H.......................................................
306 1G9N.G
LENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVGAGSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCN
DKKFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEIVIRSENFTNNAKTIIVQLNESVVINCTGAGHCNLSKTQW
ENTLEQIAIKLKEQFGNNKTIIFNPSSGGDPEIVTHSFNCGGEFFYCNSTQLFTWNDTRKLNNTGRNITLPCRIKQIINM
WQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGKDTNGTEIFRPGGGDMRDNWRSELYKYKVVKIE
.................................LH.H.............H.LL..........................
................................................................................
........................................................................H.HHH...
.......H..H.......................................................
102 1TQB.A
GLGGYMLGSVMSRPLIHFGNDYEDRYYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITVKQHTVTTTTKGENFTETDI
KIMERVVEQMCITQYQRESQAY
BB...........................C.CC.........................B..BB.BBBCBCBCCC......
......................
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102 1TPX.A
GLGGYMLGSAMSRPLIHFGNDYEDRYYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITVKQHTVTTTTKGENFTETDI
KIMERVVEQMCITQYQRESQAY
BB...........................C.CC.........................B..BB.BBBCBCBCCC......
......................
102 1TQC.A
GLGGYMLGSAMSRPLIHFGNDYEDRYYRENMYRYPNQVYYRPVDRYSNQNNFVHDCVNITVKQHTVTTTTKGENFTETDI
KIMERVVEQMCITQYQRESQAY
BB.......................C...C.CC.........................B..BB.BBBCBBCCCC......
......................
252 1AR1.B
QDVLGDLPVIGKPVNGGMNFQPASSPLAHDQQWLDHFVLYIITAVTIFVCLLLLICIVRFNRRANPVPARFTHNTPIEVI
WTLVPVLILVAIGAFSLPILFRSQEMPNDPDLVIKAIGHQWYWSYEYPNDGVAFDALMLEKEALADAGYSEDEYLLATDN
PVVVPVGKKVLVQVTATDVIHAWTIPAFAVKQDAVPGRIAQLWFSVDQEGVYFGQCSELCGINHAYMPIVVKAVSQEKYE
AWLAGAKEEFAA
........................DD..DD..................................................
................................................................................
.....CCC....................................CCDD..........................CCC..C
............
115 1OAZ.A
SDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPIEESDDRRYDLVGPCKMIAPILDEILTVAKLNIDQNPGTAPKYGIR
GIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA
................................HHH.H...H.L..L.L...............................H
HH................HHLL..L..........
239 1NFD.B
DSGVVQSPRHIIKEKGGRSVLTCIPISGHSNVVWYQQTLGKELKFLIQHYEKVERDKGFLPSRFSVQQFDDYHSEMNMSA
LELEDSAMYFCASSLRWGDEQYFGPGTRLTVLEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVN
GKEVHSGVSTDPQAYKESNYSYSLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADC
.............E..................................................................
.................................E.F............................................
....................................................E.EEEEFFFF.................
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DiscoTope data set 5
Each entry is marked with the PDB code. For each entry the antigen sequence
is shown first. The next lines mark the identification status of the residues: “.”
marks non-epitope residue and epitopes are marked with capital letters accord-
ing to the identifier of the contacting antibody chain.
430 2HMI.B
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFREL
NKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIF
QSSMTKILEPFKKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWT
VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLSKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYD
PSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWET
WWTEYWQATWIPEWEFVNTPPLVKLWYQLE
................................................................................
................................................................................
......................................D.......................DDCDD.DD..........
................................................................................
.....................................C..........................................
..............................
101 1EGJ.A
IQMAPPSLNVTKDGDSYSLRWETMKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTS
RTGYNGIWSEWSEARSWDTES
........................LHHHHL...........................H....................LL
LL.L.................
319 1EO8.A
STATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQSSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFV
ERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYPVLNVTM
PNNDNFDKLYIWGIHHPSTNQEQTSLYVQASGRVTVSTRRSQQTIIPNIGSRPWVRGLSSRISIYWTIVKPGDVLVINSN
GNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQ
.........................................H........HHHHH..........LH.HLH..H......
.H.H.H..........................................................................
................................................................................
......................H.H......................................................
317 1QFU.A
STATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQSSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFV
ERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYPVLNVTM
PNNDNFDKLYIWGIHHPSTNQEQTSLYVQASGRVTVSTRRSQQTIIPNIGSRPWVRGLSSRISIYWTIVKPGDVLVINSN
GNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPE
.......................................HHH........HHHHH..........LL..LH.........
.H.H.H................................................L.........................
................................................................................
......................HHHH...................................................
159 1FSK.A
GVFNYETETTSVIPAARLFKAFILDGDNLFPKVAPQAISSVENIEGNGGPGTIKKISFPEGLPFKYVKDRVDEVDHTNFK
YNYSVIEGGPIGDTLEKISNEIKIVATPDGGSILKISNKYHTKGDHEVKAEQVKASKEMGETLLRAVESYLLAHSDAYN
.........................................CCCCCBBBBCCC................C.C...B....
......C.........C..............................................................
452 1TY6.A
LNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVG
SQTLQTFKARQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDF
SWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVA
VGEFDGDLNTTEYVVGAPTWSWTLGAVEILDSYYQRLHRLRAEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADR
KLAEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLR
SRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQP
............................................................................LLLL
LH.H................................................................H....H...H..
129
............................................HH.LLLL.HHH.........................
................................................................................
................................................................................
....................................................
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Appendix II
A larger version of figure 3.4
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Figure 3.4 Multiple alignment of VAR2CSA DBL3X sequences. (A)
cDNA from 43 placental parasite samples were amplified with conserved
DBL3X primers and sequenced. Sequences were curated for primer sequence,
translated and aligned. The text to the left indicate the identity of the
samples. The DBL3X domain can be divided into four regions, which are
highly conserved, C1-C4, and three regions, which are polymorphic and/or
harbour deletions V1-V3.
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